<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">8914275</journal-id><journal-id journal-id-type="pubmed-jr-id">1426</journal-id><journal-id journal-id-type="nlm-ta">Crit Rev Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Crit Rev Toxicol</journal-id><journal-title-group><journal-title>Critical reviews in toxicology</journal-title></journal-title-group><issn pub-type="ppub">1040-8444</issn><issn pub-type="epub">1547-6898</issn></journal-meta><article-meta><article-id pub-id-type="pmid">35822508</article-id><article-id pub-id-type="pmc">9716650</article-id><article-id pub-id-type="doi">10.1080/10408444.2022.2082918</article-id><article-id pub-id-type="manuscript">NIHMS1848342</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>E-Cigarette Vaping Associated Acute Lung Injury (EVALI): State of science and future research needs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Marrocco</surname><given-names>Antonella</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Dilpreet</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Christiani</surname><given-names>David C.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Demokritou</surname><given-names>Philip</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Center for Nanotechnology and Nanotoxicology, T.H. Chan School of Public Health, Harvard University, 665 Huntington Ave., Boston, MA 02115, USA</aff><aff id="A2"><label>2</label>Environmental Occupational Health Sciences Institute, School of Public Health, Rutgers University, 170 Piscataway, NJ 08854, USA</aff><author-notes><corresp id="CR1"><label>*</label><bold>Corresponding author:</bold> Prof. Philip Demokritou, Department of Environmental Health, Center for Nanotechnology and Nanotoxicology, Harvard T.H. Chan School of Public Health, 665 Huntington Ave, Building 1, Room 1310, Boston, MA 02115, USA, Tel: +1 617 432 3481, <email>pdemokri@hsph.harvard.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>25</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>13</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>7</month><year>2023</year></pub-date><volume>52</volume><issue>3</issue><fpage>188</fpage><lpage>220</lpage><abstract id="ABS1"><p id="P1">&#x0201c;E-Cigarette (e-cig) Vaping-Associated Acute Lung Injury&#x0201d; (EVALI) has been linked to vitamin-E-acetate (VEA) and &#x00394;-9-tetrahydrocannabinol (THC), due to their presence in patients&#x02019; e-cigs and biological samples. Lacking standardized methodologies for patients&#x02019; data collection and comprehensive physicochemical/toxicological studies using real-world-vapor exposures, very little data are available, thus the underlying pathophysiological mechanism of EVALI is still unknown. This review aims to provide a comprehensive and critical appraisal of existing literature on clinical/epidemiological features and physicochemical-toxicological characterization of vaping emissions associated with EVALI. The literature review of 161 medical case reports revealed that the predominant demographic pattern was healthy white male, adolescent, or young adult, vaping illicit/informal THC-containing e-cigs. The main histopathologic pattern consisted of diffuse alveolar damage with bilateral ground-glass-opacities at chest radiograph/CT, and increased number of macrophages or neutrophils and foamy-macrophages in the bronchoalveolar lavage. The chemical analysis of THC/VEA e-cig vapors showed a chemical difference between THC/VEA and the single THC or VEA. The chemical characterization of vapors from counterfeit THC-based e-cigs or in-house-prepared e-liquids using either cannabidiol (CBD), VEA, or medium-chain triglycerides (MCT), identified many toxicants such as carbonyls, volatile organic compounds, terpenes, silicon compounds, hydrocarbons, heavy metals, pesticides and various industrial/manufacturing/automotive-related chemicals. There is very scarce published toxicological data on emissions from THC/VEA e-liquids. However, CBD, MCT, and VEA emissions exert varying degrees of cytotoxicity, inflammation, and lung damage, depending on puffing topography and cell line. Major knowledge gaps were identified, including the need for more systematic-standardized epidemiological surveys; comprehensive physicochemical characterization of real-world e-cig emissions, and mechanistic studies linking emission properties to specific toxicological outcomes.</p></abstract><kwd-group><kwd>EVALI</kwd><kwd>Vitamin E Acetate (VEA)</kwd><kwd>&#x00394;-9-tetrahydrocannabinol (THC)</kwd><kwd>e-cigarettes</kwd><kwd>vaping</kwd><kwd>counterfeit cartridges</kwd><kwd>pneumonia</kwd><kwd>acute lung injury</kwd><kwd>acute respiratory distress syndrome (ARDS)</kwd></kwd-group></article-meta></front><body><sec id="S1"><label>1</label><title>Introduction</title><p id="P2">The &#x0201c;E-cigarette (e-cig), or Vaping product use, associated Acute Lung Injury&#x0201d; (EVALI) outbreak started in the United States in July 2019, leading to 2807 hospitalizations, including 68 deaths, until February 18, 2020, when the Centers for Disease Control and Prevention (CDC) ended case reporting as SARS-Cov2 arose in the USA. The EVALI outbreak raised public health concerns about the health risks associated with vaping, especially among the young population (<xref rid="R50" ref-type="bibr">CDC 2020a</xref>).</p><p id="P3">The use of e-cigs in the USA has constantly and rapidly grown, since they became commercially available in the marketplace in 2007, among the general population, mainly young adults and middle and high school students.(<xref rid="R274" ref-type="bibr">Wang and Wu 2020</xref>; <xref rid="R276" ref-type="bibr">Wang L et al. 2020</xref>). Despite the slow decline registered in 2020 in terms of e-cigs&#x02019; sales and users, the number of current young consumers is still relatively high (3.6 million) (<xref rid="R277" ref-type="bibr">Wang TW et al. 2020</xref>), and the e-cig market continues to expand exponentially especially in North America, reaching a market value of 12.41 billion US dollars in 2019, and projected to reach 104.51 billion US dollars by 2028 (<xref rid="R238" ref-type="bibr">Research 2021</xref>). Some of the reasons that favored such exponential growth included the misconception that e-cigs are a healthier and safer alternative to conventional cigarettes (<xref rid="R109" ref-type="bibr">Gilbert 1965</xref>; <xref rid="R48" ref-type="bibr">CDC 2016</xref>). In addition, the extensive availability of more than 466 e-cig brands and 7700 flavors (2014 data) (<xref rid="R292" ref-type="bibr">Zhu et al. 2014</xref>; <xref rid="R48" ref-type="bibr">CDC 2016</xref>) and the recent introduction of &#x00394;-9-tetrahydrocannabinol (D9THC) and cannabinoid (CBD) oils in the vape market further contributed to their increased marketability. Moreover, the lack of regulations and controls in manufacturing and commercialization allowed the tremendous expansion of the e-cig market (<xref rid="R114" ref-type="bibr">Gottlieb 2019</xref>).</p><p id="P4">There is a growing literature on the potential short- and long-term health effects associated with e-cigs and vaping, including mechanical injury, nicotine poisoning (<xref rid="R129" ref-type="bibr">Hua M. and Talbot 2016</xref>; <xref rid="R144" ref-type="bibr">Jonas AM and Raj 2020</xref>), and effects on the respiratory, cardiovascular system, and gastrointestinal systems (<xref rid="R73" ref-type="bibr">Darnell and Sofi</xref>; <xref rid="R132" ref-type="bibr">Hureaux et al. 2014</xref>; <xref rid="R265" ref-type="bibr">Thota and Latham 2014</xref>; <xref rid="R27" ref-type="bibr">Atkins and Drescher 2015</xref>; <xref rid="R194" ref-type="bibr">Modi et al. 2015</xref>; <xref rid="R195" ref-type="bibr">Moore et al. 2015</xref>; <xref rid="R239" ref-type="bibr">Ring Madsen et al. 2016</xref>). However, the recent EVALI outbreak posed even more serious questions about the health risks and safety of vaping.</p><p id="P5">To date, many medical case reports have been published, which highlighted the main features of the EVALI patients: a healthy white male, adolescent or young adult, predominantly vaping THC and vitamin E acetate (VEA) containing e-cigs, obtained from illicit sources (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R55" ref-type="bibr">Chatham-Stephens et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R169" ref-type="bibr">Lozier et al. 2019</xref>; <xref rid="R196" ref-type="bibr">Moritz et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R223" ref-type="bibr">Perrine et al. 2019</xref>; Aberegg, <xref rid="R64" ref-type="bibr">Cirulis, et al. 2020</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington, et al. 2020; <xref rid="R162" ref-type="bibr">Layden J. E. et al. 2020</xref>; <xref rid="R192" ref-type="bibr">Mikosz et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>). In addition, in a small percentage of cases, nicotine has also been linked to EVALI (<xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>). The clinical signs and symptoms of EVALI are unspecific, similar to an acute viral infectious disease or other respiratory diseases characterized by diffuse alveolar damage and hypoxemia, therefore, the diagnosis is a process of elimination. As clearly stated from CDC, the main diagnostic criteria are: 1) history of e-cigs vaping in the 90 days before the onset of the symptoms; 2) signs of pulmonary infiltrates, such as opacities, on chest radiograph, or ground-glass opacities on chest-computed tomography (CT); 3) respiratory symptoms in absence of pulmonary infection or any alternative diagnosis for lung injury (<xref rid="R49" ref-type="bibr">CDC 2019</xref>).</p><p id="P6">Although the CDC investigations indicated that counterfeit THC/VEA containing e-cigs were strongly linked to the EVALI outbreak based on the presence of THC and VEA in patients&#x02019; bronchoalveolar-lavage (BAL) (<xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>), the presence of many more toxicants, including pesticides, oils, diluents, plasticizers in the illicit THC vaping products (<xref rid="R203" ref-type="bibr">Muthumalage, Friedman, et al. 2020</xref>; <xref rid="R62" ref-type="bibr">Ciolino, Falconer, et al. 2021</xref>; <xref rid="R171" ref-type="bibr">Lu SJ et al. 2021</xref>), and the decreased but not erased number of EVALI cases even after banning the VEA as well as illicit vaping products (<xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>; <xref rid="R168" ref-type="bibr">Lim et al. 2022</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>), increased the needs for a comprehensive physicochemical and toxicological properties of THC/VEA e-cig vapors.</p><p id="P7">While to date many efforts have been made to characterize physicochemically and toxicologically the nicotine-based e-cig vapors (<xref rid="R281" ref-type="bibr">Williams et al. 2013</xref>; <xref rid="R290" ref-type="bibr">Zhao et al. 2016</xref>; <xref rid="R289" ref-type="bibr">Zhao, Nelson, et al. 2018</xref>; <xref rid="R291" ref-type="bibr">Zhao, Zhang, et al. 2018</xref>; <xref rid="R133" ref-type="bibr">Hwang et al. 2020</xref>; <xref rid="R164" ref-type="bibr">Lee M-S and Christiani 2020</xref>), the literature regarding vapors emitted from THC/VEA-based e-liquids is very scarce, making it difficult for health risk assessors to perform risk assessment evaluations. To date, the majority of published studies focus on the physicochemical characterization (<xref rid="R188" ref-type="bibr">Meehan-Atrash et al. 2019</xref>; <xref rid="R83" ref-type="bibr">Duffy B et al. 2020</xref>; <xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>; <xref rid="R160" ref-type="bibr">Lanzarotta et al. 2020</xref>; <xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>; <xref rid="R203" ref-type="bibr">Muthumalage, Friedman, et al. 2020</xref>; <xref rid="R273" ref-type="bibr">Wagner et al. 2020</xref>; <xref rid="R62" ref-type="bibr">Ciolino, Falconer, et al. 2021</xref>; <xref rid="R63" ref-type="bibr">Ciolino, Ranieri, et al. 2021</xref>; <xref rid="R84" ref-type="bibr">Duffy BC et al. 2021</xref>; <xref rid="R112" ref-type="bibr">Gonzalez-Jimenez et al. 2021</xref>; <xref rid="R116" ref-type="bibr">Guo et al. 2021</xref>; <xref rid="R154" ref-type="bibr">Kovach et al. 2021</xref>; <xref rid="R171" ref-type="bibr">Lu SJ et al. 2021</xref>; <xref rid="R172" ref-type="bibr">Lynch et al. 2021</xref>; <xref rid="R42" ref-type="bibr">Brosius et al. 2022</xref>; <xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>; <xref rid="R186" ref-type="bibr">McGuigan et al. 2022</xref>; <xref rid="R190" ref-type="bibr">Mikheev and Ivanov 2022</xref>) or biological <italic toggle="yes">in vivo/in vitro</italic> assessment (<xref rid="R206" ref-type="bibr">Muthumalage and Rahman 2019</xref>; <xref rid="R35" ref-type="bibr">Bhat et al. 2020</xref>; <xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>; <xref rid="R182" ref-type="bibr">Matsumoto et al. 2020</xref>; <xref rid="R204" ref-type="bibr">Muthumalage, Lucas, et al. 2020a</xref>; <xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>; <xref rid="R183" ref-type="bibr">Matsumoto et al. 2022</xref>) of e-liquids or vapors generated from a single e-liquid compound (i.e., THC or VEA or other additives). Despite the paucity of data, many lung irritants and toxicant chemicals have been identified in the vaping emissions, which can play crucial roles in the development of EVALI, such as carbonyls, alkyl alcohols, esters, carboxylic acids, short-chain alkanes, silicon compounds, hydrocarbons, volatile organic compounds (VOC), terpenes, reactive oxygen species (ROS) and heavy metals, which have been found to exert varying degrees of cytotoxicity, alveolar epithelial damage and lung inflammation both <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic>.</p><p id="P8">The complex chemistry of these chemicals depends on many variables, such as e-liquid composition, the device type (coil materials, heating power, operational voltage, temperature, etc.), and users puffing topography. The lack of regulations on manufacturing and commercialization allows for wide customizability of the devices that consequently drives the generation of a variety of chemical mixtures in the e-cig vapors, in which the toxic components can potentially exert a synergistic effect in the development of EVALI.</p><p id="P9">Moreover, the lack of standardized methodologies to generate e-cig emissions under &#x0201c;real-world&#x0201d; vaping conditions prevents the generation of reliable and generalizable physicochemical and toxicological characterization data, which are necessary to link specific properties of e-cig vapors to the etiopathogenesis of EVALI.</p><p id="P10">The current risk uncertainties related to EVALI are also hindered by the limited and inconsistent clinical data. Many pieces of information are often missing, improperly collected, or misreported, on the human behavior, clinical history, specimen collection, or analysis. The limited physicochemical and toxicological data based on &#x0201c;real world&#x0201d; vaping conditions also make it difficult to derive proper hazard characterization data and understand potential mechanistic pathways related to EVALI.</p><p id="P11">This review aims to provide a comprehensive and critical appraisal of the existing literature on the clinical and epidemiological aspects of EVALI, as well as the physicochemical and toxicological characterization of vaping emissions associated with the EVALI syndrome in order to identify current knowledge gaps and future research needs.</p></sec><sec id="S2"><label>2</label><title>Methods.</title><p id="P12">Online searches were performed using, <ext-link xlink:href="https://www.science.gov/" ext-link-type="uri">Science.gov</ext-link> (<ext-link xlink:href="http://www.science.gov/" ext-link-type="uri">www.science.gov</ext-link>), PubMed, EMBASE, and Web of Science search engines with the search phrases: &#x0201c;electronic cigarette or vaping and associated lung Injury&#x0201d;, &#x0201c;EVALI&#x0201d;, &#x0201c;electronic cigarette and acute lung injury&#x0201d;, &#x0201c;vaping and acute lung injury&#x0201d;, &#x0201c;electronic cigarette and pneumonia&#x0201d;, &#x0201c;vaping and pneumonia&#x0201d;, &#x0201c;EVALI and vitamin E acetate&#x0201d;, &#x0201c;EVALI and tetrahydrocannabinol&#x0201d;, &#x0201c;electronic cigarette and vitamin E acetate&#x0201d;, &#x0201c;vaping and vitamin E acetate&#x0201d;, &#x0201c;electronic cigarette and tetrahydrocannabinol&#x0201d;, &#x0201c;vaping and tetrahydrocannabinol&#x0201d;, &#x0201c;electronic cigarette and acute respiratory distress syndrome&#x0201d;, &#x0201c;vaping and acute respiratory distress syndrome&#x0201d;. A literature search for regulations and policies related to electronic cigarettes was also performed. This search included the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Food and Drug Administration&#x02019;s Center for Tobacco Products (FDA-CTP), and the World Health Organization (WHO). For this review, only the papers that reported clinical case reports, physicochemical characterization of emissions generated from THC and VEA e-cigs, and <italic toggle="yes">in vivo/in vitro</italic> toxicological studies associated with the EVALI syndrome, as defined by the CDC, were included. All other studies evaluating the general health consequences of e-cigs, as well as toxicological and physicochemical characterization of emissions not directly associated with EVALI syndrome, were excluded. The search was also restricted to peer-reviewed publications in English from the years 2019&#x02013;2022.</p></sec><sec id="S3"><label>3</label><title>Results and Discussion.</title><p id="P13">A total of 3903 peer-reviewed articles were identified and then screened for duplicates. It is worth noting that editorials, commentary, notes, conference papers, and perspective papers were excluded from the review. Finally, 186 peer-reviewed articles specifically related to EVALI, THC, and VEA were identified and reviewed. Among these articles, 161 were medical reports, including 85 clinical case reports, 59 clinical case series, 17 epidemiological reports, and 25 were research articles addressing the physicochemical (18 studies) and toxicological (7 studies) characterization of the e-cig liquids or vapors. In more detail:</p><sec id="S4"><label>3.1</label><title>Demographic pattern, prior medical history, and symptoms manifestation of EVALI patients.</title><p id="P14">The analysis of the patients from the 161 medical reports showed that the predominant demographic pattern of the EVALI patients is a healthy white male, adolescent, or young adult. In more detail, among the 15,748 cases reported and summarized in <xref rid="SD1" ref-type="supplementary-material">supplemental Table S1</xref>, 65% of patients were males, and 35% females (<xref rid="F1" ref-type="fig">Figure 1A</xref>). 37% of 15,748 patients had an age between 18 and 24 years, followed by age 25&#x02013;34 (26%), 13&#x02013;17 (17%), 35&#x02013;44 (16%), 45&#x02013;64 (16%) and over 65 (4%) (<xref rid="F1" ref-type="fig">Figure 1B</xref>). Non-Hispanic White adults (68%) were more likely than Hispanic (18%), Non-Hispanic black (14%), Non-Hispanic Asian (3%), or Native American (1%) to develop EVALI (<xref rid="F1" ref-type="fig">Figure 1C</xref>) (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R55" ref-type="bibr">Chatham-Stephens et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R169" ref-type="bibr">Lozier et al. 2019</xref>; <xref rid="R196" ref-type="bibr">Moritz et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R223" ref-type="bibr">Perrine et al. 2019</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington, et al. 2020; <xref rid="R162" ref-type="bibr">Layden J. E. et al. 2020</xref>; <xref rid="R192" ref-type="bibr">Mikosz et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>; <xref rid="R226" ref-type="bibr">Podguski et al. 2022</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>).</p><p id="P15">Interestingly, 17% of 15,748 patients were between 13 and 17 years of age, which may be related to the current spread of e-cigs among high school students (27.5%, 4.11 million, in 2019) and middle school students (10.5%, 1.24 million, in 2019) (<xref rid="R72" ref-type="bibr">Cullen et al. 2019</xref>). Despite the measures taken at the local, state, or federal level to moderate the epidemic of e-cigs among the younger population, including increasing the minimum age for purchase from 18 to 21 years (<xref rid="R69" ref-type="bibr">Congress 2019</xref>) and prohibition of attractive advertisements or packaging (<xref rid="R95" ref-type="bibr">FDA 2018</xref>), still, the number of middle or high school students currently vaping is not declining.</p><p id="P16">The case reports were also screened for pre-existing conditions. Even though the majority of EVALI patients were healthy or without any documented pre-existing condition (80% of 15,748 patients) (<xref rid="F1" ref-type="fig">Figure 1D</xref>), from the records available, some patients reported suffering from &#x0201c;one or more&#x0201d; and &#x0201c;two or more&#x0201d; chronic conditions (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; <xref rid="R192" ref-type="bibr">Mikosz et al. 2020</xref>). Specifically, among the patients that reported pre-existing conditions (n=3,171/15,748, 20%) the most common referred disorders included mental health diseases (n=1,205/3,171, 38%), of whom 30% (n=362/1,205) suffering from mental behavioral disorder, 26% (n=313/1,205) anxiety, 21% (n=253/1,205) depression, 17% (n=205/1,205) substance use disorder, and 6% (n=73/1,205) attention deficit hyperactivity disorder. In addition, among the 3,171 patients, 37% were former/current tobacco smokers, 37% were former/current marijuana smokers, and 31% reported chronic respiratory diseases (asthma, chronic obstructive pulmonary disease, obstructive sleep apnea) (<xref rid="F1" ref-type="fig">Figure 1D</xref>) (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R55" ref-type="bibr">Chatham-Stephens et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R169" ref-type="bibr">Lozier et al. 2019</xref>; <xref rid="R196" ref-type="bibr">Moritz et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R223" ref-type="bibr">Perrine et al. 2019</xref>; Aberegg, <xref rid="R64" ref-type="bibr">Cirulis, et al. 2020</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington, et al. 2020; <xref rid="R162" ref-type="bibr">Layden J. E. et al. 2020</xref>; <xref rid="R192" ref-type="bibr">Mikosz et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R237" ref-type="bibr">Regmi et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>). Other pre-existing syndromes referred to by EVALI patients were cardiovascular diseases (i.e. hypertension, heart failure, and congenital malformation), chronic pain, metabolic diseases (i.e. diabetes mellitus and obesity), gastrointestinal diseases (i.e. chronic liver diseases, gastroesophageal reflux, and inflammatory bowel diseases) (<xref rid="F1" ref-type="fig">Figure 1D</xref>), allergies, immune suppression, chronic kidney diseases, and seizures/epilepsy (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>) (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R55" ref-type="bibr">Chatham-Stephens et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R169" ref-type="bibr">Lozier et al. 2019</xref>; <xref rid="R196" ref-type="bibr">Moritz et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R223" ref-type="bibr">Perrine et al. 2019</xref>; Aberegg, <xref rid="R64" ref-type="bibr">Cirulis, et al. 2020</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington, et al. 2020; <xref rid="R162" ref-type="bibr">Layden J. E. et al. 2020</xref>; <xref rid="R192" ref-type="bibr">Mikosz et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>). The correlation between conventional cigarette smoke, chronic respiratory disease, such as asthma or chronic obstructive pulmonary disease (COPD), and EVALI is intuitive. Cigarette smoke affects almost every organ in the body, causing many diseases, including coronary heart disease, stroke, COPD, and lung cancer (<xref rid="R47" ref-type="bibr">CDC 2014</xref>). The underlying epithelial inflammatory status and lung damage due to the chemicals, irritants, and toxicants released in the cigarette smoke can sensitize the respiratory epithelium and induce a stronger response even against inhalants that are normally well-tolerated. In contrast, mental health and substance addiction have been underestimated in vapers and smokers (<xref rid="R221" ref-type="bibr">Patten 2021</xref>), and very few studies have examined the correlation between substance abuse/addiction and vaping (<xref rid="R287" ref-type="bibr">Young-Wolff et al. 2021</xref>), while none are available on the correlation with EVALI.</p><p id="P17">The initial EVALI manifestation, that drove the patients to the emergency department, was unspecific, but included respiratory, gastrointestinal, and constitutional symptoms (fever, weight loss, fatigue, etc.), resembling the general presentation of a relatively acute viral disease (<xref rid="F1" ref-type="fig">Figure 1E</xref>) (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R55" ref-type="bibr">Chatham-Stephens et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R169" ref-type="bibr">Lozier et al. 2019</xref>; <xref rid="R196" ref-type="bibr">Moritz et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R223" ref-type="bibr">Perrine et al. 2019</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington, et al. 2020; <xref rid="R162" ref-type="bibr">Layden J. E. et al. 2020</xref>; <xref rid="R192" ref-type="bibr">Mikosz et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R226" ref-type="bibr">Podguski et al. 2022</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>). In particular, 95% of the 15,748 patients experienced respiratory symptoms, more frequently including dyspnea and cough (&#x0003e;80% of 15,748), accompanied by chest pain, hemoptysis, dyspnea on exertion, and/or wheezing. In addition, 80% of the 15,748 patients reported gastrointestinal symptoms, characterized primarily by emesis and nausea, followed by diarrhea, and abdominal pain. Lastly, 86% of the 15,748 patients manifested constitutional symptoms, including fever, fatigue, chills, weight loss, night sweats, headache, and myalgia (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>) (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R55" ref-type="bibr">Chatham-Stephens et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R169" ref-type="bibr">Lozier et al. 2019</xref>; <xref rid="R196" ref-type="bibr">Moritz et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R223" ref-type="bibr">Perrine et al. 2019</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington, et al. 2020; <xref rid="R162" ref-type="bibr">Layden J. E. et al. 2020</xref>; <xref rid="R192" ref-type="bibr">Mikosz et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>; <xref rid="R226" ref-type="bibr">Podguski et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>). The duration of symptoms before hospitalization was generally 20 days (range 1&#x02013;240 days) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>) (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R55" ref-type="bibr">Chatham-Stephens et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; <xref rid="R192" ref-type="bibr">Mikosz et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>).</p></sec><sec id="S5"><label>3.2</label><title>Clinical presentation: signs and symptoms of EVALI.</title><p id="P18">The 161 identified medical case reports present a complete clinical history of 1160 cases of EVALI. Their main findings are summarized in <xref rid="T1" ref-type="table">Tables 1</xref>&#x02013;<xref rid="T4" ref-type="table">4</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>.</p><p id="P19"><xref rid="T1" ref-type="table">Table 1</xref> provides a summary of the clinical presentation of the EVALI patients, at their first admission to the emergency department or urgent care facility.</p><p id="P20">The observed acute lung injury was associated with a heterogeneous pattern of clinical signs and symptoms, including temperature &#x02265;38 &#x000b0;C, heart rate &#x0003e;100 beats/min, respiratory rate &#x0003e;20 breaths/min, oxygen saturation &#x0003c;95% on room air or with supplemental oxygen, leukocytosis with neutrophil predominance, increased inflammatory biomarkers [including erythrocyte sedimentation rate (ESR) &#x0003e;30 mm/hr, C-reactive protein (CRP)&#x0003e; 10 mg/l, procalcitonin &#x0003e;0.07 ng/ml, lactate dehydrogenase (LDH) &#x0003e;280 U/L and pro-BNP &#x0003e;125 pg/ml], and absence of bacterial, viral or fungal infection, or autoimmune disease (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SD1" ref-type="supplementary-material">S1</xref>). Lung auscultation was positive for diffuse bibasilar crackles, wheezes, or rhonchi; when performed, the pulmonary function test revealed either an obstructive or a restrictive pattern, while the arterial blood gas analysis was mostly diagnostic for a primary respiratory alkalosis, both documented only in a few patients. Interestingly, the urine toxicological screening was reported only in a small number of case reports, and it resulted often positive for cannabinoid use. (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SD1" ref-type="supplementary-material">S1</xref>)</p><p id="P21">The heterogeneity of clinical signs and symptoms was reflected in the varying pathologic findings, at chest radiograph and CT, BAL, and lung biopsy (<xref rid="T2" ref-type="table">Tables 2</xref>&#x02013;<xref rid="T4" ref-type="table">4</xref> and <xref rid="SD1" ref-type="supplementary-material">S1</xref>). While chest radiographs and CT scan findings are variable in 929 EVALI patients, they showed a predominant pattern characterized by diffuse bilateral ground-glass opacity (71%, n=661), parenchymal consolidation (12%, n=111) bilateral parenchymal/nodular opacities (24%, n=228), bilateral interstitial infiltrates (19%, n=175), interlobular septal thickening (17%, n=158) and pleural/subpleural sparing (43%, n=399). Very few cases have been described showing bilateral pleural effusion (11%, n=106), pneumothorax (2%, n=20), pneumo-mediastinum (4%, n=38), mediastinal/hilar lymphadenopathy (16%, n=147), and pulmonary emboli (0%, n=3). (<xref rid="T2" ref-type="table">Table 2</xref>).</p><p id="P22">In a cohort of 304 patients (<xref rid="T3" ref-type="table">Table 3</xref> and <xref rid="SD1" ref-type="supplementary-material">S1</xref>), bronchoscopy and collection of broncho-alveolar lavage fluid (BALF) showed the absence of any infectious agent (bacteria, virus, and fungi), fundamental for the exclusion of any other possible cause of disease. The cytological findings revealed a non-specific cellular pattern, characterized by increased total cell count with the predominance of neutrophils (38%, n=120), macrophages (22%, n=68), lymphocytes (3%, n=10), or eosinophils (2%, n=7), which was not revealing in the diagnosis of EVALI. The increased number of red and white blood cells was registered in 7% (n=21) and 7% (n=22) of patients respectively. In contrast, a more common finding in BAL of EVALI patients was the lipid-laden macrophages reported in 50% (n=158) of patients.</p><p id="P23">The presence of lipid-laden macrophages in the alveolar or interstitial spaces of vaping patients was first noted in a case of acute lung injury in 2012 (<xref rid="R185" ref-type="bibr">McCauley et al. 2012</xref>), and subsequently, it was commonly detected in the BAL of EVALI patients, which initially misguided the physicians toward the diagnosis of exogenous lipoid pneumonia, possibly correlated to the presence of VEA in the e-cigs. This finding was later found to be not specific to EVALI, since it was detected also in the BAL of healthy adult smokers, e-cig users, and never-smokers (<xref rid="R252" ref-type="bibr">Shields Peter G et al. 2020</xref>), and was not always consistent with histopathological or radiological evidence of exogenous lipoid pneumonia (<xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>).</p><p id="P24">On 85 BALF samples out of 313, chemical analysis was also performed aimed at detecting the presence of a causative agent such as THC, VEA, nicotine, or metabolites. THC, VEA, and nicotine were detected in 70 (82%), 82 (96%), and 46 (54%) samples respectively. (<xref rid="R38" ref-type="bibr">Blount et al. 2019</xref>; <xref rid="R262" ref-type="bibr">Taylor et al. 2019</xref>; <xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>); other chemicals were found in BALF and were probably associated with EVALI symptoms, like cannabinoid (CBD) oils, coconut oil, and terpenes, such as limonene (<xref rid="R38" ref-type="bibr">Blount et al. 2019</xref>; <xref rid="R262" ref-type="bibr">Taylor et al. 2019</xref>; <xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>). (<xref rid="T3" ref-type="table">Table 3</xref> and <xref rid="SD1" ref-type="supplementary-material">S1</xref>)</p><p id="P25">The cyto- and histo- pathological assessments through the trans-bronchial lung biopsy, summarized in <xref rid="T4" ref-type="table">Table 4</xref> and <xref rid="SD1" ref-type="supplementary-material">S1</xref>, showed a variety of patterns including acute lung injury, diffuse alveolar damage, and organizing pneumonia in 21%, 25%, and 46% (total cases n=249) respectively, accompanied by foamy macrophages in airspace in 76% of the 249 cases. The most common findings were type II pneumocytes hyperplasia, acute fibrinous pneumonitis with organization, fibrinous exudates in airspaces, interstitial chronic inflammation, respiratory bronchiolitis, lymphocytic infiltration, mild interstitial fibrosis, diffuse alveolar hemorrhage, and lipoid pneumonia.</p><p id="P26">To date, neither the bronchoscopy/BALF nor the lung biopsy is required for the diagnosis of EVALI, mostly because the main purpose of these exams is the exclusion of pulmonary infection or alternative cause of disease. In this regard, the chemical analysis of the BAL can be beneficial to detect chemical toxic compounds involved in the development of EVALI (<xref rid="R42" ref-type="bibr">Brosius et al. 2022</xref>). Many variables can negatively affect the result, such as the time window between the last use of e-cigs and bronchoscopy, variation in collection technique, and fluid dilution. Nevertheless, on a small number of samples (n=85) the chemical analysis of BALF was crucial to detect THC, VEA, and nicotine (82%, 96%, and 54% of samples respectively), even when any THC use was denied, as well as other chemicals probably related to EVALI, such as cannabinoid oils, coconut oil, and terpenes, such as limonene (<xref rid="R38" ref-type="bibr">Blount et al. 2019</xref>; <xref rid="R262" ref-type="bibr">Taylor et al. 2019</xref>; <xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>). In addition, making the toxicological testing for cannabinoids routinely would be beneficial in reducing EVALI diagnosis delay, especially for those patients that hide this crucial information.</p><p id="P27">In summary, such differences in clinical and radiographic EVALI manifestation may be due to a variety of factors, including underlying conditions, individual host response to the inhaled substances, but most importantly, the diversity of toxic compounds inhaled, which are still difficult to determine, given the multitude of e-cig compositions and operating parameters of the cartridges prevalent among the vaping population.</p></sec><sec id="S6"><label>3.3</label><title>Vaping devices, e-liquids, and frequency of vaping by EVALI patients.</title><p id="P28">Among the 11,350 EVALI patients that disclosed information on vaping products and behavior, an average of 34% (n=3879) and 17% (n=54) patients reported exclusive use of THC- and nicotine-based e-cigs, respectively, while 51% (n=5742) patients reported using both THC and nicotine e-cigs (<xref rid="F2" ref-type="fig">Figure 2A</xref>). Moreover, 2% (n=227) of patients reported exclusive CBD oil e-cigs, while 8% (n=851) reported using CBD and THC, 4% (n=397) reported using CBD and nicotine, and 10% (n=1078) reported using all three substances (THC, nicotine, and CBD) in e-cigs. (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R55" ref-type="bibr">Chatham-Stephens et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R169" ref-type="bibr">Lozier et al. 2019</xref>; <xref rid="R196" ref-type="bibr">Moritz et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R223" ref-type="bibr">Perrine et al. 2019</xref>; <xref rid="R262" ref-type="bibr">Taylor et al. 2019</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington, et al. 2020; <xref rid="R229" ref-type="bibr">Pray et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>) (<xref rid="F2" ref-type="fig">Figure 2A</xref>). In addition to vaping, patients reported using combustible marijuana, combustible tobacco, or both. (<xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>)</p><p id="P29">Very few papers described in more detail the length of use, type of device, brand, and source of e-cigs or e-liquids. With regard to the type of device used among the interviewed patients, irrespective of THC or nicotine e-liquids used, the majority used disposable type of e-cigs (n=135/187, 72%), followed by reusable devices (n=63/187, 34%), reusable devices for wax or dry herbs (n= 41/187, 22%), vape rig (n=36/187, 20%), and pods for vaping salts (n=24/187, 13%).(<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R223" ref-type="bibr">Perrine et al. 2019</xref>) (<xref rid="F2" ref-type="fig">Figure 2B</xref>)</p><p id="P30">The frequency of THC vaping reported by EVALI patients is summarized in <xref rid="F2" ref-type="fig">Figure 2C</xref>. 62% (n=1677/2727) reported daily vaping use, with 54% (n=1473/2727) of them reporting between 1&#x02013;5 times/day, 43% (n=1182/2727) more than 5 times/day, and 24% (n=654/2727) more than 25 times/day. 25% (n=691/2727) reported vaping 2&#x02013;3 times/week, 6% (n=164/2727) a few times per month, and 16% (n=427/2727) monthly or less (<xref rid="F2" ref-type="fig">Figure 2C</xref>) (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R262" ref-type="bibr">Taylor et al. 2019</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R229" ref-type="bibr">Pray et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>). Regarding the duration of being an e-cig user, Baglev et al. reported that of the 23 patients examined, 43% vaped for less than 1-year, 17% vaped for 1&#x02013;2 years, 26% vaped for 2&#x02013;3 years, 13% vaped for &#x02265; 3 years. (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>) The duration of use was not correlated to the onset of symptoms. (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>)</p><p id="P31">The most common brands of THC-containing devices used were Dank Vape, followed by Rove, Golden Gorilla, Smart Carts / Exotic Carts, Chronic Carts, and Cereal Carts. (<xref rid="F2" ref-type="fig">Figure 2D</xref>). Interestingly, 81% (n=1439/1773) of them were obtained from informal sources, such as family or friend, illicit dealer, online, or out-of-state dispensary, but only 15% (n=271/1773) of THC products were purchased from formal sources, including dispensary, vape or smoke shop, pop-up shop, or grocery, drug, or convenience store. (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R229" ref-type="bibr">Pray et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>) (<xref rid="F2" ref-type="fig">Figure 2E</xref>)</p><p id="P32">Because, as mentioned before, 64% of 11,244 EVALI patients also reported the use of nicotine-containing e-liquids, the frequency of use, inhalation device, and source were investigated as well. Similarly to the THC users, 69%, of the 2100 nicotine users vaped daily, among whom 64% reported vaping frequency more than 5 times/day and 55% more than 25 times/day. (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>). (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R209" ref-type="bibr">Navon et al. 2019</xref>; <xref rid="R262" ref-type="bibr">Taylor et al. 2019</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>) The most common brands of nicotine-based devices were Juul, Njoy, and Smok, (<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R105" ref-type="bibr">Gaub et al. 2019</xref>; <xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>), more frequently (n=845/1280, 66%) purchased through formal sources (such as vape shops and convenience stores) than informal sources (n=341/1280, 27%) (online dealers, friends, out of state dispensary). (<xref rid="R108" ref-type="bibr">Ghinai et al. 2019</xref>; <xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R7" ref-type="bibr">Adkins et al. 2020</xref>; <xref rid="R88" ref-type="bibr">Ellington et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>).</p><p id="P33">Previous studies have highlighted the simultaneous increase of e-cigs and/or cannabis use and mental disorders such as depressive symptoms and suicidality in the young population, emphasizing the need for screening, prevention, and intervention strategies to help mitigate both substance abuse and mental health outcomes (<xref rid="R53" ref-type="bibr">Chadi et al. 2019</xref>). This issue is particularly relevant in those states where THC e-cigs are illegal for non-medical use, such as Utah or Minnesota, where the burden of EVALI reached the highest rate nationally (<xref rid="R166" ref-type="bibr">Lewis et al. 2019</xref>; <xref rid="R66" ref-type="bibr">Cole et al. 2021</xref>), which could be attributed to the high prevalence of illicit THC-cartridges (<xref rid="R24" ref-type="bibr">Arons et al. 2021</xref>).</p><p id="P34">No major difference was found in the use of disposable and reusable e-cigs (72% vs 56% of 187, respectively); therefore, it was not possible to correlate the type of device utilized to the specific active ingredient (THC or nicotine). Nonetheless, the commercially available reusable CCell 510 thread cartridges were most commonly associated with EVALI patients, because of the higher suitability for a thick and viscous liquid, such as THC (<xref rid="R273" ref-type="bibr">Wagner et al. 2020</xref>), high rate of availability and reproducibility in the illicit market, and high customizability by the users and manufacturers. The latter aspect is particularly important because the inappropriate manipulation of cartridges and e-liquid compositions often evades oversight from the regulatory agencies and increases the likelihood of generating and inhaling toxic chemical vapors.</p><p id="P35">As clearly stated by the Centers for Disease Control and Prevention (CDC), much crucial information is missing due to the lack of a standardized data collection methodology, which generates an obvious inconsistency. The information on patients&#x02019; demographics and vaping behavior was collected through anonymous surveys or telephone interviews taken from the patients or their families. The applied methodologies give space to a lot of intrinsic bias, such as selection bias, recall bias, response bias, and social desirability bias. In addition, the patients or their families were not always aware of the chemical substances contained in the cartridges, especially because the majority of vaping products were obtained from an illicit/informal source, leading to unreliable reporting. In addition, reporting potentially mislabeled cartridges leads to exposure&#x02019;s misclassification errors in epidemiological studies. For all these reasons, it is difficult to draw strong and generalizable conclusions about the factors responsible for the evolution of EVALI.</p><p id="P36">A more accurate characterization of the vaping history is needed, especially in the younger population, including start date, last use, and method of use (aerosol, dabbing or dripping), length and frequency of vaping, device type (refillable or disposable), product brand name, source of THC- or nicotine-containing products, relative composition of the e-liquid components, number of cartridges consumed per day and volume of e-liquids vaped per day. Current or former use of combustible tobacco or marijuana or other substance abuse should be included as well.</p></sec><sec id="S7"><label>3.4</label><title>Physicochemical characterization of emissions from vaping.</title><p id="P37">The topic of physicochemical characterization of emissions from e-cigs has been widely studied since their release in the global market in 2007 and the complex chemistry of the emissions is well-documented (<xref rid="R178" ref-type="bibr">Margham et al. 2016</xref>; <xref rid="R290" ref-type="bibr">Zhao et al. 2016</xref>; <xref rid="R228" ref-type="bibr">Pourchez et al. 2018</xref>; <xref rid="R289" ref-type="bibr">Zhao, Nelson, et al. 2018</xref>; <xref rid="R291" ref-type="bibr">Zhao, Zhang, et al. 2018</xref>; <xref rid="R86" ref-type="bibr">El-Hellani et al. 2019</xref>; <xref rid="R89" ref-type="bibr">Erythropel et al. 2019</xref>; <xref rid="R215" ref-type="bibr">Omaiye et al. 2019</xref>; <xref rid="R260" ref-type="bibr">Strongin 2019</xref>; <xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>; <xref rid="R211" ref-type="bibr">Nicol et al. 2020</xref>). Of special note is the lack of regulations concerning manufacturing and commercialization of e-cig devices. As a result, a plethora of devices is available including widely customizable ones in terms of temperature, operational voltage, puffing duration, and e-liquid composition. This enormous variability makes it difficult to characterize the emissions physicochemically and toxicologically and to generalize or predict their potential health risks.</p><p id="P38">Furthermore, the available literature on the topic is limited to the physicochemical characterization of emissions from nicotine-based e-liquids, while very little is known for the case of THC, VEA, or their combination-based e-liquids. We found only ten studies focusing on the characterization of real-world liquids or emissions from <bold>counterfeit or patient-provided</bold> cartridges (<xref rid="T5" ref-type="table">Table 5</xref>), and nine on the characterization of gas and particles released from <bold>in-house prepared</bold> e-cigs containing VEA or THC/VEA. (<xref rid="T8" ref-type="table">Table 6</xref>).</p><p id="P39">On a special note, the physical inspection of the patient-provided cartridges exhibited severe burn marks, probably due to the high operating voltage and the resulting high temperature of the e-liquid. Nickel and chromium heating coils were detected in all devices, along with other metals present in the filaments, battery contact, and ceramics. Other metals identified included Cu, Pb, Au, Fe, Zr, Si, Al, Na, K, Ni, Sn (<xref rid="R273" ref-type="bibr">Wagner et al. 2020</xref>; <xref rid="R112" ref-type="bibr">Gonzalez-Jimenez et al. 2021</xref>). Other substances also found were phosphorus (P), silicon-rich rubbers, or fluorinated microplastics. Their presence in the e-cig cartridges raises concerns in terms of potential chemicals released during the vaping phase (<xref rid="R273" ref-type="bibr">Wagner et al. 2020</xref>).</p><p id="P40">The first investigation on the chemical composition of e-liquids from 38 samples collected from the first 10 New York cases of EVALI showed that compared to the marijuana medical products, the illicit cartridges contained a low concentration of cannabinoids (50% vs 80&#x02013;90% in marijuana medical products), along with an unusual ratio of &#x00394;<sup>9</sup>THC/&#x00394;<sup>8</sup>THC isomers, due to the high volume of the synthetic &#x00394;<sup>8</sup>THC. In addition, high concentrations of diluents, such as VEA (64% of samples - concentration range 16&#x02013;58%) and MCT (41% of samples - concentration range 3&#x02013;24%) were also detected. (<xref rid="R83" ref-type="bibr">Duffy B et al. 2020</xref>) This trend was confirmed by further and later investigation nationwide, that showed the presence of additional cannabinoids in the EVALI patient-provided cartridges as well as in the aerosol generated from them, such as cannabichromene (CBC), cannabidiol (CBD) cannabidivarin (CBDV), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabinol (CBN), tetrahydrocannabinolic acid (THCA) and tetrahydrocannabivarin (THCV) (<xref rid="R63" ref-type="bibr">Ciolino, Ranieri, et al. 2021</xref>; <xref rid="R84" ref-type="bibr">Duffy BC et al. 2021</xref>; <xref rid="R116" ref-type="bibr">Guo et al. 2021</xref>; <xref rid="R171" ref-type="bibr">Lu SJ et al. 2021</xref>). All the illicit/patient-ptovided cartridges were found to contain various concentration of VEA, MCT, polyethylene glycol used as diluents either in combination or alone. (<xref rid="R62" ref-type="bibr">Ciolino, Falconer, et al. 2021</xref>; <xref rid="R84" ref-type="bibr">Duffy BC et al. 2021</xref>; <xref rid="R116" ref-type="bibr">Guo et al. 2021</xref>; <xref rid="R171" ref-type="bibr">Lu SJ et al. 2021</xref>). The most common terpenes reported were caryophyllene, limonene, myrcene (<xref rid="R171" ref-type="bibr">Lu SJ et al. 2021</xref>) (<xref rid="T5" ref-type="table">Table 5</xref>).</p><p id="P41">Numerous chemicals were identified in the e-liquids contained in counterfeit cartridges used by EVALI patients, including pesticide residues (such as myclobutanil and piperonyl butoxide-<italic toggle="yes">d</italic><sub><italic toggle="yes">9,</italic></sub> bifenazate, bifenthrin), 2,2-dimethoxybutane, tetramethyl silicate, decane, methyl esters, ethyl esters, siloxanes, and acetates, as well as pine rosin acids, pine rosin derived methyl esters, dipropylene glycol dibenzoate isomers, and sucrose acetate isobutyrate compounds, (<xref rid="R203" ref-type="bibr">Muthumalage, Friedman, et al. 2020</xref>; <xref rid="R62" ref-type="bibr">Ciolino, Falconer, et al. 2021</xref>; <xref rid="R171" ref-type="bibr">Lu SJ et al. 2021</xref>) (<xref rid="T5" ref-type="table">Table 5</xref>).</p><p id="P42">Chemicals detected in the emissions generated from counterfeit cartridges included n-butane, benzene, xylene, pentene, ethanol, acetone, ethylbenzene and toluene, PCP-polycaprolactone/household constituents (e.g. methacrolein, acetaldehyde, crotonaldehyde, formaldehyde etc.), other toxic compounds (e.g. acrolein, pentadiene compounds, hexane compounds, methyl vinyl ketone, etc.), and elements such as Si, Cu, Ni, and Pb (<xref rid="R203" ref-type="bibr">Muthumalage, Friedman, et al. 2020</xref>; <xref rid="R112" ref-type="bibr">Gonzalez-Jimenez et al. 2021</xref>; <xref rid="R186" ref-type="bibr">McGuigan et al. 2022</xref>) (<xref rid="T5" ref-type="table">Table 5</xref>).</p><p id="P43">The majority of the detected chemicals, such as hydrocarbons, silicon conjugates and derivates, and VOCs, are known to be respiratory irritants, depressants, and paralytic agents, which could potentially cause dyspnea, chest tightness, and pulmonary edema (common symptoms among EVALI patients) (<xref rid="R94" ref-type="bibr">FDA 2012</xref>; <xref rid="R203" ref-type="bibr">Muthumalage, Friedman, et al. 2020</xref>; <xref rid="R186" ref-type="bibr">McGuigan et al. 2022</xref>). These chemicals can also physically interact with phospholipids and surfactants, inducing chemical pneumonitis, and interstitial and alveolar alterations, such as alveolar-capillary membranes dysfunction, pulmonary edema, and surfactant alteration, representative of acute lung injury (<xref rid="R187" ref-type="bibr">McKee et al. 2015</xref>). In addition, the identification of solvents, such as n-butane, a gaseous petroleum compound used in the illicit cartridge to increase the amount of THC released and retained in the lung (<xref rid="R270" ref-type="bibr">Varlet et al. 2016</xref>; <xref rid="R203" ref-type="bibr">Muthumalage, Friedman, et al. 2020</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>), could be accounted for the atypical/eosinophilic pneumonia, acute lung injury and pulmonary edema, as described in some EVALI cases (<xref rid="R20" ref-type="bibr">Anderson R. P. and Zechar K. 2019</xref>; <xref rid="R259" ref-type="bibr">Stephens et al. 2020</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>).</p><p id="P44">FDA&#x02019;s preliminary lab analysis, dated February 12, 2020, reported that among the 1090 samples collected from vaping devices and products containing liquid, packaging, or other documentation, related to the EVALI patients, 511 (50%) contained THC, 50% of which were diluted with VEA, in a concentration between 23% and 88%, while 29% of them were diluted with MCT. Moreover, through the chemical analysis of 677 out of the 1090 samples, directly linked to 95 EVALI patients identified with CDC case numbers, it was determined that 73% patients were exposed to THC, and among them, 81% were also exposed to VEA, 32% to aliphatic esters (e.g. triglycerides), and 9% to polyethylene glycol. (<xref rid="R99" ref-type="bibr">FDA 2020c</xref>)</p><p id="P45">Based on the presence of VEA in BAL and the liquids of THC-based e-cigs from EVALI patients (<xref rid="R83" ref-type="bibr">Duffy B et al. 2020</xref>; <xref rid="R98" ref-type="bibr">FDA 2020b</xref>; <xref rid="R203" ref-type="bibr">Muthumalage, Friedman, et al. 2020</xref>), the federal agencies, CDC and FDA, declared in the early 2020 THC and VEA the two most presumable causative agents of EVALI, even in the absence of strong mechanistic hypothesis of disease. Since then, few studies have investigated the physical and chemical properties of particles and gaseous byproducts generated from THC and VEA pyrolysis, summarized in <xref rid="T8" ref-type="table">Table 6</xref>. Indeed, we found only three papers attempting the analysis of the aerosol generated from VEA, THC, and their mixtures, (<xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>; <xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>; <xref rid="R190" ref-type="bibr">Mikheev and Ivanov 2022</xref>), while nine papers investigated the chemical analysis of liquid and vapors generated from various combination of THC, VEA, Terpenes (<xref rid="R188" ref-type="bibr">Meehan-Atrash et al. 2019</xref>; <xref rid="R160" ref-type="bibr">Lanzarotta et al. 2020</xref>; <xref rid="R172" ref-type="bibr">Lynch et al. 2021</xref>; <xref rid="R190" ref-type="bibr">Mikheev and Ivanov 2022</xref>), and two addressed the physical and chemical analysis of aerosol emitted by pyrolysis of VEA alone (<xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>; <xref rid="R154" ref-type="bibr">Kovach et al. 2021</xref>) or single diluents, either as liquid or vapor (<xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>).</p><p id="P46">The aerosol characterization showed that on average, the emitted particle number concentration in the vapors ranged from 10<sup>6</sup> to 10<sup>8</sup> particles/cm<sup>3</sup>, while the count median diameter varied from 50 to 200 nm, depending upon the device type, heating power, and puffing topography. Interestingly, for the case of VEA 100%, as the flow rate or the voltage increased, the count median diameter decreased while the particle number concentration increased (<xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>; <xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>; <xref rid="R190" ref-type="bibr">Mikheev and Ivanov 2022</xref>). The total number concentration, mean and modal aerosol size of particles generated from different combinations of D8THC/VEA/Terpenes varied also according to the e-liquid composition and voltages, but without any apparent specific trend. The released VOC and total PM mass concentration significantly rose with increasing e-liquid VEA concentration and operational voltages. Specifically, the concentration of VOCs increased linearly or exponentially with time, within a range between 0.173 and 24.5 ppm, while the total PM mass concentration ranged widely between 67 and 910 mg/m<sup>3</sup>, with the bulk of PM mass distributed between the PM<sub>0.1</sub> and PM<sub>0.1&#x02013;2.5</sub>; in both cases, the higher number was reached by emissions from VEA 100% at 5V. (<xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>) (<xref rid="T8" ref-type="table">Table 6</xref>) The only three studies addressing the physical properties of the particles emitted from the pyrolysis of e-liquids containing different concentrations of THC, VEA and Terpenes confirmed that the e-liquid composition, device type, heating power, and puffing topography influenced the aerosol particles&#x02019; size and concentration (<xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>; <xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>). Although these studies represent a first attempt to clarify the possible link between the nanoparticles released from e-cigs and EVALI, they highlighted the concept that there is a significant difference between vapors generated from individual e-liquid components (ie, VEA 100%) and e-liquid mixture (ie, &#x00394;8THC + VEA + Terp): the combination of VEA with THC and terpenes would certainly affect the physical characteristics of released particles (size and number concentration) and induce chemical heterogeneity in the released particles and gaseous byproducts.</p><p id="P47">Lanzarotta et al investigated the chemical properties of vapor generated from the combination THC/VEA (~50:50 w/w) from a CCell cartridge connected to a vaping device, operated at 3.7V, with a puff duration of 4 seconds and an interval between puffs of 30 seconds, sampled at flow rate 1.0 liter/min, mimicking the real-word exposure. The main finding of the study was that the THC/VEA liquids exhibit sufficient chemical differences compared to the individual THC and VEA controls, and the chemical spectrum generated from the pure VEA vapor exhibited a carbonyl peak, similar to THC/VEA, which was absent in the case of THC-only vapor spectrum. (<xref rid="R160" ref-type="bibr">Lanzarotta et al. 2020</xref>) A similar study was subsequently performed by Lynch et al. Starting from the same e-liquid composition (THC/VEA ~50:50 w/w) and puffing topography (puff duration 4 sec, interval 30s, flow 1L/min), they measured the coil temperature at increasing operational voltages, from 3.0 V to 4.5 or 5V, using 6 in-house prepared cartridges, as well as one black-market cartridge and 1 &#x0201c;authentic&#x0201d; cartridge containing D9THC from EVALI investigations (<xref rid="R172" ref-type="bibr">Lynch et al. 2021</xref>). Regardless of the type of cartridges, the following degradant products were identified in the emitted vapors: D9THC, VEA, 1-pristene, durohydroquinone monoacetate (DHQMA), 4-acetoxy-2,3,5trimethyl-6-methylene-2,4-cyclohexadienone (ATMMC). However, as intuitively expected, they also measured a voltage-dependent increase of the coil temperature during vaping: from a range of 217&#x02013;300&#x000b0;C at 3.0 V to 415&#x02013;476&#x000b0; C at 5.0 V for the in-house prepared cartridges, to 454&#x02013;510&#x000b0;C at 5.5 V and 548&#x02013;632&#x000b0;C at 6V for black-market and authentic cartridges. (<xref rid="R172" ref-type="bibr">Lynch et al. 2021</xref>) This temperature trend was further confirmed by Mikheev at al, who reported a coil temperature rise dependent on chemical liquids and temperature setting. Specifically, the authors used the &#x0201c;Kind Dream&#x0201d; vape pen, loaded with combination of THC 100%, THC/VEA 50%/50% w/w or VEA 100% and operated at 2 different temperature settings, low (177&#x000b0;C) and high (221&#x000b0;C), following a puffing protocol of 5 sec puff, 60 sec interval for 8 puffs. Interestingly, they found that regardless of the e-liquid composition, when operated at low temperature (177&#x000b0;C), the coil temperature was stably below 250&#x000b0;C; increasing the operational temperature to 221&#x000b0;C led to a rise of coil temperature up to 500&#x02013;550&#x000b0;C, that was faster in cartridges containing the higher concentration of VEA (50%&#x02212;100%). (<xref rid="R190" ref-type="bibr">Mikheev and Ivanov 2022</xref>)</p><p id="P48">In order to characterize the production of VOCs and other harmful and potentially harmful constituents (HPHCs) from THC pyrolysis, Meehan-Atrash et al. investigated the chemical composition of vapors generated from dabbing pure THC or the synthetic distillate THC:terpenes 90:10 v/v, compared to the vapor generated from vaping the mixture THC/Terpenes 90:10 v/v using a CCell cartridge vaporizer, operated at 3 voltages, 3.2 V, 4.0 V, and 4.8 V, with 1 puff of 55 ml volume over 3 seconds. The adsorption/thermal desorption gas chromatography&#x02212;mass spectrometry (ATD-GCMS) helped to selectively identify the following chemical species in the gas phase: methacrolein, benzene, xylenes, toluene, styrene, ethylbenzene, isoprene, other non-target hydrocarbons, and total VOCs. Interestingly, as shown also by <xref rid="R180" ref-type="bibr">Marrocco et al. (2022)</xref> the relative amount of each species, as well as the other hydrocarbons, and total VOCs, increased depending on e-liquid composition (THC vs THC/Terpenes) and the operating voltage (when compared among the three vaping voltage conditions) (<xref rid="R188" ref-type="bibr">Meehan-Atrash et al. 2019</xref>).</p><p id="P49">Jiang et al. studied the vaping emission products from commonly used liquid diluents, such as propylene glycol (PG), vegetable glycerin (VG), VEA, vitamin e (VE), MCT oil, squalane (SQL), and triethyl citrate (TEC). It is worth noting that this study does not represent the real-world human exposures (cartridges containing only diluents are not commercially available). However, it was confirmed that the chemical composition of aerosols is very different from their parent e-liquid, due to the formation of new by-products during the vaping process. The detected new products included carbonyls, alkyl alcohols, esters, carboxylic acids, and short-chain alkanes, likely resulting from thermal decomposition and oxidation of liquid diluents. In particular, VEA and VE released carbonyls, long-chain alcohols, and quinone-like products (<xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>).</p><p id="P50">From the analysis of the degradation products of VEA 100% or THC/VEA 50%/50% pyrolysis, several products were identified. In the vapors generated from VEA 100%, the most common by-products were 1-pristene, durohydroquinone monoacetate (DHQMA), duroquinone (DQ),, while 2,6,10,14-tetramethyl-1-pentadecene (TMPD) was not confirmed (<xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>; <xref rid="R154" ref-type="bibr">Kovach et al. 2021</xref>); in addition, in vapor generated from combination of THC/VEA 50%/50%, but not in VEA 100%, 4-acetoxy-2,3,5trimethyl-6-methylene-2,4-cyclohexadienone (ATMMC) was also found (<xref rid="R172" ref-type="bibr">Lynch et al. 2021</xref>) (<xref rid="T8" ref-type="table">Table 6</xref>).</p><p id="P51">In summary, the main finding of the presented studies is that there is a substantial difference in the chemical composition and structure between the parent e-liquid and the generated vapors (<xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>; <xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>), and between the vapors generated from a single e-cig constituent compared to the vapors from real-world e-liquid mixtures (<xref rid="R188" ref-type="bibr">Meehan-Atrash et al. 2019</xref>; <xref rid="R160" ref-type="bibr">Lanzarotta et al. 2020</xref>; <xref rid="R172" ref-type="bibr">Lynch et al. 2021</xref>; <xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>; <xref rid="R190" ref-type="bibr">Mikheev and Ivanov 2022</xref>). Although the process toward understanding the possible cause of EVALI starts with the identification of the e-liquids ingredients, it is not useful, besides being unrealistic, to rely only on the e-liquids&#x02019; physicochemical properties aiming to clarify the mechanistic pathway of EVALI, since it is clear that the thermal degradation generates byproducts with substantial differences from the parental e-liquids, and increases the likelihood of having a mixture of toxic chemicals in the vapor, which can exert synergistic effects on the respiratory system, and potentially leading to the development of EVALI.</p><p id="P52">An interesting hypothesis on the causative agent of EVALI has been the possibility of the release of ketene from the thermal degradation of VEA. Ketene is a highly reactive and highly toxic molecule, produced by cleavage of the acetate group from the whole VEA molecule (Committee on Acute Exposure Guideline Level et al. ; <xref rid="R208" ref-type="bibr">National Institute for Occupational Safety and Health NIOSH 1994</xref>). Although very few and historic studies have documented that the minimum lethal in-air concentration of ketene is 200 ppm, causing death after single 10-min inhalation exposure in primates, and concentrations as low as 5 ppm can trigger severe alveolar damage and secondary cerebral anoxia 24 h after inhalation in humans and animals (Committee on Acute Exposure Guideline Level et al. ; <xref rid="R268" ref-type="bibr">Treon et al. 1949</xref>; <xref rid="R208" ref-type="bibr">National Institute for Occupational Safety and Health NIOSH 1994</xref>), to date, the role of ketene in the development of EVALI, its generation in the vaping process, and consequently its presence in the BAL are still unknown. Indeed, the chemical analysis of VEA and VE vaping emissions under real-world vaping conditions did not identify the presence of ketene (<xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>; <xref rid="R285" ref-type="bibr">Wu and O&#x02019;Shea 2020</xref>; <xref rid="R190" ref-type="bibr">Mikheev and Ivanov 2022</xref>). Recently, few studies have addressed the possibility to generate ketene in the vaping atmosphere, however many discrepancies have been characterized: 1) the difference between the VEA boiling point 220&#x002da;C, and the temperature at which e-cigs typically operate, 170&#x000b0;C, in a wet-through-wick condition (<xref rid="R58" ref-type="bibr">Chen W et al. 2018</xref>; <xref rid="R79" ref-type="bibr">Dibaji et al. 2018</xref>); 2) the high power (30W or 50W - 11.0 or 15.5 A, respectively) (<xref rid="R285" ref-type="bibr">Wu and O&#x02019;Shea 2020</xref>) or high temperature (700&#x000b0;C-1000&#x000b0;C) (<xref rid="R207" ref-type="bibr">Narimani and da Silva 2020</xref>) of VEA pyrolysis necessary to generate ketene not comparable with the power and temperature of real-world e-cigs (3.6 V, 9.4 W, 2.5 A), at which ketene was not detectable in vaping emissions (<xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>). Nevertheless, Narimani et al revealed that such high temperatures could be reached in &#x0201c;dry-hits&#x0201d; conditions, i.e. in those devices where the temperature is not automatically adjusted based on the e-liquid level, and lower e-liquid levels increase the operating temperature (<xref rid="R207" ref-type="bibr">Narimani and da Silva 2020</xref>). This information is particularly important if related to the fact that THC counterfeit vaping cartridges from EVALI patients showed severe burn marks (extensive charred, blackened material on the inside and outside of the oil-soaked ceramics and insulation), distinctive signs of devices that were operating at very high internal temperatures (<xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>).</p><p id="P53">To better understand and predict the lung response to the e-cig emissions, it is of great importance to understand the chemical and physical properties of vapors, including both the gaseous and particulate phase, and their diffusion/deposition patterns in the various regions of the respiratory tract, that can help explain the distinctive health effects from such complex exposures. The lack of standardized methodologies and platforms to generate and characterize vaping emissions under real-world consumer vaping conditions prevents the generation of reliable and generalizable physicochemical data, which are necessary to understand the etiopathogenesis of EVALI.</p></sec><sec id="S8"><label>3.5</label><title>Toxicological studies related to EVALI</title><p id="P54">While the toxicological properties of aerosols emitted from nicotine-based e-cigs have been under investigation in the last decade, there is still a limited number of studies focusing on the <italic toggle="yes">in vivo/in vitro</italic> toxicity of vapors generated from THC/VEA e-cigs associated with EVALI syndrome. Indeed, very few studies have focused on the toxicity of aerosols emitted from the use of pure VEA or other diluents, while only one study has investigated the effect of THC/VEA pyrolysis byproducts (including both particles and vapors) on lung epithelial cells, thus highlighting a major knowledge gap preventing the understanding of the mechanistic pathways leading to EVALI.</p><p id="P55"><xref rid="T9" ref-type="table">Table 7</xref> summarizes the most relevant studies published since 2019 focusing on the <italic toggle="yes">in vitro/in vivo</italic> toxicological characterization of the aerosols generated from e-liquids containing THC/VEA, CBD, and other common diluents, aiming to find a causative link to EVALI. Among them, five studies assessed the acute cytotoxic effect of counterfeit CBD or commonly used liquid diluents, including PG, VG, MCT, VEA, as either e-liquids or vapors, either <italic toggle="yes">in vivo</italic> (C57BL/6NCr mice) (<xref rid="R35" ref-type="bibr">Bhat et al. 2020</xref>; <xref rid="R182" ref-type="bibr">Matsumoto et al. 2020</xref>; <xref rid="R204" ref-type="bibr">Muthumalage, Lucas, et al. 2020a</xref>; <xref rid="R183" ref-type="bibr">Matsumoto et al. 2022</xref>) or <italic toggle="yes">in vitro</italic> (human bronchial epithelial cells, human monocytes, human lung fibroblasts cells, human primary AT-II cells) (<xref rid="R206" ref-type="bibr">Muthumalage and Rahman 2019</xref>; <xref rid="R35" ref-type="bibr">Bhat et al. 2020</xref>; <xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>; <xref rid="R182" ref-type="bibr">Matsumoto et al. 2020</xref>; <xref rid="R204" ref-type="bibr">Muthumalage, Lucas, et al. 2020a</xref>). Their findings revealed that the aerosols could induce a varying degree of cytotoxicity, barrier dysfunction, and inflammation <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> depending on e-liquid composition, puffing protocol, operational voltage, and cell lines. Acute (24 h) <italic toggle="yes">in vitro</italic> exposure of human bronchial epithelial cells (BEAS-2B or 16-HBE) or human monocytes cells (MM6) to aerosols generated from MCT, VEA or CBD, induced a substantial secretion of pro-inflammatory cytokines such as IL-6, IL-8, Eotaxin, MCP-1, CXCL1, and CXCL2, massive generation of reactive oxygen species (ROS), increased cytotoxicity and lactate dehydrogenase (LDH) release (<xref rid="R206" ref-type="bibr">Muthumalage and Rahman 2019</xref>; <xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>; <xref rid="R204" ref-type="bibr">Muthumalage, Lucas, et al. 2020a</xref>).</p><p id="P56">Mice challenged with VEA, MCT or CBD e-cig vapors from 3 to 15 or 28 days also exhibited increased inflammatory markers, such as IL-6, IL-8, Eotaxin, G-CSF, and MCP-3, and reduction of RANTES, IL-4, IL-17A, and IL-12p40, accompanied by the presence of VEA in the BAL (only in the VEA-treated mice), the disruption of alveolar-capillary barrier, progressive increase of BAL total fluid volume, total cell count (mono/macrophages and neutrophils), increased total protein (including albumin), presence of large vacuolated macrophages, decreased lung surfactant protein A or increased surfactant protein-D, and alteration of lipidomic profile (<xref rid="R35" ref-type="bibr">Bhat et al. 2020</xref>; <xref rid="R182" ref-type="bibr">Matsumoto et al. 2020</xref>; <xref rid="R204" ref-type="bibr">Muthumalage, Lucas, et al. 2020a</xref>; <xref rid="R183" ref-type="bibr">Matsumoto et al. 2022</xref>). The lung parenchymal alteration was represented by alveolar and parenchymal inflammation in a bronchiolocentric pattern with an increased number of monocytes and neutrophils, and large, foamy and vacuolated macrophages, also associated with alveolar septal thickening and pulmonary blood vessels surrounded by lymphocyte-rich cell aggregates (<xref rid="R35" ref-type="bibr">Bhat et al. 2020</xref>; <xref rid="R183" ref-type="bibr">Matsumoto et al. 2022</xref>). (<xref rid="T9" ref-type="table">Table 7</xref>)</p><p id="P57">We found only one research study that systematically investigated the <italic toggle="yes">in vitro</italic> toxicity of aerosol generated from real-world combination of D8THC/VEA/Terpenes, operated at 2 different voltages (3.7 and 5V). Using 2 physiologically relevant cell lines, Calu 3 human lung epithelial cells and THP-1 human monocytes, Marrocco et al investigated the cytotoxic effect of 2 doses of the collected vapors, representative of 1 and 3 months vaping exposure. Overall, the aerosol generated from D8THC 36% + VEA 54% + Terpenes 10% was the most bioactive, on both cell lines, as demonstrated by the increased LDH release, increased ROS generation (only in THP-1), significant decrease in mitochondrial membrane potential, and increase in caspase 3 activation, and upregulation of a limited number of pro-inflammatory markers, while suppressing the majority of them. (<xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>)</p><p id="P58">From the studies analyzed, while it is clear that the injury of the alveolar epithelium is crucial in the pathogenesis of EVALI, it is still difficult to delineate a precise cascade of events. The only one study, performed by Matsumoto et al, approaching the identification of the specific mechanistic pathway through the RNA sequencing on two VEA-exposed alveolar epithelial (AT-II) cells from a single donor, revealed that the VEA-induced severe inflammatory status was correlated to the enrichment in the IL-17, MAPK and TNF signaling pathways (<xref rid="R182" ref-type="bibr">Matsumoto et al. 2020</xref>).</p><p id="P59">A common feature between the <italic toggle="yes">in vivo</italic> toxicology studies and the clinical reports was the presence of lipid-laden macrophages in the airspace, which is a non-specific marker of EVALI. Yet, since lipid-laden macrophages were characterized in mice exposed to e-cig vapors generated from PG and VG regardless of the presence of nicotine or VEA as a result of the alteration of lipid homeostasis (<xref rid="R177" ref-type="bibr">Madison M. C. et al. 2019</xref>), as well as in lungs of individuals exposed to other chemicals and healthy smokers (<xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R61" ref-type="bibr">Christiani 2020</xref>; <xref rid="R143" ref-type="bibr">Jonas A 2020</xref>; <xref rid="R253" ref-type="bibr">Shields P. G. et al. 2020</xref>), it raises questions about the possible role of these macrophages on lung injury development and progression. The involvement of alveolar and interstitial macrophages is crucial both in the recognition, activation, and reaction against a foreign body or pathogenic factors at early stages (<xref rid="R125" ref-type="bibr">Higgins et al. 2008</xref>) and in the resolution of inflammation, regulation of fibro-proliferative response, and wound healing in the late stage of disease (<xref rid="R33" ref-type="bibr">Bellingan 2002</xref>; <xref rid="R113" ref-type="bibr">Gordon 2003</xref>; <xref rid="R131" ref-type="bibr">Huang X et al. 2018</xref>; <xref rid="R183" ref-type="bibr">Matsumoto et al. 2022</xref>).</p><p id="P60">The detection of ROS in MCT, VEA, and CBD e-cig vapors has also been demonstrated (<xref rid="R206" ref-type="bibr">Muthumalage and Rahman 2019</xref>; <xref rid="R204" ref-type="bibr">Muthumalage, Lucas, et al. 2020a</xref>; <xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>). Previous studies have already identified the presence of ROS in conventional tobacco smoke and nicotine e-cig emissions (<xref rid="R111" ref-type="bibr">Goel et al. 2015</xref>; <xref rid="R165" ref-type="bibr">Lerner et al. 2015</xref>; <xref rid="R266" ref-type="bibr">Tierney et al. 2016</xref>; <xref rid="R291" ref-type="bibr">Zhao, Zhang, et al. 2018</xref>; <xref rid="R258" ref-type="bibr">Son et al. 2019</xref>), and their role as mediators both <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> of oxidative stress, cell death, DNA damage, and lung inflammation, underlying also the pathogenesis of chronic obstructive pulmonary disease and lung cancer (<xref rid="R19" ref-type="bibr">Anderson et al. 2016</xref>; <xref rid="R288" ref-type="bibr">Yu et al. 2016</xref>; <xref rid="R243" ref-type="bibr">Rouabhia et al. 2017</xref>). Even though the generation of ROS by pyrolysis of e-liquids cannot be directly accounted as a specific cause or marker of EVALI, the simultaneous release of heavy metals and organic compounds in the e-liquid vapor can increase the generation of ROS, thus potentiating their dangerous health effects.</p><p id="P61">Even though these results highlight a certain correlation between the nature of vaping exposures (mainly VEA) and EVALI, major limitations still need to be addressed to understand the mechanistic pathophysiological pathway underlying EVALI.</p><p id="P62">The major limitation consist on the fact that among the available toxicological studies only one has tested the effect of vapors generated from combination D8THC/VEA/Terpenes on the human lung epithelial cells <italic toggle="yes">in vitro</italic>, and none has tested D9THC either <italic toggle="yes">in vitro</italic> or <italic toggle="yes">in vivo</italic>, which is mostly due to ongoing strict federal research restrictions on D9THC; moreover the majority of the studies focused on the cytotoxicity of pure VEA e-liquid or its vapor, which is unrealistic, and not representative of complex mixtures containing VEA. Although VEA serves mainly as a diluent of the active agent THC, the mixture of distinct chemicals in the combination THC/VEA vapor can exert synergistic effects on bioactivity and toxicity, which can further be modulated by the relative composition of ingredients and e-cig operating conditions. Moreover, there is no consistency in the puffing topography, cartridges&#x02019; operational voltage, and vapor sampling method among the studies, as well as the dose ranges and time-points assessed for toxicity, leading to inconsistencies in the physicochemical characterization of vapors and incomparable biological endpoints between different studies. These issues prevent the generalizability of the data that could be used to explain the EVALI-related health effects observed in the general population. Finally, as mentioned before, <italic toggle="yes">in vitro</italic> or <italic toggle="yes">in vivo</italic> exposure to e-liquids obtained as-is does not help to understand if the aerosols generated from them during vaping will be harmful to the alveolar epithelial cells, because pyrolysis involves drastic changes in physicochemical properties during the transformation from the e-liquid to the vapor phase and thus they can have significantly different toxicological profiles.</p><p id="P63">In the absence of strong and reliable data on the mechanism of toxicity of THC/VEA vapor, to date many hypotheses on the pathogenesis of EVALI have been proposed, mostly correlating to the presence of VEA, such as the longer residence of un-hydrolyzed VEA in the lung airspace, due to the absence of pancreatic carboxyl ester hydrolase and cholesteryl ester hydrolase. (<xref rid="R135" ref-type="bibr">Hybertson et al. 1998</xref>; <xref rid="R140" ref-type="bibr">Jensen et al. 1999</xref>; <xref rid="R134" ref-type="bibr">Hybertson et al. 2005</xref>; <xref rid="R78" ref-type="bibr">Desmarchelier et al. 2013</xref>; <xref rid="R163" ref-type="bibr">Lee H 2020</xref>) Moreover, the hydrophobic nanoparticles potentially generated by VEA aerosolization could reach the alveoli surface and directly interact with the lipid monolayer or the liquid crystalline phase of the pulmonary surfactant (<xref rid="R163" ref-type="bibr">Lee H 2020</xref>; <xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>), leading to increased surface tension (<xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>; <xref rid="R81" ref-type="bibr">DiPasquale et al. 2020</xref>), impairment of alveolar-capillary function of gas exchange (<xref rid="R81" ref-type="bibr">DiPasquale et al. 2020</xref>), and respiratory compression-expansion cycling (<xref rid="R163" ref-type="bibr">Lee H 2020</xref>), consequently inducing acute lung injury.</p><p id="P64">As mentioned before, the role of ketene in the development of EVALI has also been supposed. The acute respiratory distress syndrome manifested by acute occupational intoxication with a mixture of ketene and crotonaldehyde, consisting in respiratory failure and ground-glass opacities presented 12 hours post-5-minutes exposure (<xref rid="R130" ref-type="bibr">Huang J-F et al. 2013</xref>; <xref rid="R28" ref-type="bibr">Attfield et al. 2020</xref>), was consistent with the small number of young EVALI patients who developed life-threatening symptoms literally within hours after initial constitutional, respiratory, and gastrointestinal symptoms (<xref rid="R162" ref-type="bibr">Layden J. E. et al. 2020</xref>). However, this hypothesis was not supported by the <italic toggle="yes">in vivo</italic> acute exposure of mice to the aerosol generated by pure VEA under real-world vaping conditions (<xref rid="R35" ref-type="bibr">Bhat et al. 2020</xref>; <xref rid="R182" ref-type="bibr">Matsumoto et al. 2020</xref>). Besides these speculations, the exclusive correlation between EVALI and VEA has failed to be proven (<xref rid="R151" ref-type="bibr">Kleinman et al. 2020</xref>), while many other toxicants contained in THC-based aerosol (for example, silica and silicon-derivates) are already known to react with alveolar surfactant and induce respiratory failure due to alveolar damage (<xref rid="R187" ref-type="bibr">McKee et al. 2015</xref>; <xref rid="R61" ref-type="bibr">Christiani 2020</xref>).</p><p id="P65">Other authors have considered that either inhalation of a single chemical contained in the e-cig vapor, such as diacetyl, chlorine, VEA, can be directly cytotoxic to certain lung cells, leading to cellular necrosis, neutrophilic inflammation, collateral damage, or inhalation of the base ingredients of e-liquids (PG and VG) from the e-cigs vapor can alter the physiologic state of the immune system, making the lung sensitive to any other inhalants that are normally well tolerated (<xref rid="R14" ref-type="bibr">Alexander et al. 2020</xref>).</p><p id="P66">However, it is also reasonable to speculate that the mixture of chemicals and particles released in the THC/VEA e-cigs vapors can exert a synergistic and direct cytotoxic effect on the alveolar epithelial cells, inducing cells membrane damages, cellular necrosis, and impairment of the alveolar-capillary barrier leading to increased permeability, pulmonary edema, and recruitment of inflammatory cells. In alternative, it is also possible that alveolar macrophages can recognize and engulf the particles and give rise to the cytokine storm and ROS generation, which induces a strong pro-inflammatory phenotype, leading to cytotoxicity in the alveolar epithelial cells, impairment of the alveolar-capillary barrier, and in turn acute lung injury pattern.</p><p id="P67">Given the multitude of unanswered questions, further and more comprehensive molecular biology and toxicological studies are needed to investigate the mechanism of immune response to vapors generated from THC/VEA e-cigs and the resulting acute, sub-acute, and chronic health effects.</p><p id="P68">Besides the cytokine/chemokine profile assessment, previous studies on nicotine e-cig exposure have also focused on the membrane pattern recognition receptors and cellular protein expression. For example, Singh et al described alteration of proteins related to cellular processes including cell adhesion, cell migration, membrane trafficking, cell communication, apoptosis, and transcriptional regulation. In particular, they illustrated an overexpression of TLR-4 (toll-like receptor 4) and cytosolic receptor NOD-1 (nucleotide-binding oligomerization domain-containing protein-1), and a lipid raft-associated protein caveolin-1, which governed the amplified downstream signaling cascade, leading to the inflammatory response to the nicotine e-cig vapors <italic toggle="yes">in vitro</italic> (Singh DP et al. 2021). If it is clear that EVALI is driven by a severe alveolar pro-inflammatory status, the precise cytokines/chemokine profile is still unknown, and many inconsistencies are reported in the literature. Therefore, a more systematic proteomic approach can help elucidate the trigger event, and subsequently the signaling cascade leading to the diffuse and massive alveolar damage.</p><p id="P69">In addition to the protein profile, transcriptomic RNA-sequencing analysis would be of great help in elucidating the alteration in the expression of key genes involved in the pathogenesis of EVALI, as already tentatively shown for the VEA treated cells by Matsumoto et al (<xref rid="R182" ref-type="bibr">Matsumoto et al. 2020</xref>). Previous investigation on the effect of nicotine e-cigs vapors on gene expression and subsequent molecular pathways of vapers&#x02019; oral epithelium have shown a significant number of aberrantly expressed transcripts, mostly related to regulatory non-coding RNAs associated with the development of cancer (<xref rid="R267" ref-type="bibr">Tommasi et al. 2019</xref>). More importantly, Park et al reported significant transcriptomic changes in pathways related to downregulation of ciliogenesis, leading to a decreased number of ciliated cells, downregulation of new protein synthesis, and upregulation of inflammatory response, in normal human bronchial epithelial cells treated with nicotine e-cigs vapors which can ultimately impair the immune response against foreign bodies and pathogens (<xref rid="R218" ref-type="bibr">Park H-R et al. 2019</xref>; <xref rid="R219" ref-type="bibr">Park HR et al. 2021</xref>).</p><p id="P70">A preliminary study on the lipidomic profile alteration induced by pure VEA or counterfeit CBD e-cig vapors in mice was proposed by Muthumalage et al. They reported an increased level of leukotrienes in mice, and increased hydroxyeicosatetraenoic acids (HETEs) in plasma of e-cigs users, both of which are implicated in oxidative stress and inflammatory response in lungs (<xref rid="R204" ref-type="bibr">Muthumalage, Lucas, et al. 2020a</xref>). Many studies have reported the dysregulation of lung lipid homeostasis in response to e-cigs vapors (<xref rid="R176" ref-type="bibr">Madison Matthew C et al. 2020</xref>; <xref rid="R256" ref-type="bibr">Singh DP et al. 2021</xref>), however, Moshensky et al. reported that mice exposed to nicotine e-cigs vapors for 1 h daily for 12 days exhibited changes in circulating metabolites depending on the type of device, e-liquid composition, puffing protocol, operational voltage and temperature (<xref rid="R197" ref-type="bibr">Moshensky et al. 2021</xref>). This study is particularly relevant because it supports the need for a systematic and standardized vapor generation and sampling methodology and also highlights the need for studies addressing the potential health effects of real-world THC/VEA and nicotine e-cigs vapors.</p><p id="P71">A comprehensive genomic, proteomic and metabolomic approach would help to elucidate crucial processes of lung inflammation, cell damage, and death, aiming to understand the mechanistic pathways underlying EVALI.</p></sec><sec id="S9"><label>3.6</label><title>Regulations</title><p id="P72">E-cigs and their components and parts have been under the jurisdiction of the Food and Drug Administration since May 2016 (<xref rid="R236" ref-type="bibr">Register 2016</xref>), when they were classified under the definition of &#x0201c;tobacco products&#x0201d;, and consequently subjected to the Tobacco Control Act provisions, addressing advertising/promotion, child safety, health warning labeling, restriction of marketing and sales to youth (of minimum age), and reporting/notification. In more detail, the regulation includes 1. Enforcement action against adulterated and misbranded products; 2. Disclosure of ingredient listing, including Harmful and Potentially Harmful Constituents (HPHCs); 3. Registration of manufacturers and product listings; 4. Restrictions on sale and distribution of products with mislabeled risk description; 5. Prohibition on sales or distribution of free samples; 6. Premarket review of tobacco products. In addition, the FDA established 3 further restrictions, concerning the minimum age of purchase, the health warning labeling on packages and advertisements, and the prohibition on vending machine distribution.</p><p id="P73">In 2018, in an attempt to mitigate the expansion of youth sales, the FDA began to regulate e-liquid packaging to make them less appealing to minors. (<xref rid="R95" ref-type="bibr">FDA 2018</xref>) Following the FDA provision, on December 20, 2019, a federal law raised the federal minimum legal sales age for all tobacco products, including e-cigarettes, from 18 to 21 across the United States. (<xref rid="R69" ref-type="bibr">Congress 2019</xref>) The legislation was passed in all 50 states on December 31, 2020. (<xref rid="R51" ref-type="bibr">CDC 2020b</xref>)</p><p id="P74">In conjunction with all the efforts taken to limit and constrain the spread of e-cigs especially among the young population, in September 2019, the President of the United States announced his plan to clear the market of unauthorized, non-tobacco-flavored e-cigs products. (<xref rid="R97" ref-type="bibr">FDA 2020a</xref>), which was finalized in January 2020 by the FDA through the enforcement of the policy on unauthorized flavored cartridge-based e-cigarettes that appealed to children, including fruit and mint flavorings. (<xref rid="R98" ref-type="bibr">FDA 2020b</xref>) It is also worth mentioning that although flavors were not found to be correlated to the development of EVALI, the flavor contribution to the vapor toxicity has been already recognized, and correlated either to the presence of toxic ingredients in the parent e-liquid, or the release of toxic chemicals after vaporization (<xref rid="R32" ref-type="bibr">Behar et al. 2014</xref>; <xref rid="R65" ref-type="bibr">Clapp et al. 2017</xref>; <xref rid="R128" ref-type="bibr">Hua My et al. 2019</xref>; <xref rid="R244" ref-type="bibr">Rowell et al. 2020</xref>; <xref rid="R247" ref-type="bibr">Salam et al. 2020</xref>).</p><p id="P75">Subsequently, in December 2019, due to the EVALI outbreak, the FDA and Drug Enforcement Administration (DEA) started a law enforcement response against the sales of illicit THC-containing products, and the elimination of VEA from vaping products (<xref rid="R96" ref-type="bibr">FDA 2019</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington 2020).</p><p id="P76">In February 2020, the U.S. House of Representatives approved the &#x0201c;Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act&#x0201d;, to prohibit all flavored tobacco products, among the other restrictions.</p><p id="P77">In addition to the federal measures, state governors have enacted measures to prevent the escalation of EVALI cases. For example, in 2019 many states like Washington and Colorado banned the use of vitamin E acetate in vaping products, while the State of Oregon only issued a recommendation for cannabis retailers to carefully review their vaping products for potential safety concerns. The Governor of Massachusetts declared a public health emergency in September 2019 due to the increased number of vaping-related illnesses and deaths, with a moratorium on vaping produced, and two months later, in November 2019, the Massachusetts House Bill No. 4196 (&#x0201c;An act Modernizing Tobacco control&#x0201d;) imposed a 75% excise tax on nicotine-containing vaping products, temporary banning all flavors and flavored products from the market, except in licensed smoking bars starting on June 1, 2020 (<xref rid="R181" ref-type="bibr">Massachusetts 2019</xref>). Similarly, the Governor of New York State prohibited the sale of flavored e-cigs and e-liquids (<xref rid="R210" ref-type="bibr">NewYorkState 2020</xref>), while the Governor of California proposed a 12.5% increase in excise taxes on e-cigs (Senate Bill No.395 signed in October 2021 (<xref rid="R44" ref-type="bibr">California 2021</xref>).</p><p id="P78">It is also important to highlight that until 2019, only 7 states had legalized cannabis and THC-containing products for recreational use, while only medical marijuana was allowed in 26 States, and the remaining 18 states prohibited all cannabis use. (<xref rid="R282" ref-type="bibr">Wing et al. 2020</xref>) Many pitfalls are strictly correlated to the legalization of cannabis. While some studies have speculated a higher incidence of EVALi in the States where THC is prohibited (<xref rid="R282" ref-type="bibr">Wing et al. 2020</xref>), the legalization of cannabis has led to an expansion of the uncontaminated and un-adulterated THC products in the legal market, as well as of contaminated e-liquids and counterfeit cartridges both in the states where the THC-e-cigs are prohibited and in more liberal states, due to the trafficking across the States. (<xref rid="R64" ref-type="bibr">Cirulis et al. 2020</xref>; <xref rid="R282" ref-type="bibr">Wing et al. 2020</xref>; <xref rid="R119" ref-type="bibr">Hall et al. 2021b</xref>, <xref rid="R118" ref-type="bibr">2021a</xref>) Although more accurate surveys, data reports and new study designs design are necessary to confirm these hypotheses, the Governments should put into policies that discourage illicit trade market, and estabilish laws to protect the THC-users rather than just banning THC products. To date, in fact, there are very limited existing policies, regulations, and standards at the local, state, and federal level that address permissible or recommended volumes and/or concentrations of ingredients (including nicotine, THC, flavors, and diluents) and safety/hygiene parameters of e-liquids and cartridges (e.g., standardization and quality control for liquids and vaporizers, disclosure of ingredients in liquids).</p></sec></sec><sec id="S10"><label>4</label><title>Conclusions and the way forward</title><p id="P79">&#x0201c;E-cigs, or vaping, associated acute lung injury&#x0201d; is characterized by an acute inflammatory process of the lungs that disrupts the lung endothelial and epithelial barriers (alveolar-capillary membrane damage), leading to increased permeability, excessive transudation of fluid, recruitment of neutrophils and monocytes in the alveoli, and release of pro-inflammatory cytokines (<xref rid="R142" ref-type="bibr">Johnson and Matthay 2010</xref>). This acute inflammation, which results in collapse of alveoli and severe impairment of gas exchange, has been presumably attributed in the e-cig or vaping product users to the presence of THC and VEA in the e-liquids, due to their detection in the majority of patients&#x02019; biological samples and vaping products. However, scant, non-standardized and inconclusive studies have been performed to assess the physical-chemical and toxicological properties of vaping aerosols and to delineate the possible pathophysiological mechanisms leading to acute lung injury. Consequently, big knowledge gaps still exist at multiple levels, such that the mechanistic pathway(s) that lead to respiratory failure in e-cig users are still unknown.</p><p id="P80">The very few vaping atmospheres examined in the current literature are not always representative of the real-world e-cigs aerosols, thus are not comparable. Subsequently, the <italic toggle="yes">in vivo</italic>/<italic toggle="yes">in vitro</italic> toxicological studies performed are based on variable experimental approaches, due to the lack of standardized methodologies to generate and characterize controlled real-world e-cigs aerosols. In the absence of sufficient reliable data on the physico-chemical and toxicological properties of THC/VEA aerosol, it is therefore difficult to draw specific conclusions on the etiopathogenesis of EVALI.</p><p id="P81">More studies are warranted to fill in the existing gaps: a comprehensive analytical assessment of the VOC, hydrocarbons, ROS, elements, and other organic constituents of the THC/VEA emissions, along with an extensive physicochemical characterization of the aerosol particulates, and exhaustive <italic toggle="yes">in vitro/in vivo</italic> toxicological investigations, through a multi-omics approach, would help to delineate the cascade of events leading to the acute lung injury, to detect pathognomonic signs or biomarkers of disease, and also characterize long-term cardiopulmonary consequences of the EVALI patients and asymptomatic users. Such a multi-disciplinary approach would also help the federal regulatory agencies in future decisions on the regulation of e-cigs or vaping products.</p><p id="P82">Besides the prompt law enforcement response to the illicit products, and the elimination of VEA from vaping products (<xref rid="R96" ref-type="bibr">FDA 2019</xref>; Krishnasamy, Hallowell, Ko, Board, Hartnett, Salvatore, Danielson, Kite-Powell, Twentyman, Kim, Cyrus, Wallace, Melstrom, Haag, King, Briss, Jones, Pollack, Ellington 2020), which helped to dampen the EVALI outbreak, to date, no other measure has been taken to prevent future outbreaks. Indeed, the possibility of a resurgence of the EVALI crisis may still resurface given the lack of measures against the use of illicit or widely customizable e-cigs products. In addition to dismantling the illicit market and increasing the minimum age from 18 to 21 years old, there are still more actions that need to be taken. For example, the prohibition of flavoring sales should be applied also to the disposable and large cartridges, as well as pods, flavored with tobacco or menthol. Moreover, limiting the parameters easily customizable by the user, such as e-liquid ingredient proportions, voltage, and temperature, can greatly help toward the prevention of a future EVALI epidemic or other accidental health hazards. In addition, the identification of released harmful chemical compounds in the e-cig vapors and available information on their individual toxicological dose parameters (such as lethal dose, lethal concentration, no/lowest-observed adverse effect level) can be a useful tool for risk assessors and legislators to implement e-cig restrictions based on evidence of toxicity.</p><p id="P83">Human epidemiological studies, based on standardized and more comprehensive surveys or interviews along with regular follow-ups and clinical testing, could also be beneficial in gathering pertinent information on the e-cigs or vaping product use (such as type of device, source, brand, composition, operating conditions) and vapers&#x02019; behavioral patterns (such as frequency of use), and linking them to any observed pulmonary abnormalities to prevent future outbreaks.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>Supp 1</label><media xlink:href="NIHMS1848342-supplement-Supp_1.docx" id="d64e2144" position="anchor"/></supplementary-material></sec></body><back><ack id="S11"><title>Acknowledgment</title><p id="P84">The authors gratefully acknowledge all the past and present members of the Center for Nanotechnology and Nanotoxicology, Harvard T.H. Chan School of Public Health, including Jeff Rawson Ph.D., Postdoctoral Fellow from Prof. George M. Whitesides Laboratory, Department of Chemistry and Chemical Biology, Harvard University, for helpful discussions and comments; Professor Dhimiter Bello, Department of Public Health, UMass Lowell, and Professor Ilias Kavouras, Environmental, Occupational, and Geospatial Health Sciences, CUNY Graduate School of Public Health and Health Policy, for the internal review of the manuscript; the Editor in Chief and the anonymous peer-reviewers selected by the editor for their suggestions and comments that helped to improve the quality of this manuscript.</p></ack><fn-group><fn id="FN1" fn-type="COI-statement"><p id="P85">Declaration of Interest</p><p id="P86">This review aims to provide a comprehensive and critical appraisal of existing literature on clinical/epidemiological features and physicochemical-toxicological characterization of vaping emissions associated with EVALI. The authors believe that highlighting the knowledge gaps in the current literature and the limitations in the e-cigs regulations is necessary for the development of new study designs and for the federal regulatory agencies in future decisions on the regulation of e-cigs or vaping products, to prevent future outbreaks.</p><p id="P87">This review was made possible by the T32 Grant No. HL007118 from NIH. The authors have not participated in and do not anticipate participation in any legal, regulatory, or advocacy proceedings related to the contents of the paper.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><mixed-citation publication-type="journal"><name><surname>Abeles</surname><given-names>M</given-names></name>, <name><surname>Popofsky</surname><given-names>S</given-names></name>, <name><surname>Wen</surname><given-names>A</given-names></name>, <name><surname>Valsamis</surname><given-names>C</given-names></name>, <name><surname>Webb</surname><given-names>A</given-names></name>, <name><surname>Halaby</surname><given-names>C</given-names></name>, <name><surname>Pirzada</surname><given-names>M</given-names></name>. <year>2020</year>. <article-title>Vaping-associated lung injury caused by inhalation of cannabis oil [case report]</article-title>. <source>Pediatr Pulmonol</source>. <volume>55</volume>(<issue>1</issue>):<fpage>226</fpage>&#x02013;<lpage>228</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31746559</pub-id></mixed-citation></ref><ref id="R2"><mixed-citation publication-type="journal"><name><surname>Aberegg</surname><given-names>SK</given-names></name>, <name><surname>Cirulis</surname><given-names>MM</given-names></name>, <name><surname>Maddock</surname><given-names>SD</given-names></name>, <name><surname>Freeman</surname><given-names>A</given-names></name>, <name><surname>Keenan</surname><given-names>LM</given-names></name>, <name><surname>Pirozzi</surname><given-names>CS</given-names></name>, <name><surname>Raman</surname><given-names>SM</given-names></name>, <name><surname>Schroeder</surname><given-names>J</given-names></name>, <name><surname>Mann</surname><given-names>H</given-names></name>, <name><surname>Callahan</surname><given-names>SJ</given-names></name>. <year>2020</year>. <article-title>Clinical, Bronchoscopic, and Imaging Findings of e-Cigarette, or Vaping, Product Use-Associated Lung Injury Among Patients Treated at an Academic Medical Center [case series]</article-title>. <source>JAMA Netw Open</source>. <volume>3</volume>(<issue>11</issue>):<fpage>e2019176</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33156346</pub-id></mixed-citation></ref><ref id="R3"><mixed-citation publication-type="journal"><name><surname>Aberegg</surname><given-names>SK</given-names></name>, <name><surname>Maddock</surname><given-names>SD</given-names></name>, <name><surname>Blagev</surname><given-names>DP</given-names></name>, <name><surname>Callahan</surname><given-names>SJ</given-names></name>. <year>2020</year>. <article-title>Diagnosis of EVALI: General Approach and the Role of Bronchoscopy [review]</article-title>. <source>Chest</source>. <volume>158</volume>(<issue>2</issue>):<fpage>820</fpage>&#x02013;<lpage>827</lpage>.<pub-id pub-id-type="pmid">32092322</pub-id></mixed-citation></ref><ref id="R4"><mixed-citation publication-type="journal"><name><surname>Acharya</surname><given-names>S</given-names></name>, <name><surname>Ali</surname><given-names>SI</given-names></name>, <name><surname>Anwar</surname><given-names>S</given-names></name>, <name><surname>Glaser</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>DO NOT FALL to the VAPE TRAP! [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>31</volume>:<fpage>101165</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32685366</pub-id></mixed-citation></ref><ref id="R5"><mixed-citation publication-type="journal"><name><surname>Adhikari</surname><given-names>R</given-names></name>, <name><surname>Koritala</surname><given-names>T</given-names></name>, <name><surname>Gotur</surname><given-names>R</given-names></name>, <name><surname>Malayala</surname><given-names>SV</given-names></name>, <name><surname>Jain</surname><given-names>NK</given-names></name>. <year>2021</year>. <article-title>EVALI - E-Cigarette or Vaping Product Use-Associated Lung Injury: A Case Report [case report]</article-title>. <source>Cureus</source>. <volume>13</volume>(<issue>2</issue>):<fpage>e13541</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33815967</pub-id></mixed-citation></ref><ref id="R6"><mixed-citation publication-type="journal"><name><surname>Adhikari</surname><given-names>R</given-names></name>, <name><surname>Manduva</surname><given-names>D</given-names></name>, <name><surname>Malayala</surname><given-names>SV</given-names></name>, <name><surname>Singh</surname><given-names>R</given-names></name>, <name><surname>Jain</surname><given-names>NK</given-names></name>, <name><surname>Deepika</surname><given-names>K</given-names></name>, <name><surname>Koritala</surname><given-names>T</given-names></name>. <year>2021</year>. <article-title>A Rare Case of Vaping-Induced Spontaneous Pneumomediastinum [case report]</article-title>. <source>Cureus</source>. <volume>13</volume>(<issue>8</issue>):<fpage>e17166</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34532191</pub-id></mixed-citation></ref><ref id="R7"><mixed-citation publication-type="journal"><name><surname>Adkins</surname><given-names>SH</given-names></name>, <name><surname>Anderson</surname><given-names>KN</given-names></name>, <name><surname>Goodman</surname><given-names>AB</given-names></name>, <name><surname>Twentyman</surname><given-names>E</given-names></name>, <name><surname>Danielson</surname><given-names>ML</given-names></name>, <name><surname>Kimball</surname><given-names>A</given-names></name>, <name><surname>Click</surname><given-names>ES</given-names></name>, <name><surname>Ko</surname><given-names>JY</given-names></name>, <name><surname>Evans</surname><given-names>ME</given-names></name>, <name><surname>Weissman</surname><given-names>DN</given-names></name>
<etal/>
<year>2020</year>. <article-title>Demographics, Substance Use Behaviors, and Clinical Characteristics of Adolescents With e-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) in the United States in 2019 [epidemiology survey]</article-title>. <source>JAMA Pediatr</source>. <volume>174</volume>(<issue>7</issue>):<fpage>e200756</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32421164</pub-id></mixed-citation></ref><ref id="R8"><mixed-citation publication-type="journal"><name><surname>Aftab</surname><given-names>G</given-names></name>, <name><surname>Ahmad</surname><given-names>M</given-names></name>, <name><surname>Frenia</surname><given-names>D</given-names></name>. <year>2019</year>. <article-title>Vaping-associated Lung Injury [case report]</article-title>. <source>Cureus</source>. <volume>11</volume>(<issue>11</issue>):<fpage>e6216</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31890417</pub-id></mixed-citation></ref><ref id="R9"><mixed-citation publication-type="journal"><name><surname>Ahmad</surname><given-names>M</given-names></name>, <name><surname>Aftab</surname><given-names>G</given-names></name>, <name><surname>Rehman</surname><given-names>S</given-names></name>, <name><surname>Frenia</surname><given-names>D</given-names></name>. <year>2020</year>. <article-title>Long-term Impact of E-cigarette and Vaping Product Use-associated Lung Injury on Diffusing Capacity for Carbon Monoxide Values: A Case Series [case series]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>2</issue>):<fpage>e7002</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32206466</pub-id></mixed-citation></ref><ref id="R10"><mixed-citation publication-type="journal"><name><surname>Ahmed</surname><given-names>A</given-names></name>, <name><surname>Shapiro</surname><given-names>D</given-names></name>, <name><surname>Su</surname><given-names>J</given-names></name>, <name><surname>Nelson</surname><given-names>LP</given-names></name>. <year>2021</year>. <article-title>Vaping Cannabis Butane Hash Oil Leads to Severe Acute Respiratory Distress Syndrome-A Case of EVALI in a Teenager With Hypertrophic Cardiomyopathy [case report]</article-title>. <source>J Intensive Care Med</source>. <volume>36</volume>(<issue>5</issue>):<fpage>617</fpage>&#x02013;<lpage>621</lpage>.<pub-id pub-id-type="pmid">32686568</pub-id></mixed-citation></ref><ref id="R11"><mixed-citation publication-type="journal"><name><surname>Al-Abdouh</surname><given-names>A</given-names></name>, <name><surname>Phillips</surname><given-names>E</given-names></name>, <name><surname>Allison</surname><given-names>MG</given-names></name>. <year>2020</year>. <article-title>E-Cigarette or Vaping Product Use-Associated Lung Injury: A Severe Case That Responded to Corticosteroid Treatment [case report]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>11</issue>):<fpage>e11544</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33365213</pub-id></mixed-citation></ref><ref id="R12"><mixed-citation publication-type="journal"><name><surname>Al-Hamdani</surname><given-names>M</given-names></name>, <name><surname>Hopkins</surname><given-names>DB</given-names></name>, <name><surname>Hardardottir</surname><given-names>A</given-names></name>, <name><surname>Davidson</surname><given-names>M</given-names></name>. <year>2021</year>. <article-title>Perceptions and Experiences of Vaping Among Youth and Young Adult E-Cigarette Users: Considering Age, Gender, and Tobacco Use [epidemiology]</article-title>. <source>J Adolesc Health</source>. <volume>68</volume>(<issue>4</issue>):<fpage>787</fpage>&#x02013;<lpage>793</lpage>.<pub-id pub-id-type="pmid">32943292</pub-id></mixed-citation></ref><ref id="R13"><mixed-citation publication-type="journal"><name><surname>Aldy</surname><given-names>K</given-names></name>, <name><surname>Cao</surname><given-names>DJ</given-names></name>, <name><surname>McGetrick</surname><given-names>M</given-names></name>, <name><surname>Willcutts</surname><given-names>D</given-names></name>, <name><surname>Verbeck</surname><given-names>G</given-names></name>, <name><surname>De Silva</surname><given-names>I</given-names></name>, <name><surname>Hsu</surname><given-names>S</given-names></name>. <year>2020</year>. <article-title>Severe E-Cigarette, or Vaping, Product Use Associated Lung Injury Requiring Venovenous Extracorporeal Membrane Oxygenation [case report]</article-title>. <source>Pediatr Crit Care Med</source>. <volume>21</volume>(<issue>4</issue>):<fpage>385</fpage>&#x02013;<lpage>388</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32150124</pub-id></mixed-citation></ref><ref id="R14"><mixed-citation publication-type="journal"><name><surname>Alexander</surname><given-names>LEC</given-names></name>, <name><surname>Bellinghausen</surname><given-names>AL</given-names></name>, <name><surname>Eakin</surname><given-names>MN</given-names></name>. <year>2020</year>. <article-title>What are the mechanisms underlying vaping-induced lung injury?</article-title>
<source>The Journal of clinical investigation</source>. <volume>130</volume>(<issue>6</issue>):<fpage>2754</fpage>&#x02013;<lpage>2756</lpage>.<pub-id pub-id-type="pmid">32391805</pub-id></mixed-citation></ref><ref id="R15"><mixed-citation publication-type="journal"><name><surname>Ali</surname><given-names>M</given-names></name>, <name><surname>Khan</surname><given-names>K</given-names></name>, <name><surname>Buch</surname><given-names>M</given-names></name>, <name><surname>Ramos-Ramirez</surname><given-names>M</given-names></name>, <name><surname>Sharma</surname><given-names>M</given-names></name>, <name><surname>Patel</surname><given-names>S</given-names></name>, <name><surname>Choudhury</surname><given-names>S</given-names></name>, <name><surname>Anjum</surname><given-names>H</given-names></name>, <name><surname>Khan</surname><given-names>A</given-names></name>, <name><surname>Surani</surname><given-names>S</given-names></name>. <year>2020</year>. <article-title>A Case Series of Vaping-Induced Lung Injury in a Community Hospital Setting [case series]</article-title>. <source>Case Rep Pulmonol</source>. <volume>2020</volume>:<fpage>9631916</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32082682</pub-id></mixed-citation></ref><ref id="R16"><mixed-citation publication-type="journal"><name><surname>Alqahtani</surname><given-names>A</given-names></name>, <name><surname>Ammari</surname><given-names>Z</given-names></name>, <name><surname>Ramahi</surname><given-names>A</given-names></name>, <name><surname>Said Ahmed</surname><given-names>TS</given-names></name>, <name><surname>Klada</surname><given-names>E</given-names></name>. <year>2019</year>. <article-title>Cannabis Smoking-induced Diffuse Alveolar Hemorrhage [case series]</article-title>. <source>Cureus</source>. <volume>11</volume>(<issue>7</issue>):<fpage>e5089</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31511809</pub-id></mixed-citation></ref><ref id="R17"><mixed-citation publication-type="journal"><name><surname>Alzghoul</surname><given-names>BN</given-names></name>, <name><surname>Innabi</surname><given-names>A</given-names></name>, <name><surname>Mukhtar</surname><given-names>F</given-names></name>, <name><surname>Jantz</surname><given-names>MA</given-names></name>. <year>2020</year>. <article-title>Rapid Resolution of Severe Vaping-induced Acute Lipoid Pneumonia after Corticosteroid Treatment [case report]</article-title>. <source>Am J Respir Crit Care Med</source>. <volume>202</volume>(<issue>2</issue>):<fpage>e32</fpage>&#x02013;<lpage>e33</lpage>.<pub-id pub-id-type="pmid">32142357</pub-id></mixed-citation></ref><ref id="R18"><mixed-citation publication-type="journal"><name><surname>Amin</surname><given-names>AA</given-names></name>, <name><surname>Haught</surname><given-names>E</given-names></name>, <name><surname>Mousattat</surname><given-names>Y</given-names></name>. <year>2020</year>. <article-title>Do Not Huff, Puff, or Vape That Stuff: Interstitial Airspace Disease in a Teenager [case report]</article-title>. <source>Case Rep Pediatr</source>. <volume>2020</volume>:<fpage>8822362</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33343957</pub-id></mixed-citation></ref><ref id="R19"><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>C</given-names></name>, <name><surname>Majeste</surname><given-names>A</given-names></name>, <name><surname>Hanus</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>. <year>2016</year>. <article-title>E-cigarette aerosol exposure induces reactive oxygen species, DNA damage, and cell death in vascular endothelial cells</article-title>. <source>Toxicological Sciences</source>. <volume>154</volume>(<issue>2</issue>):<fpage>332</fpage>&#x02013;<lpage>340</lpage>.<pub-id pub-id-type="pmid">27613717</pub-id></mixed-citation></ref><ref id="R20"><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>RP</given-names></name>, <name><surname>Zechar</surname><given-names>K</given-names></name>. <year>2019</year>. <article-title>Lung injury from inhaling butane hash oil mimics pneumonia</article-title>. <source>Respir Med Case Rep</source>. <volume>26</volume>:<fpage>171</fpage>&#x02013;<lpage>173</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">30671339</pub-id></mixed-citation></ref><ref id="R21"><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>RP</given-names></name>, <name><surname>Zechar</surname><given-names>K</given-names></name>. <year>2019</year>. <article-title>Lung injury from inhaling butane hash oil mimics pneumonia [case report]</article-title>. <source>Respiratory medicine case reports</source>. <volume>26</volume>:<fpage>171</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">30671339</pub-id></mixed-citation></ref><ref id="R22"><mixed-citation publication-type="journal"><name><surname>Ansari-Gilani</surname><given-names>K</given-names></name>, <name><surname>Petraszko</surname><given-names>AM</given-names></name>, <name><surname>Teba</surname><given-names>CV</given-names></name>, <name><surname>Reeves</surname><given-names>AR</given-names></name>, <name><surname>Gupta</surname><given-names>A</given-names></name>, <name><surname>Gupta</surname><given-names>A</given-names></name>, <name><surname>Ramaiya</surname><given-names>NH</given-names></name>, <name><surname>Gilkeson</surname><given-names>RC</given-names></name>. <year>2020</year>. <article-title>E-cigarette use related lung disease, review of clinical and imaging findings in 3 cases [case report]</article-title>. <source>Heart Lung</source>. <volume>49</volume>(<issue>2</issue>):<fpage>139</fpage>&#x02013;<lpage>143</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32008808</pub-id></mixed-citation></ref><ref id="R23"><mixed-citation publication-type="journal"><name><surname>Aokage</surname><given-names>T</given-names></name>, <name><surname>Tsukahara</surname><given-names>K</given-names></name>, <name><surname>Fukuda</surname><given-names>Y</given-names></name>, <name><surname>Tokioka</surname><given-names>F</given-names></name>, <name><surname>Taniguchi</surname><given-names>A</given-names></name>, <name><surname>Naito</surname><given-names>H</given-names></name>, <name><surname>Nakao</surname><given-names>A</given-names></name>. <year>2019</year>. <article-title>Heat-not-burn cigarettes induce fulminant acute eosinophilic pneumonia requiring extracorporeal membrane oxygenation [case report]</article-title>. <source>Respiratory medicine case reports</source>. <volume>26</volume>:<fpage>87</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">30560050</pub-id></mixed-citation></ref><ref id="R24"><mixed-citation publication-type="journal"><name><surname>Arons</surname><given-names>MM</given-names></name>, <name><surname>Barnes</surname><given-names>SR</given-names></name>, <name><surname>Cheng</surname><given-names>R</given-names></name>, <name><surname>Whittle</surname><given-names>K</given-names></name>, <name><surname>Elsholz</surname><given-names>C</given-names></name>, <name><surname>Bui</surname><given-names>D</given-names></name>, <name><surname>Gilley</surname><given-names>S</given-names></name>, <name><surname>Maldonado</surname><given-names>A</given-names></name>, <name><surname>LaCross</surname><given-names>N</given-names></name>, <name><surname>Sage</surname><given-names>K</given-names></name>
<etal/>
<year>2021</year>. <article-title>Examining the temporality of vitamin E acetate in illicit THC-containing e-cigarette, or vaping, products from a public health and law enforcement response to EVALI - Utah, 2018&#x02013;2020 [policy]</article-title>. <source>Int J Drug Policy</source>. <volume>88</volume>:<fpage>103026</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33246266</pub-id></mixed-citation></ref><ref id="R25"><mixed-citation publication-type="journal"><name><surname>Arter</surname><given-names>ZL</given-names></name>, <name><surname>Wiggins</surname><given-names>A</given-names></name>, <name><surname>Hudspath</surname><given-names>C</given-names></name>, <name><surname>Kisling</surname><given-names>A</given-names></name>, <name><surname>Hostler</surname><given-names>DC</given-names></name>, <name><surname>Hostler</surname><given-names>JM</given-names></name>. <year>2019</year>. <article-title>Acute eosinophilic pneumonia following electronic cigarette use [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>27</volume>:<fpage>100825</fpage>.<pub-id pub-id-type="pmid">30963023</pub-id></mixed-citation></ref><ref id="R26"><mixed-citation publication-type="journal"><name><surname>Artunduaga</surname><given-names>M</given-names></name>, <name><surname>Rao</surname><given-names>D</given-names></name>, <name><surname>Friedman</surname><given-names>J</given-names></name>, <name><surname>Kwon</surname><given-names>JK</given-names></name>, <name><surname>Pfeifer</surname><given-names>CM</given-names></name>, <name><surname>Dettori</surname><given-names>A</given-names></name>, <name><surname>Winant</surname><given-names>AJ</given-names></name>, <name><surname>Lee</surname><given-names>EY</given-names></name>. <year>2020</year>. <article-title>Pediatric Chest Radiographic and CT Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI) [case series]</article-title>. <source>Radiology</source>. <volume>295</volume>(<issue>2</issue>):<fpage>430</fpage>&#x02013;<lpage>438</lpage>.<pub-id pub-id-type="pmid">32125258</pub-id></mixed-citation></ref><ref id="R27"><mixed-citation publication-type="journal"><name><surname>Atkins</surname><given-names>G</given-names></name>, <name><surname>Drescher</surname><given-names>F</given-names></name>. <year>2015</year>. <article-title>Acute Inhalational Lung Injury Related to the Use of Electronic Nicotine Delivery System (ENDS)</article-title>. <source>CHEST</source>. <volume>148</volume>(<issue>4</issue>):<fpage>83A</fpage>.</mixed-citation></ref><ref id="R28"><mixed-citation publication-type="journal"><name><surname>Attfield</surname><given-names>KR</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Cummings</surname><given-names>KJ</given-names></name>, <name><surname>Jacob</surname><given-names>P</given-names><suffix>3rd</suffix></name>, <name><surname>O&#x02019;Shea</surname><given-names>DF</given-names></name>, <name><surname>Wagner</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <name><surname>Fowles</surname><given-names>J</given-names></name>. <year>2020</year>. <article-title>Potential of Ethenone (Ketene) to Contribute to Electronic Cigarette, or Vaping, Product Use-associated Lung Injury [chemical]</article-title>. <source>Am J Respir Crit Care Med</source>. <volume>202</volume>(<issue>8</issue>):<fpage>1187</fpage>&#x02013;<lpage>1189</lpage>.<pub-id pub-id-type="pmid">32551843</pub-id></mixed-citation></ref><ref id="R29"><mixed-citation publication-type="journal"><name><surname>Ayoub</surname><given-names>M</given-names></name>, <name><surname>Quamme</surname><given-names>M</given-names></name>, <name><surname>Abdel-Reheem</surname><given-names>AK</given-names></name>, <name><surname>Lwin</surname><given-names>P</given-names></name>. <year>2021</year>. <article-title>COVID or Not COVID? A Great Mimicker Behind the Smoke Screen [case report]</article-title>. <source>Cureus</source>. <volume>13</volume>(<issue>11</issue>):<fpage>e19480</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34912621</pub-id></mixed-citation></ref><ref id="R30"><mixed-citation publication-type="journal"><name><surname>Baumann</surname><given-names>B</given-names></name>, <name><surname>Churg</surname><given-names>A</given-names></name>, <name><surname>Aboulhosn</surname><given-names>K</given-names></name>. <year>2020</year>. <article-title>Vaping-associated lung injury causing organizing pneumonia: A case report [case report]</article-title>. <source>British Columbia Medical Journal</source>. <volume>62</volume>(<issue>8</issue>):<fpage>268</fpage>&#x02013;<lpage>271</lpage>.</mixed-citation></ref><ref id="R31"><mixed-citation publication-type="journal"><name><surname>Baxter</surname><given-names>RD</given-names></name>, <name><surname>Vaquera</surname><given-names>K</given-names></name>, <name><surname>George</surname><given-names>TJ</given-names></name>. <year>2020</year>. <article-title>Extracorporeal Membrane Oxygenation Support for Vaping-Induced Acute Lung Injury [case report]</article-title>. <source>Ann Thorac Surg</source>. <volume>110</volume>(<issue>3</issue>):<fpage>e193</fpage>&#x02013;<lpage>e194</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32114044</pub-id></mixed-citation></ref><ref id="R32"><mixed-citation publication-type="journal"><name><surname>Behar</surname><given-names>R</given-names></name>, <name><surname>Davis</surname><given-names>B</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Bahl</surname><given-names>V</given-names></name>, <name><surname>Lin</surname><given-names>S</given-names></name>, <name><surname>Talbot</surname><given-names>P</given-names></name>. <year>2014</year>. <article-title>Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids</article-title>. <source>Toxicology in vitro</source>. <volume>28</volume>(<issue>2</issue>):<fpage>198</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">24516877</pub-id></mixed-citation></ref><ref id="R33"><mixed-citation publication-type="journal"><name><surname>Bellingan</surname><given-names>GJ</given-names></name>. <year>2002</year>. <article-title>The pulmonary physician in critical care * 6: The pathogenesis of ALI/ARDS</article-title>. <source>Thorax</source>. <volume>57</volume>(<issue>6</issue>):<fpage>540</fpage>&#x02013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">12037231</pub-id></mixed-citation></ref><ref id="R34"><mixed-citation publication-type="journal"><name><surname>Bharat</surname><given-names>A</given-names></name>, <name><surname>Jain</surname><given-names>N</given-names></name>, <name><surname>Sheikh</surname><given-names>B</given-names></name>, <name><surname>Jeelani</surname><given-names>HM</given-names></name>, <name><surname>Shayuk</surname><given-names>M</given-names></name>. <year>2020</year>. <article-title>Vaping-Induced Lung Injury: An Uncharted Territory [case report]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>7</issue>):<fpage>e8970</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32766012</pub-id></mixed-citation></ref><ref id="R35"><mixed-citation publication-type="journal"><name><surname>Bhat</surname><given-names>TA</given-names></name>, <name><surname>Kalathil</surname><given-names>SG</given-names></name>, <name><surname>Bogner</surname><given-names>PN</given-names></name>, <name><surname>Blount</surname><given-names>BC</given-names></name>, <name><surname>Goniewicz</surname><given-names>ML</given-names></name>, <name><surname>Thanavala</surname><given-names>YM</given-names></name>. <year>2020</year>. <article-title>An Animal Model of Inhaled Vitamin E Acetate and EVALI-like Lung Injury [research in vivo]</article-title>. <source>N Engl J Med</source>. <volume>382</volume>(<issue>12</issue>):<fpage>1175</fpage>&#x02013;<lpage>1177</lpage>.<pub-id pub-id-type="pmid">32101656</pub-id></mixed-citation></ref><ref id="R36"><mixed-citation publication-type="journal"><name><surname>Billa</surname><given-names>R</given-names></name>, <name><surname>Tigges</surname><given-names>C</given-names></name>, <name><surname>Vijayakumar</surname><given-names>N</given-names></name>, <name><surname>Radke</surname><given-names>J</given-names></name>, <name><surname>Pedati</surname><given-names>C</given-names></name>, <name><surname>Weiner</surname><given-names>R</given-names></name>, <name><surname>McCabe</surname><given-names>D</given-names></name>. <year>2020</year>. <article-title>E-Cigarette, or Vaping, Product Use Associated Lung Injury (EVALI) with Acute Respiratory Failure in Three Adolescent Patients: a Clinical Timeline, Treatment, and Product Analysis [case series]</article-title>. <source>J Med Toxicol</source>. <volume>16</volume>(<issue>3</issue>):<fpage>248</fpage>&#x02013;<lpage>254</lpage>.<pub-id pub-id-type="pmid">32193828</pub-id></mixed-citation></ref><ref id="R37"><mixed-citation publication-type="journal"><name><surname>Blagev</surname><given-names>DP</given-names></name>, <name><surname>Harris</surname><given-names>D</given-names></name>, <name><surname>Dunn</surname><given-names>AC</given-names></name>, <name><surname>Guidry</surname><given-names>DW</given-names></name>, <name><surname>Grissom</surname><given-names>CK</given-names></name>, <name><surname>Lanspa</surname><given-names>MJ</given-names></name>. <year>2019</year>. <article-title>Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study [case series]</article-title>. <source>Lancet</source>. <volume>394</volume>(<issue>10214</issue>):<fpage>2073</fpage>&#x02013;<lpage>2083</lpage>. <comment>English.</comment><pub-id pub-id-type="pmid">31711629</pub-id></mixed-citation></ref><ref id="R38"><mixed-citation publication-type="journal"><name><surname>Blount</surname><given-names>BC</given-names></name>, <name><surname>Karwowski</surname><given-names>MP</given-names></name>, <name><surname>Morel-Espinosa</surname><given-names>M</given-names></name>, <name><surname>Rees</surname><given-names>J</given-names></name>, <name><surname>Sosnoff</surname><given-names>C</given-names></name>, <name><surname>Cowan</surname><given-names>E</given-names></name>, <name><surname>Gardner</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Valentin-Blasini</surname><given-names>L</given-names></name>, <name><surname>Silva</surname><given-names>L</given-names></name>
<etal/>
<year>2019</year>. <article-title>Evaluation of Bronchoalveolar Lavage Fluid from Patients in an Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - 10 States, August-October 2019 [case report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>45</issue>):<fpage>1040</fpage>&#x02013;<lpage>1041</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31725707</pub-id></mixed-citation></ref><ref id="R39"><mixed-citation publication-type="journal"><name><surname>Blount</surname><given-names>BC</given-names></name>, <name><surname>Karwowski</surname><given-names>MP</given-names></name>, <name><surname>Shields</surname><given-names>PG</given-names></name>, <name><surname>Morel-Espinosa</surname><given-names>M</given-names></name>, <name><surname>Valentin-Blasini</surname><given-names>L</given-names></name>, <name><surname>Gardner</surname><given-names>M</given-names></name>, <name><surname>Braselton</surname><given-names>M</given-names></name>, <name><surname>Brosius</surname><given-names>CR</given-names></name>, <name><surname>Caron</surname><given-names>KT</given-names></name>, <name><surname>Chambers</surname><given-names>D</given-names></name>
<etal/>
<year>2020</year>. <article-title>Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI [case series]</article-title>. <source>N Engl J Med</source>. <volume>382</volume>(<issue>8</issue>):<fpage>697</fpage>&#x02013;<lpage>705</lpage>.<pub-id pub-id-type="pmid">31860793</pub-id></mixed-citation></ref><ref id="R40"><mixed-citation publication-type="journal"><name><surname>Bolona</surname><given-names>E</given-names></name>, <name><surname>Felix</surname><given-names>M</given-names></name>, <name><surname>Vanegas</surname><given-names>E</given-names></name>, <name><surname>Vera Paz</surname><given-names>C</given-names></name>, <name><surname>Cherrez-Ojeda</surname><given-names>I</given-names></name>. <year>2020</year>. <article-title>A Case of Vaping-associated Pulmonary Illness in South America: Highlighting the Need for Awareness and Surveillance Programs in the Region [case report]</article-title>. <source>Am J Respir Crit Care Med</source>. <volume>201</volume>(<issue>6</issue>):<fpage>733</fpage>&#x02013;<lpage>735</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31810372</pub-id></mixed-citation></ref><ref id="R41"><mixed-citation publication-type="journal"><name><surname>Bozkanat</surname><given-names>KM</given-names></name>, <name><surname>Rao</surname><given-names>DR</given-names></name>, <name><surname>Lieu</surname><given-names>TJ</given-names></name>, <name><surname>Rivera-Sanchez</surname><given-names>YM</given-names></name>. <year>2020</year>. <article-title>The perfect storm: A case of COVID-19 infection in an adolescent patient with EVALI [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>31</volume>:<fpage>101306</fpage>. <comment>English.</comment><pub-id pub-id-type="pmid">33251101</pub-id></mixed-citation></ref><ref id="R42"><mixed-citation publication-type="journal"><name><surname>Brosius</surname><given-names>CR</given-names></name>, <name><surname>Caron</surname><given-names>KT</given-names></name>, <name><surname>Sosnoff</surname><given-names>CS</given-names></name>, <name><surname>Blount</surname><given-names>BC</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>. <year>2022</year>. <article-title>Rapid Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method to Measure Cannabinoids in Bronchoalveolar-Lavage Fluid of Patients with e-Cigarette, or Vaping, Product Use-Associated Lung Injury [chemical analysis]</article-title>. <source>ACS Omega</source>. <volume>7</volume>(<issue>1</issue>):<fpage>443</fpage>&#x02013;<lpage>452</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">35036713</pub-id></mixed-citation></ref><ref id="R43"><mixed-citation publication-type="journal"><name><surname>Butt</surname><given-names>YM</given-names></name>, <name><surname>Smith</surname><given-names>ML</given-names></name>, <name><surname>Tazelaar</surname><given-names>HD</given-names></name>, <name><surname>Vaszar</surname><given-names>LT</given-names></name>, <name><surname>Swanson</surname><given-names>KL</given-names></name>, <name><surname>Cecchini</surname><given-names>MJ</given-names></name>, <name><surname>Boland</surname><given-names>JM</given-names></name>, <name><surname>Bois</surname><given-names>MC</given-names></name>, <name><surname>Boyum</surname><given-names>JH</given-names></name>, <name><surname>Froemming</surname><given-names>AT</given-names></name>
<etal/>
<year>2019</year>. <article-title>Pathology of Vaping-Associated Lung Injury [Case series]</article-title>. <source>N Engl J Med</source>. <volume>381</volume>(<issue>18</issue>):<fpage>1780</fpage>&#x02013;<lpage>1781</lpage>.<pub-id pub-id-type="pmid">31577870</pub-id></mixed-citation></ref><ref id="R44"><mixed-citation publication-type="webpage"><collab>California TSo</collab>. <year>2021</year>. <source>SB-395 Excise tax: electronic cigarettes: Health Careers Opportunity Grant Program: Small and Rural Hospital Relief Program.(2021&#x02013;2022)</source>
<comment><ext-link xlink:href="https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202120220SB395" ext-link-type="uri">https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202120220SB395</ext-link></comment>.</mixed-citation></ref><ref id="R45"><mixed-citation publication-type="journal"><name><surname>Carroll</surname><given-names>BJ</given-names></name>, <name><surname>Kim</surname><given-names>M</given-names></name>, <name><surname>Hemyari</surname><given-names>A</given-names></name>, <name><surname>Thakrar</surname><given-names>P</given-names></name>, <name><surname>Kump</surname><given-names>TE</given-names></name>, <name><surname>Wade</surname><given-names>T</given-names></name>, <name><surname>De Vela</surname><given-names>G</given-names></name>, <name><surname>Hall</surname><given-names>J</given-names></name>, <name><surname>Diaz</surname><given-names>CD</given-names></name>, <name><surname>D&#x02019;Andrea</surname><given-names>LA</given-names></name>. <year>2020</year>. <article-title>Impaired lung function following e-cigarette or vaping product use associated lung injury in the first cohort of hospitalized adolescents [case series]</article-title>. <source>Pediatr Pulmonol</source>. <volume>55</volume>(<issue>7</issue>):<fpage>1712</fpage>&#x02013;<lpage>1718</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32320538</pub-id></mixed-citation></ref><ref id="R46"><mixed-citation publication-type="journal"><name><surname>Casanova</surname><given-names>GS</given-names></name>, <name><surname>Amaro</surname><given-names>R</given-names></name>, <name><surname>Soler</surname><given-names>N</given-names></name>, <name><surname>Sanchez</surname><given-names>M</given-names></name>, <name><surname>Badia</surname><given-names>JR</given-names></name>, <name><surname>Barbera</surname><given-names>JA</given-names></name>, <name><surname>Agusti</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>An imported case of e-cigarette or vaping associated lung injury in Barcelona [case report]</article-title>. <source>Eur Respir J</source>. <volume>55</volume>(<issue>2</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R47"><mixed-citation publication-type="book"><collab>CDC</collab>. <year>2014</year>. <source>The Health Consequences of Smoking&#x02014;50 Years of Progress: A Report of the Surgeon General</source>. <publisher-loc>Atlanta</publisher-loc>: <publisher-name>U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health</publisher-name>, <volume>2014</volume></mixed-citation></ref><ref id="R48"><mixed-citation publication-type="book"><collab>CDC</collab>. <year>2016</year>. <source>E-cigarette use among youth and young adults: a report of the Surgeon General</source>. <publisher-loc>Atlanta, GA</publisher-loc>
<publisher-name>US Department of Health and Human Services [book]</publisher-name>.</mixed-citation></ref><ref id="R49"><mixed-citation publication-type="book"><collab>CDC</collab>. <year>2019</year>. <part-title>Centers for Disease Control and Prevention. For state, local, territorial, and tribal health departments. Electronic cigarettes</part-title>. <source>Smoking &#x00026; tobacco use</source>. <publisher-name>2019 Lung Injury Surveillance Primary Case Definition (CDC)</publisher-name> &#x02013; <month>September</month>
<day>18</day>, <comment>2019</comment></mixed-citation></ref><ref id="R50"><mixed-citation publication-type="book"><collab>CDC</collab>. <year>2020a</year>. <publisher-name>Centers for Disease Control and Prevention</publisher-name>. <source>Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products</source>. <comment>Page last reviewed: November 27, 2020.</comment></mixed-citation></ref><ref id="R51"><mixed-citation publication-type="webpage"><collab>CDC</collab>. <year>2020b</year>. <source>State Tobacco Activities Tracking and Evaluation (STATE) System, STATE System E-Cigarette Fact Sheet</source>, <comment>at <ext-link xlink:href="https://www.cdc.gov/statesystem/factsheets/ecigarette/ECigarette.html#state-legislative-activity" ext-link-type="uri">https://www.cdc.gov/statesystem/factsheets/ecigarette/ECigarette.html#state-legislative-activity</ext-link></comment>.</mixed-citation></ref><ref id="R52"><mixed-citation publication-type="journal"><name><surname>Cedano</surname><given-names>J</given-names></name>, <name><surname>Sah</surname><given-names>A</given-names></name>, <name><surname>Cedeno-Mendoza</surname><given-names>R</given-names></name>, <name><surname>Fish</surname><given-names>H</given-names></name>, <name><surname>Remolina</surname><given-names>C</given-names></name>. <year>2020</year>. <article-title>Confirmed E-cigarette or vaping product use associated lung injury (EVALI) with lung biopsy; A case report and literature review [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>30</volume>:<fpage>101122</fpage>.<pub-id pub-id-type="pmid">32577363</pub-id></mixed-citation></ref><ref id="R53"><mixed-citation publication-type="journal"><name><surname>Chadi</surname><given-names>N</given-names></name>, <name><surname>Li</surname><given-names>G</given-names></name>, <name><surname>Cerda</surname><given-names>N</given-names></name>, <name><surname>Weitzman</surname><given-names>ER</given-names></name>. <year>2019</year>. <article-title>Depressive symptoms and suicidality in adolescents using e-cigarettes and marijuana: A secondary data analysis from the Youth Risk Behavior Survey</article-title>. <source>Journal of addiction medicine</source>. <volume>13</volume>(<issue>5</issue>):<fpage>362</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">30688723</pub-id></mixed-citation></ref><ref id="R54"><mixed-citation publication-type="journal"><name><surname>Chapman</surname><given-names>R</given-names></name>, <name><surname>Tweed</surname><given-names>CD</given-names></name>, <name><surname>Moonsie</surname><given-names>I</given-names></name>. <year>2020</year>. <article-title>Lung injury from e-cigarette use: a foul and pestilent congregation of vapours [case report]</article-title>. <source>BMJ Case Rep</source>. <volume>13</volume>(<issue>11</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R55"><mixed-citation publication-type="journal"><name><surname>Chatham-Stephens</surname><given-names>K</given-names></name>, <name><surname>Roguski</surname><given-names>K</given-names></name>, <name><surname>Jang</surname><given-names>Y</given-names></name>, <name><surname>Cho</surname><given-names>P</given-names></name>, <name><surname>Jatlaoui</surname><given-names>TC</given-names></name>, <name><surname>Kabbani</surname><given-names>S</given-names></name>, <name><surname>Glidden</surname><given-names>E</given-names></name>, <name><surname>Ussery</surname><given-names>EN</given-names></name>, <name><surname>Trivers</surname><given-names>KF</given-names></name>, <name><surname>Evans</surname><given-names>ME</given-names></name>
<etal/>
<year>2019</year>. <article-title>Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, November 2019 [MMWR REPORT]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>46</issue>):<fpage>1076</fpage>&#x02013;<lpage>1080</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31751326</pub-id></mixed-citation></ref><ref id="R56"><mixed-citation publication-type="journal"><name><surname>Chawla</surname><given-names>H</given-names></name>, <name><surname>Weiler</surname><given-names>T</given-names></name>. <year>2020</year>. <article-title>E-cigarette or Vaping Product Use-Associated Lung Injury Presenting as Sub-Acute Hypoxemia Without Increased Work of Breathing [case report]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>8</issue>):<fpage>e9855</fpage>.<pub-id pub-id-type="pmid">32963897</pub-id></mixed-citation></ref><ref id="R57"><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>English</surname><given-names>S</given-names></name>, <name><surname>Ogilvie</surname><given-names>JA</given-names></name>, <name><surname>Siu</surname><given-names>MKM</given-names></name>, <name><surname>Tammara</surname><given-names>A</given-names></name>, <name><surname>Haas</surname><given-names>CJ</given-names></name>. <year>2020</year>. <article-title>All up in smoke: vaping-associated lung injury [case series]</article-title>. <source>J Community Hosp Intern Med Perspect</source>. <volume>10</volume>(<issue>6</issue>):<fpage>571</fpage>&#x02013;<lpage>578</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33194132</pub-id></mixed-citation></ref><ref id="R58"><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <name><surname>Ito</surname><given-names>K</given-names></name>, <name><surname>Fowles</surname><given-names>J</given-names></name>, <name><surname>Shusterman</surname><given-names>D</given-names></name>, <name><surname>Jaques</surname><given-names>PA</given-names></name>, <name><surname>Kumagai</surname><given-names>K</given-names></name>. <year>2018</year>. <article-title>Measurement of heating coil temperature for e-cigarettes with a &#x0201c;top-coil&#x0201d; clearomizer</article-title>. <source>PLoS One</source>. <volume>13</volume>(<issue>4</issue>):<fpage>e0195925</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">29672571</pub-id></mixed-citation></ref><ref id="R59"><mixed-citation publication-type="journal"><name><surname>Chidambaram</surname><given-names>AG</given-names></name>, <name><surname>Dennis</surname><given-names>RA</given-names></name>, <name><surname>Biko</surname><given-names>DM</given-names></name>, <name><surname>Hook</surname><given-names>M</given-names></name>, <name><surname>Allen</surname><given-names>J</given-names></name>, <name><surname>Rapp</surname><given-names>JB</given-names></name>. <year>2020</year>. <article-title>Clinical and radiological characteristics of e-cigarette or vaping product use associated lung injury [case series]</article-title>. <source>Emerg Radiol</source>. <volume>27</volume>(<issue>5</issue>):<fpage>495</fpage>&#x02013;<lpage>501</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32462343</pub-id></mixed-citation></ref><ref id="R60"><mixed-citation publication-type="journal"><name><surname>Choe</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>P</given-names></name>, <name><surname>Falk</surname><given-names>JA</given-names></name>, <name><surname>Nguyen</surname><given-names>L</given-names></name>, <name><surname>Ng</surname><given-names>D</given-names></name>, <name><surname>Parimon</surname><given-names>T</given-names></name>, <name><surname>Ghandehari</surname><given-names>S</given-names></name>. <year>2020</year>. <article-title>A Case Series of Vaping-Associated Lung Injury Requiring Mechanical Ventilation [case series]</article-title>. <source>Crit Care Explor</source>. <volume>2</volume>(<issue>1</issue>):<fpage>e0079</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32166299</pub-id></mixed-citation></ref><ref id="R61"><mixed-citation publication-type="journal"><name><surname>Christiani</surname><given-names>DC</given-names></name>. <year>2020</year>. <article-title>Vaping-Induced Acute Lung Injury [letter]</article-title>. <source>N Engl J Med</source>. <volume>382</volume>(<issue>10</issue>):<fpage>960</fpage>&#x02013;<lpage>962</lpage>.<pub-id pub-id-type="pmid">31491071</pub-id></mixed-citation></ref><ref id="R62"><mixed-citation publication-type="journal"><name><surname>Ciolino</surname><given-names>LA</given-names></name>, <name><surname>Falconer</surname><given-names>TM</given-names></name>, <name><surname>Ranieri</surname><given-names>TL</given-names></name>, <name><surname>Brueggemeyer</surname><given-names>JL</given-names></name>, <name><surname>Taylor</surname><given-names>AM</given-names></name>, <name><surname>Mohrhaus</surname><given-names>AS</given-names></name>. <year>2021</year>. <article-title>EVALI Vaping Liquids Part 2: Mass Spectrometric Identification of Diluents and Additives [chemical analysis]</article-title>. <source>Front Chem</source>. <volume>9</volume>:<fpage>746480</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34760870</pub-id></mixed-citation></ref><ref id="R63"><mixed-citation publication-type="journal"><name><surname>Ciolino</surname><given-names>LA</given-names></name>, <name><surname>Ranieri</surname><given-names>TL</given-names></name>, <name><surname>Brueggemeyer</surname><given-names>JL</given-names></name>, <name><surname>Taylor</surname><given-names>AM</given-names></name>, <name><surname>Mohrhaus</surname><given-names>AS</given-names></name>. <year>2021</year>. <article-title>EVALI Vaping Liquids Part 1: GC-MS Cannabinoids Profiles and Identification of Unnatural THC Isomers [chemical analysis]</article-title>. <source>Front Chem</source>. <volume>9</volume>:<fpage>746479</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34631667</pub-id></mixed-citation></ref><ref id="R64"><mixed-citation publication-type="journal"><name><surname>Cirulis</surname><given-names>MM</given-names></name>, <name><surname>Callahan</surname><given-names>SJ</given-names></name>, <name><surname>Aberegg</surname><given-names>SK</given-names></name>. <year>2020</year>. <article-title>Marijuana Legislation and Electronic Cigarette&#x02013; or Vaping&#x02013;Associated Lung Injury: A Historical Perspective</article-title>. <source>JAMA Network Open</source>. <volume>3</volume>(<issue>4</issue>):<fpage>e202238</fpage>&#x02013;<lpage>e202238</lpage>.<pub-id pub-id-type="pmid">32250430</pub-id></mixed-citation></ref><ref id="R65"><mixed-citation publication-type="journal"><name><surname>Clapp</surname><given-names>PW</given-names></name>, <name><surname>Pawlak</surname><given-names>EA</given-names></name>, <name><surname>Lackey</surname><given-names>JT</given-names></name>, <name><surname>Keating</surname><given-names>JE</given-names></name>, <name><surname>Reeber</surname><given-names>SL</given-names></name>, <name><surname>Glish</surname><given-names>GL</given-names></name>, <name><surname>Jaspers</surname><given-names>I</given-names></name>. <year>2017</year>. <article-title>Flavored e-cigarette liquids and cinnamaldehyde impair respiratory innate immune cell function</article-title>. <source>American Journal of Physiology-Lung Cellular and Molecular Physiology</source>. <volume>313</volume>(<issue>2</issue>):<fpage>L278</fpage>&#x02013;<lpage>L292</lpage>.<pub-id pub-id-type="pmid">28495856</pub-id></mixed-citation></ref><ref id="R66"><mixed-citation publication-type="journal"><name><surname>Cole</surname><given-names>C</given-names></name>, <name><surname>Wiens</surname><given-names>T</given-names></name>, <name><surname>Taylor</surname><given-names>J</given-names></name>, <name><surname>Danila</surname><given-names>R</given-names></name>, <name><surname>D&#x02019;Heilly</surname><given-names>P</given-names></name>, <name><surname>Margetta</surname><given-names>J</given-names></name>, <name><surname>Bye</surname><given-names>M</given-names></name>, <name><surname>Mumm</surname><given-names>E</given-names></name>, <name><surname>Schwerzler</surname><given-names>L</given-names></name>, <name><surname>Makhtal</surname><given-names>R</given-names></name>
<etal/>
<year>2021</year>. <article-title>Vaping, lung injury, and mental health Minnesota 2018&#x02013;2019 [case reports]</article-title>. <source>Minn Med</source>. <volume>104</volume>(<issue>3</issue>):<fpage>41</fpage>&#x02013;<lpage>43</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34413546</pub-id></mixed-citation></ref><ref id="R67"><mixed-citation publication-type="journal"><name><surname>Colesar</surname><given-names>MT</given-names></name>, <name><surname>McCollum</surname><given-names>DJ</given-names></name>. <year>2020</year>. <article-title>E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) in an Active Duty Service Member [case report]</article-title>. <source>Mil Med</source>.</mixed-citation></ref><ref id="R68"><mixed-citation publication-type="book"><collab>Committee on Acute Exposure Guideline Level, Committee on Toxicology, Board on Environmental Studies and Toxicology, Division on Earth and Life Studies, National Research Council</collab>. <source>Acute Exposure Guideline Levels for Selected Airborne Chemicals</source>: Volume <volume>16</volume>. <publisher-loc>Washington (DC)</publisher-loc>: <publisher-name>National Academies Press (US)</publisher-name>; <year>2014</year>
<month>Mar</month>
<day>21</day>. <fpage>6</fpage>, <comment>Ketene. [BOOK].</comment></mixed-citation></ref><ref id="R69"><mixed-citation publication-type="webpage"><collab>Congress t</collab>. <year>2019</year>. <source>S.1258 - Tobacco to 21 Act</source>, at <comment><ext-link xlink:href="https://www.congress.gov/bill/116th-congress/senate-bill/1258/text" ext-link-type="uri">https://www.congress.gov/bill/116th-congress/senate-bill/1258/text</ext-link></comment>.</mixed-citation></ref><ref id="R70"><mixed-citation publication-type="journal"><name><surname>Conuel</surname><given-names>EJ</given-names></name>, <name><surname>Chieng</surname><given-names>HC</given-names></name>, <name><surname>Fantauzzi</surname><given-names>J</given-names></name>, <name><surname>Pokhrel</surname><given-names>K</given-names></name>, <name><surname>Goldman</surname><given-names>C</given-names></name>, <name><surname>Smith</surname><given-names>TC</given-names></name>, <name><surname>Tiwari</surname><given-names>A</given-names></name>, <name><surname>Chopra</surname><given-names>A</given-names></name>, <name><surname>Judson</surname><given-names>MA</given-names></name>. <year>2020</year>. <article-title>Cannabinoid Oil Vaping-Associated Lung Injury and its Radiographic Appearance [case series]</article-title>. <source>Am J Med</source>. <volume>133</volume>(<issue>7</issue>):<fpage>865</fpage>&#x02013;<lpage>867</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31751528</pub-id></mixed-citation></ref><ref id="R71"><mixed-citation publication-type="journal"><name><surname>Cruz-Vidal</surname><given-names>DA</given-names></name>, <name><surname>Mull</surname><given-names>ES</given-names></name>, <name><surname>Taveras</surname><given-names>J</given-names></name>, <name><surname>Shell</surname><given-names>R</given-names></name>, <name><surname>Hunt</surname><given-names>GW</given-names></name>, <name><surname>Fowler</surname><given-names>B</given-names></name>, <name><surname>Wallihan</surname><given-names>R</given-names></name>, <name><surname>Erdem</surname><given-names>G</given-names></name>. <year>2021</year>. <article-title>EVALI versus MIS-C, one more overlapping diagnosis to consider [case series]</article-title>. <source>Pediatr Pulmonol</source>. <volume>56</volume>(<issue>9</issue>):<fpage>2918</fpage>&#x02013;<lpage>2924</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34219413</pub-id></mixed-citation></ref><ref id="R72"><mixed-citation publication-type="journal"><name><surname>Cullen</surname><given-names>KA</given-names></name>, <name><surname>Gentzke</surname><given-names>AS</given-names></name>, <name><surname>Sawdey</surname><given-names>MD</given-names></name>, <name><surname>Chang</surname><given-names>JT</given-names></name>, <name><surname>Anic</surname><given-names>GM</given-names></name>, <name><surname>Wang</surname><given-names>TW</given-names></name>, <name><surname>Creamer</surname><given-names>MR</given-names></name>, <name><surname>Jamal</surname><given-names>A</given-names></name>, <name><surname>Ambrose</surname><given-names>BK</given-names></name>, <name><surname>King</surname><given-names>BA</given-names></name>. <year>2019</year>. <article-title>E-cigarette use among youth in the United States, 2019</article-title>. <source>Jama</source>. <volume>322</volume>(<issue>21</issue>):<fpage>2095</fpage>&#x02013;<lpage>2103</lpage>.<pub-id pub-id-type="pmid">31688912</pub-id></mixed-citation></ref><ref id="R73"><mixed-citation publication-type="book"><name><surname>Darnell</surname><given-names>RT</given-names></name>, <name><surname>Sofi</surname><given-names>U</given-names></name>. <source>Vapor Lung: Bronchiolitis Obliterans Organizing Pneumonia (BOOP) in Patient with E-Cigarette Use</source>. <publisher-name>D22 REDUCING HARMS OF TOBACCO USE</publisher-name>. p. <fpage>A6513</fpage>&#x02013;<lpage>A6513</lpage>.</mixed-citation></ref><ref id="R74"><mixed-citation publication-type="journal"><name><surname>Davidson</surname><given-names>K</given-names></name>, <name><surname>Brancato</surname><given-names>A</given-names></name>, <name><surname>Heetderks</surname><given-names>P</given-names></name>, <name><surname>Mansour</surname><given-names>W</given-names></name>, <name><surname>Matheis</surname><given-names>E</given-names></name>, <name><surname>Nario</surname><given-names>M</given-names></name>, <name><surname>Rajagopalan</surname><given-names>S</given-names></name>, <name><surname>Underhill</surname><given-names>B</given-names></name>, <name><surname>Wininger</surname><given-names>J</given-names></name>, <name><surname>Fox</surname><given-names>D</given-names></name>. <year>2019</year>. <article-title>Outbreak of Electronic-Cigarette-Associated Acute Lipoid Pneumonia - North Carolina, July-August 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>36</issue>):<fpage>784</fpage>&#x02013;<lpage>786</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31513559</pub-id></mixed-citation></ref><ref id="R75"><mixed-citation publication-type="journal"><name><surname>DeCarli</surname><given-names>K</given-names></name>, <name><surname>Arabiat</surname><given-names>M</given-names></name>, <name><surname>Ward</surname><given-names>C</given-names></name>, <name><surname>Levinson</surname><given-names>A</given-names></name>, <name><surname>Carino</surname><given-names>G</given-names></name>. <year>2020</year>. <article-title>A Case of Vaping-Associated Lung Injury in Rhode Island [case report]</article-title>. <source>R I Med J (2013)</source>. <volume>103</volume>(<issue>1</issue>):<fpage>38</fpage>&#x02013;<lpage>41</lpage>. <comment>eng.</comment></mixed-citation></ref><ref id="R76"><mixed-citation publication-type="journal"><name><surname>Deliwala</surname><given-names>S</given-names></name>, <name><surname>Sundus</surname><given-names>S</given-names></name>, <name><surname>Haykal</surname><given-names>T</given-names></name>, <name><surname>Theophilus</surname><given-names>N</given-names></name>, <name><surname>Bachuwa</surname><given-names>G</given-names></name>. <year>2020</year>. <article-title>E-cigarette, or Vaping, Product Use-associated Lung Injury (EVALI): Acute Lung Illness within Hours of Switching from Traditional to E-cigarettes [case report]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>4</issue>):<fpage>e7513</fpage>.<pub-id pub-id-type="pmid">32373415</pub-id></mixed-citation></ref><ref id="R77"><mixed-citation publication-type="journal"><name><surname>Derespina</surname><given-names>KR</given-names></name>, <name><surname>Kaushik</surname><given-names>S</given-names></name>, <name><surname>Mitchell</surname><given-names>W</given-names></name>, <name><surname>Gorstein</surname><given-names>S</given-names></name>, <name><surname>Ushay</surname><given-names>HM</given-names></name>, <name><surname>Medar</surname><given-names>SS</given-names></name>. <year>2020</year>. <article-title>E-cigarette or Vaping-Associated Acute Lung Injury and Hemophagocytic Lymphohistiocytosis [case report]</article-title>. <source>Pediatrics</source>. <volume>146</volume>(<issue>4</issue>).</mixed-citation></ref><ref id="R78"><mixed-citation publication-type="journal"><name><surname>Desmarchelier</surname><given-names>C</given-names></name>, <name><surname>Tourniaire</surname><given-names>F</given-names></name>, <name><surname>Preveraud</surname><given-names>DP</given-names></name>, <name><surname>Samson-Kremser</surname><given-names>C</given-names></name>, <name><surname>Crenon</surname><given-names>I</given-names></name>, <name><surname>Rosilio</surname><given-names>V</given-names></name>, <name><surname>Borel</surname><given-names>P</given-names></name>. <year>2013</year>. <article-title>The distribution and relative hydrolysis of tocopheryl acetate in the different matrices coexisting in the lumen of the small intestine during digestion could explain its low bioavailability</article-title>. <source>Mol Nutr Food Res</source>. <volume>57</volume>(<issue>7</issue>):<fpage>1237</fpage>&#x02013;<lpage>1245</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">23520193</pub-id></mixed-citation></ref><ref id="R79"><mixed-citation publication-type="journal"><name><surname>Dibaji</surname><given-names>SAR</given-names></name>, <name><surname>Guha</surname><given-names>S</given-names></name>, <name><surname>Arab</surname><given-names>A</given-names></name>, <name><surname>Murray</surname><given-names>BT</given-names></name>, <name><surname>Myers</surname><given-names>MR</given-names></name>. <year>2018</year>. <article-title>Accuracy of commercial electronic nicotine delivery systems (ENDS) temperature control technology [research]</article-title>. <source>PLoS One</source>. <volume>13</volume>(<issue>11</issue>):<fpage>e0206937</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">30395592</pub-id></mixed-citation></ref><ref id="R80"><mixed-citation publication-type="journal"><name><surname>Dicpinigaitis</surname><given-names>PV</given-names></name>, <name><surname>Trachuk</surname><given-names>P</given-names></name>, <name><surname>Fakier</surname><given-names>F</given-names></name>, <name><surname>Teka</surname><given-names>M</given-names></name>, <name><surname>Suhrland</surname><given-names>MJ</given-names></name>. <year>2020</year>. <article-title>Vaping-Associated Acute Respiratory Failure Due to Acute Lipoid Pneumonia [Case report]</article-title>. <source>Lung</source>. <volume>198</volume>(<issue>1</issue>):<fpage>31</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">31583455</pub-id></mixed-citation></ref><ref id="R81"><mixed-citation publication-type="journal"><name><surname>DiPasquale</surname><given-names>M</given-names></name>, <name><surname>Gbadamosi</surname><given-names>O</given-names></name>, <name><surname>Nguyen</surname><given-names>MHL</given-names></name>, <name><surname>Castillo</surname><given-names>SR</given-names></name>, <name><surname>Rickeard</surname><given-names>BW</given-names></name>, <name><surname>Kelley</surname><given-names>EG</given-names></name>, <name><surname>Nagao</surname><given-names>M</given-names></name>, <name><surname>Marquardt</surname><given-names>D</given-names></name>. <year>2020</year>. <article-title>A Mechanical Mechanism for Vitamin E Acetate in E-cigarette/Vaping-Associated Lung Injury [research tox]</article-title>. <source>Chem Res Toxicol</source>. <volume>33</volume>(<issue>9</issue>):<fpage>2432</fpage>&#x02013;<lpage>2440</lpage>.<pub-id pub-id-type="pmid">32842741</pub-id></mixed-citation></ref><ref id="R82"><mixed-citation publication-type="journal"><name><surname>Doukas</surname><given-names>SG</given-names></name>, <name><surname>Kavali</surname><given-names>L</given-names></name>, <name><surname>Menon</surname><given-names>RS</given-names></name>, <name><surname>Izotov</surname><given-names>BN</given-names></name>, <name><surname>Bukhari</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>E-cigarette or vaping induced lung injury: A case series and literature review [case series]</article-title>. <source>Toxicol Rep</source>. <volume>7</volume>:<fpage>1381</fpage>&#x02013;<lpage>1386</lpage>.<pub-id pub-id-type="pmid">33102141</pub-id></mixed-citation></ref><ref id="R83"><mixed-citation publication-type="journal"><name><surname>Duffy</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Lu</surname><given-names>S</given-names></name>, <name><surname>Durocher</surname><given-names>L</given-names></name>, <name><surname>Dittmar</surname><given-names>M</given-names></name>, <name><surname>Delaney-Baldwin</surname><given-names>E</given-names></name>, <name><surname>Panawennage</surname><given-names>D</given-names></name>, <name><surname>LeMaster</surname><given-names>D</given-names></name>, <name><surname>Navarette</surname><given-names>K</given-names></name>, <name><surname>Spink</surname><given-names>D</given-names></name>. <year>2020</year>. <article-title>Analysis of Cannabinoid-Containing Fluids in Illicit Vaping Cartridges Recovered from Pulmonary Injury Patients: Identification of Vitamin E Acetate as a Major Diluent [research toxic chemical analysis]</article-title>. <source>Toxics</source>. <volume>8</volume>(<issue>1</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R84"><mixed-citation publication-type="journal"><name><surname>Duffy</surname><given-names>BC</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Lu</surname><given-names>S</given-names></name>, <name><surname>Dittmar</surname><given-names>MA</given-names></name>, <name><surname>Delaney-Baldwin</surname><given-names>EM</given-names></name>, <name><surname>Durocher</surname><given-names>LA</given-names></name>, <name><surname>Spink</surname><given-names>DC</given-names></name>. <year>2021</year>. <article-title>Chemotyping of Delta8-THC-Containing e-Liquids Analyzed during the 2019&#x02013;2020 New York State EVALI Investigation [chemical analysis]</article-title>. <source>J Anal Toxicol</source>. <comment>eng.</comment></mixed-citation></ref><ref id="R85"><mixed-citation publication-type="journal"><name><surname>Edmonds</surname><given-names>PJ</given-names></name>, <name><surname>Copeland</surname><given-names>C</given-names></name>, <name><surname>Conger</surname><given-names>A</given-names></name>, <name><surname>Richmond</surname><given-names>BW</given-names></name>. <year>2020</year>. <article-title>Vaping-induced diffuse alveolar hemorrhage [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>29</volume>:<fpage>100996</fpage>.<pub-id pub-id-type="pmid">31956478</pub-id></mixed-citation></ref><ref id="R86"><mixed-citation publication-type="journal"><name><surname>El-Hellani</surname><given-names>A</given-names></name>, <name><surname>Al-Moussawi</surname><given-names>S</given-names></name>, <name><surname>El-Hage</surname><given-names>R</given-names></name>, <name><surname>Talih</surname><given-names>S</given-names></name>, <name><surname>Salman</surname><given-names>R</given-names></name>, <name><surname>Shihadeh</surname><given-names>A</given-names></name>, <name><surname>Saliba</surname><given-names>NA</given-names></name>. <year>2019</year>. <article-title>Carbon Monoxide and Small Hydrocarbon Emissions from Sub-ohm Electronic Cigarettes [research tox]</article-title>. <source>Chem Res Toxicol</source>. <volume>32</volume>(<issue>2</issue>):<fpage>312</fpage>&#x02013;<lpage>317</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">30656934</pub-id></mixed-citation></ref><ref id="R87"><mixed-citation publication-type="journal"><name><surname>El Chebib</surname><given-names>H</given-names></name>, <name><surname>McArthur</surname><given-names>K</given-names></name>, <name><surname>Gorbonosov</surname><given-names>M</given-names></name>, <name><surname>Domachowske</surname><given-names>JB</given-names></name>. <year>2020</year>. <article-title>Anaerobic Necrotizing Pneumonia: Another Potential Life-threatening Complication of Vaping? [case report]</article-title>. <source>Pediatrics</source>. <volume>145</volume>(<issue>4</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R88"><mixed-citation publication-type="journal"><name><surname>Ellington</surname><given-names>S</given-names></name>, <name><surname>Salvatore</surname><given-names>PP</given-names></name>, <name><surname>Ko</surname><given-names>J</given-names></name>, <name><surname>Danielson</surname><given-names>M</given-names></name>, <name><surname>Kim</surname><given-names>L</given-names></name>, <name><surname>Cyrus</surname><given-names>A</given-names></name>, <name><surname>Wallace</surname><given-names>M</given-names></name>, <name><surname>Board</surname><given-names>A</given-names></name>, <name><surname>Krishnasamy</surname><given-names>V</given-names></name>, <name><surname>King</surname><given-names>BA</given-names></name>
<etal/>
<year>2020</year>. <article-title>Update: Product, Substance-Use, and Demographic Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, August 2019-January 2020 [MMWR REPORT]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>69</volume>(<issue>2</issue>):<fpage>44</fpage>&#x02013;<lpage>49</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31945038</pub-id></mixed-citation></ref><ref id="R89"><mixed-citation publication-type="journal"><name><surname>Erythropel</surname><given-names>HC</given-names></name>, <name><surname>Davis</surname><given-names>LM</given-names></name>, <name><surname>de Winter</surname><given-names>TM</given-names></name>, <name><surname>Jordt</surname><given-names>SE</given-names></name>, <name><surname>Anastas</surname><given-names>PT</given-names></name>, <name><surname>O&#x02019;Malley</surname><given-names>SS</given-names></name>, <name><surname>Krishnan-Sarin</surname><given-names>S</given-names></name>, <name><surname>Zimmerman</surname><given-names>JB</given-names></name>. <year>2019</year>. <article-title>Flavorant-Solvent Reaction Products and Menthol in JUUL E-Cigarettes and Aerosol [aerosol chemistry]</article-title>. <source>Am J Prev Med</source>. <volume>57</volume>(<issue>3</issue>):<fpage>425</fpage>&#x02013;<lpage>427</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31358341</pub-id></mixed-citation></ref><ref id="R90"><mixed-citation publication-type="journal"><name><surname>Essa</surname><given-names>A</given-names></name>, <name><surname>Macaraeg</surname><given-names>J</given-names></name>, <name><surname>Jagan</surname><given-names>N</given-names></name>, <name><surname>Kwon</surname><given-names>D</given-names></name>, <name><surname>Randhawa</surname><given-names>S</given-names></name>, <name><surname>Kruse</surname><given-names>M</given-names></name>, <name><surname>Thomas</surname><given-names>S</given-names></name>, <name><surname>Velagapudi</surname><given-names>M</given-names></name>, <name><surname>Horne</surname><given-names>J</given-names></name>, <name><surname>Narechania</surname><given-names>S</given-names></name>
<etal/>
<year>2020</year>. <article-title>Review of Cases of E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) and Brief Review of the Literature [case series]</article-title>. <source>Case Rep Pulmonol</source>. <volume>2020</volume>:<fpage>1090629</fpage>.<pub-id pub-id-type="pmid">32607271</pub-id></mixed-citation></ref><ref id="R91"><mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>T</given-names></name>, <name><surname>DuBose</surname><given-names>L</given-names></name>, <name><surname>Wayne</surname><given-names>C</given-names></name>, <name><surname>Sisniega</surname><given-names>C</given-names></name>. <year>2020</year>. <article-title>E-cigarette, or Vaping, Associated Lung and Hepatic Injury [CASE REPORT]</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <volume>71</volume>(<issue>3</issue>):<fpage>e98</fpage>&#x02013;<lpage>e100</lpage>.<pub-id pub-id-type="pmid">32304558</pub-id></mixed-citation></ref><ref id="R92"><mixed-citation publication-type="journal"><name><surname>Farooq</surname><given-names>U</given-names></name>, <name><surname>Anwar</surname><given-names>M</given-names></name>, <name><surname>Alcantar</surname><given-names>D</given-names></name>, <name><surname>Amine</surname><given-names>M</given-names></name>, <name><surname>Colon Hidalgo</surname><given-names>D</given-names></name>. <year>2020</year>. <article-title>Gastroenteritis and Miliary Lung Opacities: An Interesting Combination of Findings [case report]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>6</issue>):<fpage>e8848</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32754390</pub-id></mixed-citation></ref><ref id="R93"><mixed-citation publication-type="journal"><name><surname>Fathima</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>. <year>2020</year>. <article-title>Histologic patterns of lung injury in patients using e-cigarettes [case series]</article-title>. <source>Proc (Bayl Univ Med Cent)</source>. <volume>33</volume>(<issue>4</issue>):<fpage>619</fpage>&#x02013;<lpage>620</lpage>.<pub-id pub-id-type="pmid">33100546</pub-id></mixed-citation></ref><ref id="R94"><mixed-citation publication-type="book"><collab>FDA</collab>. <year>2012</year>. <source>Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke: Established List</source>; <publisher-name>Office of the Federal Register</publisher-name>: <publisher-loc>Washington, DC, USA</publisher-loc>,.</mixed-citation></ref><ref id="R95"><mixed-citation publication-type="other"><collab>FDA</collab>. <year>2018</year>. <source>FTC take action against companies misleading kids with e-liquids that resemble children&#x02019;s juice boxes, candy and cookies [press release]</source>.</mixed-citation></ref><ref id="R96"><mixed-citation publication-type="book"><collab>FDA</collab>. <year>2019</year>. <source>FDA, DEA seize 44 websites advertising sale of illicit THC vaping cartridges to US consumers as part of Operation Vapor Lock</source>. <publisher-name>FDA</publisher-name>. <comment>from <ext-link xlink:href="https://www.fda.gov/news-events/press-announcements/fda-dea-seize-44-websites-advertising-sale-illicit-thc-vaping-cartridges-us-consumers-part-operation" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-dea-seize-44-websites-advertising-sale-illicit-thc-vaping-cartridges-us-consumers-part-operation</ext-link></comment>.</mixed-citation></ref><ref id="R97"><mixed-citation publication-type="webpage"><collab>FDA</collab>. <year>2020a</year>. <source>Commissioner of the Trump Administration Combating Epidemic of Youth E-Cigarette Use with Plan to Clear Market of Unauthorized, Non-TobaccoFlavored E-Cigarette Products</source>. . <comment><ext-link xlink:href="https://www.fda.gov/news-events/press-announcements/trumpadministration-combating-epidemic-youth-e-cigarette-use-plan-clearmarket-unauthorized-non" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/trumpadministration-combating-epidemic-youth-e-cigarette-use-plan-clearmarket-unauthorized-non</ext-link></comment>.</mixed-citation></ref><ref id="R98"><mixed-citation publication-type="other"><collab>FDA</collab>. <year>2020b</year>. <source>FDA finalizes enforcement policy on unauthorized flavored cartridge-based ecigarettes that appeal to children, including fruit and mint [press release]</source>.</mixed-citation></ref><ref id="R99"><mixed-citation publication-type="other"><collab>FDA</collab>. <year>2020c</year>. <source>Lung Illnesses Associated with Use of Vaping Products</source>. .</mixed-citation></ref><ref id="R100"><mixed-citation publication-type="journal"><name><surname>Fedt</surname><given-names>A</given-names></name>, <name><surname>Bhattarai</surname><given-names>S</given-names></name>, <name><surname>Oelstrom</surname><given-names>MJ</given-names></name>. <year>2020</year>. <article-title>Vaping-Associated Lung Injury: A New Cause of Acute Respiratory Failure [case report]</article-title>. <source>J Adolesc Health</source>. <volume>66</volume>(<issue>6</issue>):<fpage>754</fpage>&#x02013;<lpage>757</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32473722</pub-id></mixed-citation></ref><ref id="R101"><mixed-citation publication-type="journal"><name><surname>Freathy</surname><given-names>S</given-names></name>, <name><surname>Kondapalli</surname><given-names>N</given-names></name>, <name><surname>Patlolla</surname><given-names>S</given-names></name>, <name><surname>Mora</surname><given-names>A</given-names></name>, <name><surname>Trimmer</surname><given-names>C</given-names></name>. <year>2020</year>. <article-title>Acute lung injury secondary to e-cigarettes or vaping [case report]</article-title>. <source>Proc (Bayl Univ Med Cent)</source>. <volume>33</volume>(<issue>2</issue>):<fpage>227</fpage>&#x02013;<lpage>228</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32313466</pub-id></mixed-citation></ref><ref id="R102"><mixed-citation publication-type="journal"><name><surname>Fryman</surname><given-names>C</given-names></name>, <name><surname>Lou</surname><given-names>B</given-names></name>, <name><surname>Weber</surname><given-names>AG</given-names></name>, <name><surname>Steinberg</surname><given-names>HN</given-names></name>, <name><surname>Khanijo</surname><given-names>S</given-names></name>, <name><surname>Iakovou</surname><given-names>A</given-names></name>, <name><surname>Makaryus</surname><given-names>MR</given-names></name>. <year>2020</year>. <article-title>Acute Respiratory Failure Associated With Vaping [case series]</article-title>. <source>Chest</source>. <volume>157</volume>(<issue>3</issue>):<fpage>e63</fpage>&#x02013;<lpage>e68</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32145818</pub-id></mixed-citation></ref><ref id="R103"><mixed-citation publication-type="journal"><name><surname>Galo</surname><given-names>J</given-names></name>, <name><surname>Celli</surname><given-names>D</given-names></name>, <name><surname>Gross</surname><given-names>D</given-names></name>, <name><surname>Holt</surname><given-names>G</given-names></name>, <name><surname>Campos</surname><given-names>M</given-names></name>. <year>2020</year>. <article-title>A presentation of E-Cigarette vaping associated lung injury (EVALI) caused by THC-Containing electronic smoking device [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>31</volume>:<fpage>101154</fpage>.<pub-id pub-id-type="pmid">32690998</pub-id></mixed-citation></ref><ref id="R104"><mixed-citation publication-type="journal"><name><surname>Ganne</surname><given-names>N</given-names></name>, <name><surname>Palraj</surname><given-names>R</given-names></name>, <name><surname>Husted</surname><given-names>E</given-names></name>, <name><surname>Shah</surname><given-names>I</given-names></name>. <year>2021</year>. <article-title>E-cigarette or vaping product use-associated lung injury (EVALI) masquerading as COVID-19 [case report]</article-title>. <source>BMJ Case Rep</source>. <volume>14</volume>(<issue>7</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R105"><mixed-citation publication-type="journal"><name><surname>Gaub</surname><given-names>KL</given-names></name>, <name><surname>Hallyburton</surname><given-names>S</given-names></name>, <name><surname>Samanic</surname><given-names>C</given-names></name>, <name><surname>Paddack</surname><given-names>D</given-names></name>, <name><surname>Clark</surname><given-names>CR</given-names></name>, <name><surname>Pence</surname><given-names>S</given-names></name>, <name><surname>Brown</surname><given-names>JA</given-names></name>, <name><surname>Hawkins</surname><given-names>E</given-names></name>. <year>2019</year>. <article-title>Patient Characteristics and Product Use Behaviors Among Persons with E-cigarette, or Vaping, Product Use-Associated Lung Injury - Indiana, June October 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>49</issue>):<fpage>1139</fpage>&#x02013;<lpage>1141</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31830007</pub-id></mixed-citation></ref><ref id="R106"><mixed-citation publication-type="journal"><name><surname>Gay</surname><given-names>B</given-names></name>, <name><surname>Field</surname><given-names>Z</given-names></name>, <name><surname>Patel</surname><given-names>S</given-names></name>, <name><surname>Alvarez</surname><given-names>RM</given-names></name>, <name><surname>Nasser</surname><given-names>W</given-names></name>, <name><surname>Madruga</surname><given-names>M</given-names></name>, <name><surname>Carlan</surname><given-names>SJ</given-names></name>. <year>2020</year>. <article-title>Vaping-Induced Lung Injury: A Case of Lipoid Pneumonia Associated with E-Cigarettes Containing Cannabis [case report]</article-title>. <source>Case Rep Pulmonol</source>. <volume>2020</volume>:<fpage>7151834</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32309002</pub-id></mixed-citation></ref><ref id="R107"><mixed-citation publication-type="journal"><name><surname>Ghinai</surname><given-names>I</given-names></name>, <name><surname>Navon</surname><given-names>L</given-names></name>, <name><surname>Gunn</surname><given-names>JKL</given-names></name>, <name><surname>Duca</surname><given-names>LM</given-names></name>, <name><surname>Brister</surname><given-names>S</given-names></name>, <name><surname>Love</surname><given-names>S</given-names></name>, <name><surname>Brink</surname><given-names>R</given-names></name>, <name><surname>Fajardo</surname><given-names>G</given-names></name>, <name><surname>Johnson</surname><given-names>J</given-names></name>, <name><surname>Saathoff-Huber</surname><given-names>L</given-names></name>
<etal/>
<year>2020</year>. <article-title>Characteristics of Persons Who Report Using Only Nicotine-Containing Products Among Interviewed Patients with E-cigarette, or Vaping, Product Use-Associated Lung Injury - Illinois, August-December 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>69</volume>(<issue>3</issue>):<fpage>84</fpage>&#x02013;<lpage>89</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31971930</pub-id></mixed-citation></ref><ref id="R108"><mixed-citation publication-type="journal"><name><surname>Ghinai</surname><given-names>I</given-names></name>, <name><surname>Pray</surname><given-names>IW</given-names></name>, <name><surname>Navon</surname><given-names>L</given-names></name>, <name><surname>O&#x02019;Laughlin</surname><given-names>K</given-names></name>, <name><surname>Saathoff-Huber</surname><given-names>L</given-names></name>, <name><surname>Hoots</surname><given-names>B</given-names></name>, <name><surname>Kimball</surname><given-names>A</given-names></name>, <name><surname>Tenforde</surname><given-names>MW</given-names></name>, <name><surname>Chevinsky</surname><given-names>JR</given-names></name>, <name><surname>Layer</surname><given-names>M</given-names></name>
<etal/>
<year>2019</year>. <article-title>E-cigarette Product Use, or Vaping, Among Persons with Associated Lung Injury - Illinois and Wisconsin, April-September 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>39</issue>):<fpage>865</fpage>&#x02013;<lpage>869</lpage>.<pub-id pub-id-type="pmid">31581166</pub-id></mixed-citation></ref><ref id="R109"><mixed-citation publication-type="book"><name><surname>Gilbert</surname><given-names>A</given-names></name>, <collab>inventor; Brown &#x00026; Williamson Collection, assignee</collab>. <year>1965</year>. <source>U.S. Patent No. 3,200,819</source>. <publisher-name>Smokeless Non-Tobacco Cigarette</publisher-name>.</mixed-citation></ref><ref id="R110"><mixed-citation publication-type="journal"><name><surname>Girvin</surname><given-names>F</given-names></name>, <name><surname>Naidich</surname><given-names>D</given-names></name>. <year>2020</year>. <article-title>CT features of electronic-cigarette or vaping-associated lung injury (EVALI); our experience during the recent outbreak [case series]</article-title>. <source>BJR Case Rep</source>. <volume>6</volume>(<issue>3</issue>):<fpage>20200027</fpage>.<pub-id pub-id-type="pmid">32922848</pub-id></mixed-citation></ref><ref id="R111"><mixed-citation publication-type="journal"><name><surname>Goel</surname><given-names>R</given-names></name>, <name><surname>Durand</surname><given-names>E</given-names></name>, <name><surname>Trushin</surname><given-names>N</given-names></name>, <name><surname>Prokopczyk</surname><given-names>B</given-names></name>, <name><surname>Foulds</surname><given-names>J</given-names></name>, <name><surname>Elias</surname><given-names>RJ</given-names></name>, <name><surname>Richie</surname><given-names>JP</given-names><suffix>Jr</suffix></name>. <year>2015</year>. <article-title>Highly reactive free radicals in electronic cigarette aerosols</article-title>. <source>Chemical research in toxicology</source>. <volume>28</volume>(<issue>9</issue>):<fpage>1675</fpage>&#x02013;<lpage>1677</lpage>.<pub-id pub-id-type="pmid">26244921</pub-id></mixed-citation></ref><ref id="R112"><mixed-citation publication-type="journal"><name><surname>Gonzalez-Jimenez</surname><given-names>N</given-names></name>, <name><surname>Gray</surname><given-names>N</given-names></name>, <name><surname>Pappas</surname><given-names>RS</given-names></name>, <name><surname>Halstead</surname><given-names>M</given-names></name>, <name><surname>Lewis</surname><given-names>E</given-names></name>, <name><surname>Valentin-Blasini</surname><given-names>L</given-names></name>, <name><surname>Watson</surname><given-names>C</given-names></name>, <name><surname>Blount</surname><given-names>B</given-names></name>. <year>2021</year>. <article-title>Analysis of Toxic Metals in Aerosols from Devices Associated with Electronic Cigarette, or Vaping, Product Use Associated Lung Injury [chemical analysis]</article-title>. <source>Toxics</source>. <volume>9</volume>(<issue>10</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R113"><mixed-citation publication-type="journal"><name><surname>Gordon</surname><given-names>S</given-names></name>
<year>2003</year>. <article-title>Alternative activation of macrophages</article-title>. <source>Nat Rev Immunol</source>. <volume>3</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">12511873</pub-id></mixed-citation></ref><ref id="R114"><mixed-citation publication-type="journal"><name><surname>Gottlieb</surname><given-names>MA</given-names></name>. <year>2019</year>. <article-title>Regulation of e-cigarettes in the United States and its role in a youth epidemic</article-title>. <source>Children</source>. <volume>6</volume>(<issue>3</issue>):<fpage>40</fpage>.<pub-id pub-id-type="pmid">30836677</pub-id></mixed-citation></ref><ref id="R115"><mixed-citation publication-type="journal"><name><surname>Griffiths</surname><given-names>A</given-names></name>, <name><surname>Rauzi</surname><given-names>A</given-names></name>, <name><surname>Stadheim</surname><given-names>K</given-names></name>, <name><surname>Wheeler</surname><given-names>W</given-names></name>. <year>2020</year>. <article-title>Lung Injury Associated with E-Cigarette or Vaping Product Use [case report]</article-title>. <source>Pediatr Ann</source>. <volume>49</volume>(<issue>2</issue>):<fpage>e93</fpage>&#x02013;<lpage>e98</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32045489</pub-id></mixed-citation></ref><ref id="R116"><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>W</given-names></name>, <name><surname>Vrdoljak</surname><given-names>G</given-names></name>, <name><surname>Liao</surname><given-names>VC</given-names></name>, <name><surname>Moezzi</surname><given-names>B</given-names></name>. <year>2021</year>. <article-title>Major Constituents of Cannabis Vape Oil Liquid, Vapor and Aerosol in California Vape Oil Cartridge Samples [chemical analysis ]</article-title>. <source>Front Chem</source>. <volume>9</volume>:<fpage>694905</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34368078</pub-id></mixed-citation></ref><ref id="R117"><mixed-citation publication-type="journal"><name><surname>Gutsche</surname><given-names>J</given-names></name>, <name><surname>Pasternak</surname><given-names>R</given-names></name>, <name><surname>Campbell</surname><given-names>D</given-names></name>, <name><surname>Schili</surname><given-names>JL</given-names></name>, <name><surname>Boyle</surname><given-names>PJ</given-names></name>, <name><surname>Tilney</surname><given-names>P</given-names></name>. <year>2020</year>. <article-title>A 19-Year-Old Man With Vaping-Associated Lung Injury [case report]</article-title>. <source>Air Med J</source>. <volume>39</volume>(<issue>1</issue>):<fpage>6</fpage>&#x02013;<lpage>8</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32044072</pub-id></mixed-citation></ref><ref id="R118"><mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>W</given-names></name>, <name><surname>Gartner</surname><given-names>C</given-names></name>, <name><surname>Bonevski</surname><given-names>B</given-names></name>. <year>2021a</year>. <article-title>The EVALI outbreak makes a strong case for better regulation of all vaporizer products [commentary]</article-title>. <source>Addiction</source>. <volume>116</volume>(<issue>5</issue>):<fpage>999</fpage>. <comment>English.</comment><pub-id pub-id-type="pmid">33594753</pub-id></mixed-citation></ref><ref id="R119"><mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>W</given-names></name>, <name><surname>Gartner</surname><given-names>C</given-names></name>, <name><surname>Bonevski</surname><given-names>B</given-names></name>. <year>2021b</year>. <article-title>Lessons from the public health responses to the US outbreak of vaping-related lung injury [commentary]</article-title>. <source>Addiction</source>. <volume>116</volume>(<issue>5</issue>):<fpage>985</fpage>&#x02013;<lpage>993</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32364274</pub-id></mixed-citation></ref><ref id="R120"><mixed-citation publication-type="journal"><name><surname>Hallowell</surname><given-names>RW</given-names></name>, <name><surname>Feldman</surname><given-names>MB</given-names></name>, <name><surname>Little</surname><given-names>BP</given-names></name>, <name><surname>Leaf</surname><given-names>RSK</given-names></name>, <name><surname>Hariri</surname><given-names>LP</given-names></name>. <year>2019</year>. <article-title>Case 38&#x02013;2019: A 20-Year-Old Man with Dyspnea and Abnormalities on Chest Imaging [case report]</article-title>. <source>New England Journal of Medicine</source>. <volume>381</volume>(<issue>24</issue>):<fpage>2353</fpage>&#x02013;<lpage>2363</lpage>.<pub-id pub-id-type="pmid">31826344</pub-id></mixed-citation></ref><ref id="R121"><mixed-citation publication-type="journal"><name><surname>Harada</surname><given-names>HA</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Shortell</surname><given-names>JD</given-names></name>, <name><surname>Beesley</surname><given-names>SJ</given-names></name>. <year>2021</year>. <article-title>A 20-Year-Old Man with e-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) and Thrombotic Coagulopathy [Case report]</article-title>. <source>Am J Case Rep</source>. <volume>22</volume>(<issue>1</issue>):<fpage>e929915</fpage>. <comment>English.</comment><pub-id pub-id-type="pmid">33854029</pub-id></mixed-citation></ref><ref id="R122"><mixed-citation publication-type="journal"><name><surname>Hassoun</surname><given-names>A</given-names></name>, <name><surname>Brady</surname><given-names>K</given-names></name>, <name><surname>Arefi</surname><given-names>R</given-names></name>, <name><surname>Trifonova</surname><given-names>I</given-names></name>, <name><surname>Tsirilakis</surname><given-names>K</given-names></name>. <year>2021</year>. <article-title>Vaping-Associated Lung Injury During COVID-19 Multisystem Inflammatory Syndrome Outbreak [Case Report]</article-title>. <source>J Emerg Med</source>. <volume>60</volume>(<issue>4</issue>):<fpage>524</fpage>&#x02013;<lpage>530</lpage>. <comment>English.</comment><pub-id pub-id-type="pmid">33483200</pub-id></mixed-citation></ref><ref id="R123"><mixed-citation publication-type="journal"><name><surname>Heinzerling</surname><given-names>A</given-names></name>, <name><surname>Armatas</surname><given-names>C</given-names></name>, <name><surname>Karmarkar</surname><given-names>E</given-names></name>, <name><surname>Attfield</surname><given-names>K</given-names></name>, <name><surname>Guo</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Vrdoljak</surname><given-names>G</given-names></name>, <name><surname>Moezzi</surname><given-names>B</given-names></name>, <name><surname>Xu</surname><given-names>D</given-names></name>, <name><surname>Wagner</surname><given-names>J</given-names></name>
<etal/>
<year>2020</year>. <article-title>Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019 [review]</article-title>. <source>JAMA Intern Med</source>. <volume>180</volume>(<issue>6</issue>):<fpage>861</fpage>&#x02013;<lpage>869</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32142111</pub-id></mixed-citation></ref><ref id="R124"><mixed-citation publication-type="journal"><name><surname>Helfgott</surname><given-names>D</given-names></name>, <name><surname>Capozzoli</surname><given-names>G</given-names></name>, <name><surname>Madray</surname><given-names>J</given-names></name>, <name><surname>Baig</surname><given-names>A</given-names></name>, <name><surname>Uppaluri</surname><given-names>L</given-names></name>, <name><surname>Gaur</surname><given-names>S</given-names></name>, <name><surname>Simon</surname><given-names>M</given-names></name>, <name><surname>Amorosa</surname><given-names>J</given-names></name>, <name><surname>Ramagopal</surname><given-names>M</given-names></name>. <year>2022</year>. <article-title>E-cigarette or vaping product use associated lung injury (EVALI) in the time of COVID-19: A clinical dilemma</article-title>. <source>Pediatr Pulmonol</source>. <volume>57</volume>(<issue>3</issue>):<fpage>623</fpage>&#x02013;<lpage>630</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34964550</pub-id></mixed-citation></ref><ref id="R125"><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>DM</given-names></name>, <name><surname>Sanchez-Campillo</surname><given-names>J</given-names></name>, <name><surname>Rosas-Taraco</surname><given-names>AG</given-names></name>, <name><surname>Higgins</surname><given-names>JR</given-names></name>, <name><surname>Lee</surname><given-names>EJ</given-names></name>, <name><surname>Orme</surname><given-names>IM</given-names></name>, <name><surname>Gonzalez-Juarrero</surname><given-names>M</given-names></name>. <year>2008</year>. <article-title>Relative levels of M-CSF and GM-CSF influence the specific generation of macrophage populations during infection with Mycobacterium tuberculosis</article-title>. <source>J Immunol</source>. <volume>180</volume>(<issue>7</issue>):<fpage>4892</fpage>&#x02013;<lpage>4900</lpage>.<pub-id pub-id-type="pmid">18354213</pub-id></mixed-citation></ref><ref id="R126"><mixed-citation publication-type="journal"><name><surname>Hilton</surname><given-names>R</given-names></name>, <name><surname>Summer</surname><given-names>R</given-names></name>, <name><surname>Roman</surname><given-names>J</given-names></name>, <name><surname>Sundaram</surname><given-names>B</given-names></name>, <name><surname>George</surname><given-names>G</given-names></name>. <year>2020</year>. <article-title>E-cigarettes and Vaping Associated Lung Injury: A Case Series and Brief Review [case series]</article-title>. <source>Am J Med Sci</source>. <volume>359</volume>(<issue>3</issue>):<fpage>137</fpage>&#x02013;<lpage>139</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32089155</pub-id></mixed-citation></ref><ref id="R127"><mixed-citation publication-type="journal"><name><surname>Hoshina</surname><given-names>Y</given-names></name>
<year>2021</year>. <article-title>E-cigarette or vaping product use-associated lung injury: A great COVID-19 mimicker in young adult [case report]</article-title>. <source>Clin Case Rep</source>. <volume>9</volume>(<issue>10</issue>):<fpage>e05016</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34721869</pub-id></mixed-citation></ref><ref id="R128"><mixed-citation publication-type="journal"><name><surname>Hua</surname><given-names>M</given-names></name>, <name><surname>Omaiye</surname><given-names>EE</given-names></name>, <name><surname>Luo</surname><given-names>W</given-names></name>, <name><surname>McWhirter</surname><given-names>KJ</given-names></name>, <name><surname>Pankow</surname><given-names>JF</given-names></name>, <name><surname>Talbot</surname><given-names>P</given-names></name>. <year>2019</year>. <article-title>Identification of cytotoxic flavor chemicals in top-selling electronic cigarette refill fluids</article-title>. <source>Scientific reports</source>. <volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">30626917</pub-id></mixed-citation></ref><ref id="R129"><mixed-citation publication-type="journal"><name><surname>Hua</surname><given-names>M</given-names></name>, <name><surname>Talbot</surname><given-names>P</given-names></name>. <year>2016</year>. <article-title>Potential health effects of electronic cigarettes: A systematic review of case reports [review]</article-title>. <source>Prev Med Rep</source>. <volume>4</volume>:<fpage>169</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">27413679</pub-id></mixed-citation></ref><ref id="R130"><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>J-F</given-names></name>, <name><surname>Zhu</surname><given-names>D-M</given-names></name>, <name><surname>Ma</surname><given-names>J-F</given-names></name>, <name><surname>Zhong</surname><given-names>M</given-names></name>
<year>2013</year>. <article-title>Acute respiratory distress syndrome due to exposure to high-concentration mixture of ethenone and crotonaldehyde</article-title>. <source>Toxicology and Industrial Health</source>. <volume>31</volume>(<issue>7</issue>):<fpage>585</fpage>&#x02013;<lpage>587</lpage>.<pub-id pub-id-type="pmid">23448861</pub-id></mixed-citation></ref><ref id="R131"><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>X</given-names></name>, <name><surname>Xiu</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>G</given-names></name>. <year>2018</year>. <article-title>The Role of Macrophages in the Pathogenesis of ALI/ARDS</article-title>. <source>Mediators Inflamm</source>. <volume>2018</volume>:<fpage>1264913</fpage>.<pub-id pub-id-type="pmid">29950923</pub-id></mixed-citation></ref><ref id="R132"><mixed-citation publication-type="journal"><name><surname>Hureaux</surname><given-names>J</given-names></name>, <name><surname>Drouet</surname><given-names>M</given-names></name>, <name><surname>Urban</surname><given-names>T</given-names></name>. <year>2014</year>. <article-title>A case report of subacute bronchial toxicity induced by an electronic cigarette</article-title>. <source>Thorax</source>. <volume>69</volume>(<issue>6</issue>):<fpage>596</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="pmid">24436327</pub-id></mixed-citation></ref><ref id="R133"><mixed-citation publication-type="journal"><name><surname>Hwang</surname><given-names>JH</given-names></name>, <name><surname>Ryu</surname><given-names>DH</given-names></name>, <name><surname>Park</surname><given-names>I</given-names></name>, <name><surname>Park</surname><given-names>SW</given-names></name>. <year>2020</year>. <article-title>Cigarette or E-Cigarette Use as Strong Risk Factors for Heated Tobacco Product Use among Korean Adolescents</article-title>. <source>Int J Environ Res Public Health</source>. <volume>17</volume>(<issue>19</issue>).</mixed-citation></ref><ref id="R134"><mixed-citation publication-type="journal"><name><surname>Hybertson</surname><given-names>BM</given-names></name>, <name><surname>Chung</surname><given-names>JH</given-names></name>, <name><surname>Fini</surname><given-names>MA</given-names></name>, <name><surname>Lee</surname><given-names>YM</given-names></name>, <name><surname>Allard</surname><given-names>JD</given-names></name>, <name><surname>Hansen</surname><given-names>BN</given-names></name>, <name><surname>Cho</surname><given-names>OJ</given-names></name>, <name><surname>Shibao</surname><given-names>GN</given-names></name>, <name><surname>Repine</surname><given-names>JE</given-names></name>. <year>2005</year>. <article-title>Aerosol-administered alpha-tocopherol attenuates lung inflammation in rats given lipopolysaccharide intratracheally [research in vivo]</article-title>. <source>Exp Lung Res</source>. <volume>31</volume>(<issue>3</issue>):<fpage>283</fpage>&#x02013;<lpage>294</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">15962709</pub-id></mixed-citation></ref><ref id="R135"><mixed-citation publication-type="journal"><name><surname>Hybertson</surname><given-names>BM</given-names></name>, <name><surname>Kitlowski</surname><given-names>RP</given-names></name>, <name><surname>Jepson</surname><given-names>EK</given-names></name>, <name><surname>Repine</surname><given-names>JE</given-names></name>. <year>1998</year>. <article-title>Supercritical fluid-aerosolized vitamin E pretreatment decreases leak in isolated oxidant-perfused rat lungs</article-title>. <source>J Appl Physiol (1985)</source>. <volume>84</volume>(<issue>1</issue>):<fpage>263</fpage>&#x02013;<lpage>268</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">9451645</pub-id></mixed-citation></ref><ref id="R136"><mixed-citation publication-type="journal"><name><surname>Isakov</surname><given-names>KMM</given-names></name>, <name><surname>Legasto</surname><given-names>AC</given-names></name>, <name><surname>Hossain</surname><given-names>R</given-names></name>, <name><surname>Verzosa Weisman</surname><given-names>S</given-names></name>, <name><surname>Toy</surname><given-names>D</given-names></name>, <name><surname>Groner</surname><given-names>LK</given-names></name>, <name><surname>Feibusch</surname><given-names>A</given-names></name>, <name><surname>Escalon</surname><given-names>JG</given-names></name>. <year>2021</year>. <article-title>A Case-Based Review of Vaping-Induced Injury-Pulmonary Toxicity and Beyond [case series]</article-title>. <source>Curr Probl Diagn Radiol</source>. <volume>50</volume>(<issue>3</issue>):<fpage>401</fpage>&#x02013;<lpage>409</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32703539</pub-id></mixed-citation></ref><ref id="R137"><mixed-citation publication-type="journal"><name><surname>Ismail</surname><given-names>AS</given-names></name>, <name><surname>Imaduddeen</surname><given-names>T</given-names></name>, <name><surname>Ibrahim</surname><given-names>WH</given-names></name>. <year>2021</year>. <article-title>Electronic Cigarette or Vaping Product Use-Associated Lung Injury in a Previously Healthy Young Male [case report]</article-title>. <source>Cureus</source>. <volume>13</volume>(<issue>9</issue>):<fpage>e18269</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34722048</pub-id></mixed-citation></ref><ref id="R138"><mixed-citation publication-type="journal"><name><surname>Israel</surname><given-names>AK</given-names></name>, <name><surname>Velez</surname><given-names>MJ</given-names></name>, <name><surname>Staicu</surname><given-names>SA</given-names></name>, <name><surname>Ambrosini</surname><given-names>R</given-names></name>, <name><surname>McGraw</surname><given-names>M</given-names></name>, <name><surname>Agrawal</surname><given-names>T</given-names></name>. <year>2020</year>. <article-title>A Unique Case of Secondary Pulmonary Alveolar Proteinosis after E-Cigarette, or Vaping, Product Use-associated Lung Injury [case report]</article-title>. <source>Am J Respir Crit Care Med</source>. <volume>202</volume>(<issue>6</issue>):<fpage>890</fpage>&#x02013;<lpage>893</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32392077</pub-id></mixed-citation></ref><ref id="R139"><mixed-citation publication-type="journal"><name><surname>Jankharia</surname><given-names>B</given-names></name>, <name><surname>Rajan</surname><given-names>S</given-names></name>, <name><surname>Angirish</surname><given-names>B</given-names></name>. <year>2020</year>. <article-title>Vaping associated lung injury (EVALI) as an organizing pneumonia pattern- A case report [Case report]</article-title>. <source>Lung India</source>. <volume>37</volume>(<issue>6</issue>):<fpage>533</fpage>&#x02013;<lpage>535</lpage>. <comment>English.</comment><pub-id pub-id-type="pmid">33154217</pub-id></mixed-citation></ref><ref id="R140"><mixed-citation publication-type="journal"><name><surname>Jensen</surname><given-names>SK</given-names></name>, <name><surname>Engberg</surname><given-names>RM</given-names></name>, <name><surname>Hedemann</surname><given-names>MS</given-names></name>. <year>1999</year>. <article-title>All-rac-alpha-tocopherol acetate is a better vitamin E source than all-rac-alpha-tocopherol succinate for broilers</article-title>. <source>J Nutr</source>. <volume>129</volume>(<issue>7</issue>):<fpage>1355</fpage>&#x02013;<lpage>1360</lpage>.<pub-id pub-id-type="pmid">10395598</pub-id></mixed-citation></ref><ref id="R141"><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>H</given-names></name>, <name><surname>Ahmed</surname><given-names>CMS</given-names></name>, <name><surname>Martin</surname><given-names>TJ</given-names></name>, <name><surname>Canchola</surname><given-names>A</given-names></name>, <name><surname>Oswald</surname><given-names>IWH</given-names></name>, <name><surname>Garcia</surname><given-names>JA</given-names></name>, <name><surname>Chen</surname><given-names>JY</given-names></name>, <name><surname>Koby</surname><given-names>KA</given-names></name>, <name><surname>Buchanan</surname><given-names>AJ</given-names></name>, <name><surname>Zhao</surname><given-names>Z</given-names></name>
<etal/>
<year>2020</year>. <article-title>Chemical and Toxicological Characterization of Vaping Emission Products from Commonly Used Vape Juice Diluents [research tox]</article-title>. <source>Chem Res Toxicol</source>. <volume>33</volume>(<issue>8</issue>):<fpage>2157</fpage>&#x02013;<lpage>2163</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32618192</pub-id></mixed-citation></ref><ref id="R142"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>ER</given-names></name>, <name><surname>Matthay</surname><given-names>MA</given-names></name>. <year>2010</year>. <article-title>Acute lung injury: epidemiology, pathogenesis, and treatment [review]</article-title>. <source>J Aerosol Med Pulm Drug Deliv</source>. <volume>23</volume>(<issue>4</issue>):<fpage>243</fpage>&#x02013;<lpage>252</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">20073554</pub-id></mixed-citation></ref><ref id="R143"><mixed-citation publication-type="journal"><name><surname>Jonas</surname><given-names>A</given-names></name>
<year>2020</year>. <article-title>Lipid-Laden alveolar macrophages and vaping: Lessons from EVALI [commentary]</article-title>. <source>EBioMedicine</source>. <volume>60</volume>:<fpage>103010</fpage>.<pub-id pub-id-type="pmid">32971470</pub-id></mixed-citation></ref><ref id="R144"><mixed-citation publication-type="journal"><name><surname>Jonas</surname><given-names>AM</given-names></name>, <name><surname>Raj</surname><given-names>R</given-names></name>. <year>2020</year>. <article-title>Vaping-Related Acute Parenchymal Lung Injury: A Systematic Review [review]</article-title>. <source>Chest</source>. <volume>158</volume>(<issue>4</issue>):<fpage>1555</fpage>&#x02013;<lpage>1565</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32442559</pub-id></mixed-citation></ref><ref id="R145"><mixed-citation publication-type="journal"><name><surname>Kalantary</surname><given-names>A</given-names></name>, <name><surname>Abdelazeem</surname><given-names>B</given-names></name>, <name><surname>Shams</surname><given-names>N</given-names></name>, <name><surname>Pratiti</surname><given-names>R</given-names></name>, <name><surname>Al-Sanouri</surname><given-names>I</given-names></name>. <year>2021</year>. <article-title>Coagulopathy and Acute Respiratory Distress Syndrome: Dual Complications of E-Cigarette-Associated Lung Injury [case report]</article-title>. <source>Cureus</source>. <volume>13</volume>(<issue>2</issue>):<fpage>e13531</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33786238</pub-id></mixed-citation></ref><ref id="R146"><mixed-citation publication-type="journal"><name><surname>Kalininskiy</surname><given-names>A</given-names></name>, <name><surname>Bach</surname><given-names>CT</given-names></name>, <name><surname>Nacca</surname><given-names>NE</given-names></name>, <name><surname>Ginsberg</surname><given-names>G</given-names></name>, <name><surname>Marraffa</surname><given-names>J</given-names></name>, <name><surname>Navarette</surname><given-names>KA</given-names></name>, <name><surname>McGraw</surname><given-names>MD</given-names></name>, <name><surname>Croft</surname><given-names>DP</given-names></name>. <year>2019</year>. <article-title>E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach [case series]</article-title>. <source>Lancet Respir Med</source>. <volume>7</volume>(<issue>12</issue>):<fpage>1017</fpage>&#x02013;<lpage>1026</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31711871</pub-id></mixed-citation></ref><ref id="R147"><mixed-citation publication-type="journal"><name><surname>Kaous</surname><given-names>M</given-names></name>, <name><surname>Xian</surname><given-names>J</given-names></name>, <name><surname>Rongo</surname><given-names>D</given-names></name>, <name><surname>McDonald</surname><given-names>M</given-names></name>, <name><surname>Ocasionez</surname><given-names>D</given-names></name>, <name><surname>Mathew</surname><given-names>R</given-names></name>, <name><surname>Estrada</surname><given-names>YMRM</given-names></name>, <name><surname>Patel</surname><given-names>B</given-names></name>, <name><surname>Cherian</surname><given-names>SV</given-names></name>, <name><surname>Jani</surname><given-names>PP</given-names></name>. <year>2020</year>. <article-title>Clinical, radiology, pathologic patterns and outcomes of vaping related pulmonary injury in a single institution; A case series [case series]</article-title>. <source>Respir Med</source>. <volume>173</volume>:<fpage>106153</fpage>.<pub-id pub-id-type="pmid">33017782</pub-id></mixed-citation></ref><ref id="R148"><mixed-citation publication-type="journal"><name><surname>Kass</surname><given-names>AP</given-names></name>, <name><surname>Overbeek</surname><given-names>DL</given-names></name>, <name><surname>Chiel</surname><given-names>LE</given-names></name>, <name><surname>Boyer</surname><given-names>EW</given-names></name>, <name><surname>Casey</surname><given-names>AMH</given-names></name>. <year>2020</year>. <article-title>Case series: Adolescent victims of the vaping public health crisis with pulmonary complications [case series]</article-title>. <source>Pediatr Pulmonol</source>. <volume>55</volume>(<issue>5</issue>):<fpage>1224</fpage>&#x02013;<lpage>1236</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32168438</pub-id></mixed-citation></ref><ref id="R149"><mixed-citation publication-type="journal"><name><surname>Khan</surname><given-names>A</given-names></name>, <name><surname>Parlette</surname><given-names>K</given-names></name>, <name><surname>Kuntz</surname><given-names>HM</given-names></name>. <year>2021</year>. <article-title>E-cigarettes and Vaping, Product-use Associated Lung Injury: A Case Series of Adolescents [case series]</article-title>. <source>Clin Pract Cases Emerg Med</source>. <volume>5</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>16</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33560943</pub-id></mixed-citation></ref><ref id="R150"><mixed-citation publication-type="journal"><name><surname>Kinney</surname><given-names>WH</given-names></name>, <name><surname>Beckstrom</surname><given-names>C</given-names></name>, <name><surname>Snyder</surname><given-names>T</given-names></name>, <name><surname>Judiscak</surname><given-names>P</given-names></name>, <name><surname>Miller</surname><given-names>P</given-names></name>, <name><surname>Marett</surname><given-names>J</given-names></name>, <name><surname>Pessetto</surname><given-names>A</given-names></name>, <name><surname>Scherbak</surname><given-names>D</given-names></name>. <year>2020</year>. <article-title>Electronic-Cigarette or Vaping Associated Lung Injury (EVALI) [case report]</article-title>. <source>Applied Radiology</source>. <volume>49</volume>(<issue>2</issue>):<fpage>42</fpage>&#x02013;<lpage>44</lpage>.</mixed-citation></ref><ref id="R151"><mixed-citation publication-type="journal"><name><surname>Kleinman</surname><given-names>MT</given-names></name>, <name><surname>Arechavala</surname><given-names>RJ</given-names></name>, <name><surname>Herman</surname><given-names>D</given-names></name>, <name><surname>Shi</surname><given-names>J</given-names></name>, <name><surname>Hasen</surname><given-names>I</given-names></name>, <name><surname>Ting</surname><given-names>A</given-names></name>, <name><surname>Dai</surname><given-names>W</given-names></name>, <name><surname>Carreno</surname><given-names>J</given-names></name>, <name><surname>Chavez</surname><given-names>J</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>
<etal/>
<year>2020</year>. <article-title>E-cigarette or Vaping Product Use-Associated Lung Injury Produced in an Animal Model From Electronic Cigarette Vapor Exposure Without Tetrahydrocannabinol or Vitamin E Oil [research in vitro]</article-title>. <source>J Am Heart Assoc</source>. <volume>9</volume>(<issue>18</issue>):<fpage>e017368</fpage>.<pub-id pub-id-type="pmid">32896206</pub-id></mixed-citation></ref><ref id="R152"><mixed-citation publication-type="journal"><name><surname>Kligerman</surname><given-names>SJ</given-names></name>, <name><surname>Kay</surname><given-names>FU</given-names></name>, <name><surname>Raptis</surname><given-names>CA</given-names></name>, <name><surname>Henry</surname><given-names>TS</given-names></name>, <name><surname>Sechrist</surname><given-names>JW</given-names></name>, <name><surname>Walker</surname><given-names>CM</given-names></name>, <name><surname>Vargas</surname><given-names>D</given-names></name>, <name><surname>Filev</surname><given-names>PD</given-names></name>, <name><surname>Chung</surname><given-names>MS</given-names></name>, <name><surname>Digumarthy</surname><given-names>SR</given-names></name>
<etal/>
<year>2021</year>. <article-title>CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury: A Multicenter Cohort of 160 Cases [report]</article-title>. <source>Chest</source>. <volume>160</volume>(<issue>4</issue>):<fpage>1492</fpage>&#x02013;<lpage>1511</lpage>. <comment>English.</comment><pub-id pub-id-type="pmid">33957099</pub-id></mixed-citation></ref><ref id="R153"><mixed-citation publication-type="journal"><name><surname>Kooragayalu</surname><given-names>S</given-names></name>, <name><surname>El-Zarif</surname><given-names>S</given-names></name>, <name><surname>Jariwala</surname><given-names>S</given-names></name>. <year>2020</year>. <article-title>Vaping Associated Pulmonary Injury (VAPI) with superimposed Mycoplasma pneumoniae infection [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>29</volume>:<fpage>100997</fpage>.<pub-id pub-id-type="pmid">32042584</pub-id></mixed-citation></ref><ref id="R154"><mixed-citation publication-type="journal"><name><surname>Kovach</surname><given-names>AL</given-names></name>, <name><surname>Carter</surname><given-names>RR</given-names></name>, <name><surname>Thornburg</surname><given-names>JW</given-names></name>, <name><surname>Wiethe</surname><given-names>R</given-names></name>, <name><surname>Fennell</surname><given-names>TR</given-names></name>, <name><surname>Wiley</surname><given-names>JL</given-names></name>. <year>2021</year>. <article-title>Thermal Degradants Identified from the Vaping of Vitamin E Acetate [chemical analysis]</article-title>. <source>J Anal Toxicol</source>. <comment>eng.</comment></mixed-citation></ref><ref id="R155"><mixed-citation publication-type="journal"><name><surname>Krishnan</surname><given-names>S</given-names></name>, <name><surname>Thind</surname><given-names>GS</given-names></name>, <name><surname>Soliman</surname><given-names>M</given-names></name>, <name><surname>Tolle</surname><given-names>L</given-names></name>, <name><surname>Mireles-Cabodevila</surname><given-names>E</given-names></name>, <name><surname>Adi</surname><given-names>A</given-names></name>, <name><surname>Anandamurthy</surname><given-names>B</given-names></name>, <name><surname>Bribriesco</surname><given-names>A</given-names></name>, <name><surname>Yun</surname><given-names>J</given-names></name>. <year>2021</year>. <article-title>A case of vaping-induced acute respiratory distress syndrome requiring extracorporeal life support [case report]</article-title>. <source>Perfusion</source>. <volume>36</volume>(<issue>3</issue>):<fpage>308</fpage>&#x02013;<lpage>310</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32650708</pub-id></mixed-citation></ref><ref id="R156"><mixed-citation publication-type="journal"><name><surname>Krishnasamy</surname><given-names>VP</given-names></name>, <name><surname>Hallowell</surname><given-names>BD</given-names></name>, <name><surname>Ko</surname><given-names>JY</given-names></name>, <name><surname>Board</surname><given-names>A</given-names></name>, <name><surname>Hartnett</surname><given-names>KP</given-names></name>, <name><surname>Salvatore</surname><given-names>PP</given-names></name>, <name><surname>Danielson</surname><given-names>M</given-names></name>, <name><surname>Kite-Powell</surname><given-names>A</given-names></name>, <name><surname>Twentyman</surname><given-names>E</given-names></name>, <name><surname>Kim</surname><given-names>L</given-names></name>
<etal/>
<year>2020</year>. <article-title>Update: Characteristics of a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, August 2019-January 2020 [Article]</article-title>. <source>MMWR Morbidity and mortality weekly report</source>. <volume>69</volume>(<issue>3</issue>):<fpage>90</fpage>&#x02013;<lpage>94</lpage>. <comment>English.</comment><pub-id pub-id-type="pmid">31971931</pub-id></mixed-citation></ref><ref id="R157"><mixed-citation publication-type="journal"><name><surname>Krishnasamy</surname><given-names>VP</given-names></name>, <name><surname>Hallowell</surname><given-names>BD</given-names></name>, <name><surname>Ko</surname><given-names>JY</given-names></name>, <name><surname>Board</surname><given-names>A</given-names></name>, <name><surname>Hartnett</surname><given-names>KP</given-names></name>, <name><surname>Salvatore</surname><given-names>PP</given-names></name>, <name><surname>Danielson</surname><given-names>M</given-names></name>, <name><surname>Kite-Powell</surname><given-names>A</given-names></name>, <name><surname>Twentyman</surname><given-names>E</given-names></name>, <name><surname>Kim</surname><given-names>L</given-names></name>
<etal/>
<year>2020</year>. <article-title>Update: Characteristics of a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, August 2019-January 2020 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>69</volume>(<issue>3</issue>):<fpage>90</fpage>&#x02013;<lpage>94</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31971931</pub-id></mixed-citation></ref><ref id="R158"><mixed-citation publication-type="journal"><name><surname>Kupelian</surname><given-names>C</given-names></name>, <name><surname>Kim</surname><given-names>A</given-names></name>, <name><surname>Vijayan</surname><given-names>V</given-names></name>. <year>2021</year>. <article-title>E-cigarette or Vaping Product Use-Associated Lung Injury Complicated by Pulmonary Aspergillosis [case report]</article-title>. <source>Cureus</source>. <volume>13</volume>(<issue>12</issue>):<fpage>e20075</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34987937</pub-id></mixed-citation></ref><ref id="R159"><mixed-citation publication-type="journal"><name><surname>Landman</surname><given-names>ST</given-names></name>, <name><surname>Dhaliwal</surname><given-names>I</given-names></name>, <name><surname>Mackenzie</surname><given-names>CA</given-names></name>, <name><surname>Martinu</surname><given-names>T</given-names></name>, <name><surname>Steele</surname><given-names>A</given-names></name>, <name><surname>Bosma</surname><given-names>KJ</given-names></name>. <year>2019</year>. <article-title>Life-threatening bronchiolitis related to electronic cigarette use in a Canadian youth [case report]</article-title>. <source>CMAJ</source>. <volume>191</volume>(<issue>48</issue>):<fpage>E1321</fpage>&#x02013;<lpage>E1331</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31753841</pub-id></mixed-citation></ref><ref id="R160"><mixed-citation publication-type="journal"><name><surname>Lanzarotta</surname><given-names>A</given-names></name>, <name><surname>Falconer</surname><given-names>TM</given-names></name>, <name><surname>Flurer</surname><given-names>R</given-names></name>, <name><surname>Wilson</surname><given-names>RA</given-names></name>. <year>2020</year>. <article-title>Hydrogen Bonding between Tetrahydrocannabinol and Vitamin E Acetate in Unvaped, Aerosolized, and Condensed Aerosol e-Liquids [research tox]</article-title>. <source>Anal Chem</source>. <volume>92</volume>(<issue>3</issue>):<fpage>2374</fpage>&#x02013;<lpage>2378</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31951379</pub-id></mixed-citation></ref><ref id="R161"><mixed-citation publication-type="journal"><name><surname>Layden</surname><given-names>JE</given-names></name>, <name><surname>Ghinai</surname><given-names>I</given-names></name>, <name><surname>Pray</surname><given-names>I</given-names></name>, <name><surname>Kimball</surname><given-names>A</given-names></name>, <name><surname>Layer</surname><given-names>M</given-names></name>, <name><surname>Tenforde</surname><given-names>M</given-names></name>, <name><surname>Navon</surname><given-names>L</given-names></name>, <name><surname>Hoots</surname><given-names>B</given-names></name>, <name><surname>Salvatore</surname><given-names>PP</given-names></name>, <name><surname>Elderbrook</surname><given-names>M</given-names></name>
<etal/>
<year>2019</year>. <article-title>Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin &#x02014; Preliminary Report [case series]</article-title>. <source>New England Journal of Medicine</source>.</mixed-citation></ref><ref id="R162"><mixed-citation publication-type="journal"><name><surname>Layden</surname><given-names>JE</given-names></name>, <name><surname>Ghinai</surname><given-names>I</given-names></name>, <name><surname>Pray</surname><given-names>I</given-names></name>, <name><surname>Kimball</surname><given-names>A</given-names></name>, <name><surname>Layer</surname><given-names>M</given-names></name>, <name><surname>Tenforde</surname><given-names>MW</given-names></name>, <name><surname>Navon</surname><given-names>L</given-names></name>, <name><surname>Hoots</surname><given-names>B</given-names></name>, <name><surname>Salvatore</surname><given-names>PP</given-names></name>, <name><surname>Elderbrook</surname><given-names>M</given-names></name>
<etal/>
<year>2020</year>. <article-title>Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Final Report [case report]</article-title>. <source>N Engl J Med</source>. <volume>382</volume>(<issue>10</issue>):<fpage>903</fpage>&#x02013;<lpage>916</lpage>.<pub-id pub-id-type="pmid">31491072</pub-id></mixed-citation></ref><ref id="R163"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>H</given-names></name>
<year>2020</year>. <article-title>Vitamin E acetate as linactant in the pathophysiology of EVALI [Commentary]</article-title>. <source>Med Hypotheses</source>. <volume>144</volume>:<fpage>110182</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33254504</pub-id></mixed-citation></ref><ref id="R164"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>M-S</given-names></name>, <name><surname>Christiani</surname><given-names>DC</given-names></name>. <year>2020</year>. <article-title>Microbial toxins in nicotine vaping liquids</article-title>. <source>American journal of respiratory and critical care medicine</source>. <volume>201</volume>(<issue>6</issue>):<fpage>741</fpage>&#x02013;<lpage>743</lpage>.<pub-id pub-id-type="pmid">31816248</pub-id></mixed-citation></ref><ref id="R165"><mixed-citation publication-type="journal"><name><surname>Lerner</surname><given-names>CA</given-names></name>, <name><surname>Sundar</surname><given-names>IK</given-names></name>, <name><surname>Yao</surname><given-names>H</given-names></name>, <name><surname>Gerloff</surname><given-names>J</given-names></name>, <name><surname>Ossip</surname><given-names>DJ</given-names></name>, <name><surname>McIntosh</surname><given-names>S</given-names></name>, <name><surname>Robinson</surname><given-names>R</given-names></name>, <name><surname>Rahman</surname><given-names>I</given-names></name>. <year>2015</year>. <article-title>Vapors produced by electronic cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung</article-title>. <source>PloS one</source>. <volume>10</volume>(<issue>2</issue>):<fpage>e0116732</fpage>.<pub-id pub-id-type="pmid">25658421</pub-id></mixed-citation></ref><ref id="R166"><mixed-citation publication-type="journal"><name><surname>Lewis</surname><given-names>N</given-names></name>, <name><surname>McCaffrey</surname><given-names>K</given-names></name>, <name><surname>Sage</surname><given-names>K</given-names></name>, <name><surname>Cheng</surname><given-names>CJ</given-names></name>, <name><surname>Green</surname><given-names>J</given-names></name>, <name><surname>Goldstein</surname><given-names>L</given-names></name>, <name><surname>Campbell</surname><given-names>H</given-names></name>, <name><surname>Ferrell</surname><given-names>D</given-names></name>, <name><surname>Malan</surname><given-names>N</given-names></name>, <name><surname>LaCross</surname><given-names>N</given-names></name>
<etal/>
<year>2019</year>. <article-title>E-cigarette Use, or Vaping, Practices and Characteristics Among Persons with Associated Lung Injury - Utah, April-October 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>42</issue>):<fpage>953</fpage>&#x02013;<lpage>956</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31647788</pub-id></mixed-citation></ref><ref id="R167"><mixed-citation publication-type="journal"><name><surname>Lilley</surname><given-names>J</given-names></name>, <name><surname>Kravitz</surname><given-names>S</given-names></name>, <name><surname>Haynes</surname><given-names>Z</given-names></name>, <name><surname>Church</surname><given-names>T</given-names></name>, <name><surname>McKay</surname><given-names>S</given-names></name>, <name><surname>Mertz</surname><given-names>A</given-names></name>. <year>2021</year>. <article-title>E-cigarette, or vaping, product use associated lung injury and the risks and benefits of a thorough infectious work-up [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>33</volume>:<fpage>101465</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34401301</pub-id></mixed-citation></ref><ref id="R168"><mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>W</given-names></name>, <name><surname>Suhail</surname><given-names>M</given-names></name>, <name><surname>Diaz</surname><given-names>K</given-names></name>. <year>2022</year>. <article-title>A Case of E-cigarette or Vaping Product Use-Associated Lung Injury Mimicking Miliary Tuberculosis</article-title>. <source>Cureus</source>. <volume>14</volume>(<issue>2</issue>):<fpage>e22406</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">35345753</pub-id></mixed-citation></ref><ref id="R169"><mixed-citation publication-type="journal"><name><surname>Lozier</surname><given-names>MJ</given-names></name>, <name><surname>Wallace</surname><given-names>B</given-names></name>, <name><surname>Anderson</surname><given-names>K</given-names></name>, <name><surname>Ellington</surname><given-names>S</given-names></name>, <name><surname>Jones</surname><given-names>CM</given-names></name>, <name><surname>Rose</surname><given-names>D</given-names></name>, <name><surname>Baldwin</surname><given-names>G</given-names></name>, <name><surname>King</surname><given-names>BA</given-names></name>, <name><surname>Briss</surname><given-names>P</given-names></name>, <name><surname>Mikosz</surname><given-names>CA</given-names></name>
<etal/>
<year>2019</year>. <article-title>Update: Demographic, Product, and Substance-Use Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injuries - United States, December 2019 [MMWR REPORT]</article-title>. <source>Mmwr-Morbidity and Mortality Weekly Report</source>. <volume>68</volume>(<issue>49</issue>):<fpage>1142</fpage>&#x02013;<lpage>1148</lpage>.<pub-id pub-id-type="pmid">31830008</pub-id></mixed-citation></ref><ref id="R170"><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>MA</given-names></name>, <name><surname>Jabre</surname><given-names>NA</given-names></name>, <name><surname>Mogayzel</surname><given-names>PJ</given-names><suffix>Jr.</suffix></name>
<year>2020</year>. <article-title>Vaping-related Lung Injury in an Adolescent [case report]</article-title>. <source>Am J Respir Crit Care Med</source>. <volume>201</volume>(<issue>4</issue>):<fpage>481</fpage>&#x02013;<lpage>482</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31904992</pub-id></mixed-citation></ref><ref id="R171"><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>SJ</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Duffy</surname><given-names>BC</given-names></name>, <name><surname>Dittmar</surname><given-names>MA</given-names></name>, <name><surname>Durocher</surname><given-names>LA</given-names></name>, <name><surname>Panawennage</surname><given-names>D</given-names></name>, <name><surname>Delaney-Baldwin</surname><given-names>ER</given-names></name>, <name><surname>Spink</surname><given-names>DC</given-names></name>. <year>2021</year>. <article-title>Investigation of Vaping Fluids Recovered From New York State E-Cigarette or Vaping Product Use-Associated Lung Injury Patients [chemical analysis]</article-title>. <source>Front Chem</source>. <volume>9</volume>:<fpage>748935</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34778204</pub-id></mixed-citation></ref><ref id="R172"><mixed-citation publication-type="journal"><name><surname>Lynch</surname><given-names>J</given-names></name>, <name><surname>Lorenz</surname><given-names>L</given-names></name>, <name><surname>Brueggemeyer</surname><given-names>JL</given-names></name>, <name><surname>Lanzarotta</surname><given-names>A</given-names></name>, <name><surname>Falconer</surname><given-names>TM</given-names></name>, <name><surname>Wilson</surname><given-names>RA</given-names></name>. <year>2021</year>. <article-title>Simultaneous Temperature Measurements and Aerosol Collection During Vaping for the Analysis of Delta(9)-Tetrahydrocannabinol and Vitamin E Acetate Mixtures in Ceramic Coil Style Cartridges [aerosol chemical analysis]</article-title>. <source>Front Chem</source>. <volume>9</volume>:<fpage>734793</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34434923</pub-id></mixed-citation></ref><ref id="R173"><mixed-citation publication-type="journal"><name><surname>Macedonia</surname><given-names>TV</given-names></name>, <name><surname>Krefft</surname><given-names>SD</given-names></name>, <name><surname>Rose</surname><given-names>CS</given-names></name>. <year>2020</year>. <article-title>Persistent Severe Fixed Airways Obstruction in a High-Dosing E-cigarette User [case report]</article-title>. <source>J Gen Intern Med</source>. <volume>35</volume>(<issue>1</issue>):<fpage>345</fpage>&#x02013;<lpage>349</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31705470</pub-id></mixed-citation></ref><ref id="R174"><mixed-citation publication-type="journal"><name><surname>MacMurdo</surname><given-names>M</given-names></name>, <name><surname>Lin</surname><given-names>C</given-names></name>, <name><surname>Saeedan</surname><given-names>MB</given-names></name>, <name><surname>Doxtader</surname><given-names>EE</given-names></name>, <name><surname>Mukhopadhyay</surname><given-names>S</given-names></name>, <name><surname>Arrossi</surname><given-names>V</given-names></name>, <name><surname>Reynolds</surname><given-names>J</given-names></name>, <name><surname>Ghosh</surname><given-names>S</given-names></name>, <name><surname>Choi</surname><given-names>H</given-names></name>. <year>2020</year>. <article-title>e-Cigarette or Vaping Product Use-Associated Lung Injury: Clinical, Radiologic, and Pathologic Findings of 15 Cases [case series]</article-title>. <source>Chest</source>. <volume>157</volume>(<issue>6</issue>):<fpage>e181</fpage>&#x02013;<lpage>e187</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32505323</pub-id></mixed-citation></ref><ref id="R175"><mixed-citation publication-type="journal"><name><surname>Maddock</surname><given-names>SD</given-names></name>, <name><surname>Cirulis</surname><given-names>MM</given-names></name>, <name><surname>Callahan</surname><given-names>SJ</given-names></name>, <name><surname>Keenan</surname><given-names>LM</given-names></name>, <name><surname>Pirozzi</surname><given-names>CS</given-names></name>, <name><surname>Raman</surname><given-names>SM</given-names></name>, <name><surname>Aberegg</surname><given-names>SK</given-names></name>. <year>2019</year>. <article-title>Pulmonary Lipid-Laden Macrophages and Vaping [case series]</article-title>. <source>N Engl J Med</source>. <volume>381</volume>(<issue>15</issue>):<fpage>1488</fpage>&#x02013;<lpage>1489</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31491073</pub-id></mixed-citation></ref><ref id="R176"><mixed-citation publication-type="journal"><name><surname>Madison</surname><given-names>MC</given-names></name>, <name><surname>Landers</surname><given-names>CT</given-names></name>, <name><surname>Gu</surname><given-names>B-H</given-names></name>, <name><surname>Chang</surname><given-names>C-Y</given-names></name>, <name><surname>Tung</surname><given-names>H-Y</given-names></name>, <name><surname>You</surname><given-names>R</given-names></name>, <name><surname>Hong</surname><given-names>MJ</given-names></name>, <name><surname>Baghaei</surname><given-names>N</given-names></name>, <name><surname>Song</surname><given-names>L-Z</given-names></name>, <name><surname>Porter</surname><given-names>P</given-names></name>. <year>2020</year>. <article-title>Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine</article-title>. <source>The Journal of clinical investigation</source>. <volume>129</volume>(<issue>10</issue>):<fpage>4290</fpage>&#x02013;<lpage>4304</lpage>.</mixed-citation></ref><ref id="R177"><mixed-citation publication-type="journal"><name><surname>Madison</surname><given-names>MC</given-names></name>, <name><surname>Landers</surname><given-names>CT</given-names></name>, <name><surname>Gu</surname><given-names>BH</given-names></name>, <name><surname>Chang</surname><given-names>CY</given-names></name>, <name><surname>Tung</surname><given-names>HY</given-names></name>, <name><surname>You</surname><given-names>R</given-names></name>, <name><surname>Hong</surname><given-names>MJ</given-names></name>, <name><surname>Baghaei</surname><given-names>N</given-names></name>, <name><surname>Song</surname><given-names>LZ</given-names></name>, <name><surname>Porter</surname><given-names>P</given-names></name>
<etal/>
<year>2019</year>. <article-title>Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine [research in vitro]</article-title>. <source>J Clin Invest</source>. <volume>129</volume>(<issue>10</issue>):<fpage>4290</fpage>&#x02013;<lpage>4304</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31483291</pub-id></mixed-citation></ref><ref id="R178"><mixed-citation publication-type="journal"><name><surname>Margham</surname><given-names>J</given-names></name>, <name><surname>McAdam</surname><given-names>K</given-names></name>, <name><surname>Forster</surname><given-names>M</given-names></name>, <name><surname>Liu</surname><given-names>C</given-names></name>, <name><surname>Wright</surname><given-names>C</given-names></name>, <name><surname>Mariner</surname><given-names>D</given-names></name>, <name><surname>Proctor</surname><given-names>C</given-names></name>. <year>2016</year>. <article-title>Chemical Composition of Aerosol from an E-Cigarette: A Quantitative Comparison with Cigarette Smoke [research tox]</article-title>. <source>Chem Res Toxicol</source>. <volume>29</volume>(<issue>10</issue>):<fpage>1662</fpage>&#x02013;<lpage>1678</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">27641760</pub-id></mixed-citation></ref><ref id="R179"><mixed-citation publication-type="journal"><name><surname>Marliere</surname><given-names>C</given-names></name>, <name><surname>De Greef</surname><given-names>J</given-names></name>, <name><surname>Gohy</surname><given-names>S</given-names></name>, <name><surname>Hoton</surname><given-names>D</given-names></name>, <name><surname>Wallemacq</surname><given-names>P</given-names></name>, <name><surname>Jacquet</surname><given-names>LM</given-names></name>, <name><surname>Belkhir</surname><given-names>L</given-names></name>. <year>2020</year>. <article-title>Fatal e-cigarette or vaping associated lung injury (EVALI): a first case report in Europe [case report]</article-title>. <source>Eur Respir J</source>. <volume>56</volume>(<issue>1</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R180"><mixed-citation publication-type="journal"><name><surname>Marrocco</surname><given-names>A</given-names></name>, <name><surname>Singh</surname><given-names>D</given-names></name>, <name><surname>Christiani</surname><given-names>DC</given-names></name>, <name><surname>Demokritou</surname><given-names>P</given-names></name>. <year>2022</year>. <article-title>E-cigarette (E-cig) liquid composition and operational voltage define the in vitro toxicity of Delta8Tetrahydrocannabinol/Vitamin E Acetate (Delta8THC/VEA) e-cig aerosols [research in vitro]</article-title>. <source>Toxicol Sci</source>.</mixed-citation></ref><ref id="R181"><mixed-citation publication-type="book"><collab>Massachusetts Co</collab>. <year>2019</year>. <source>Bill H.4196, 191st (2019&#x02013;2020)</source>. <publisher-name>An Act modernizing tobacco control</publisher-name>. <comment><ext-link xlink:href="https://malegislature.gov/Bills/191/H4196" ext-link-type="uri">https://malegislature.gov/Bills/191/H4196</ext-link></comment>. (<comment>H4196</comment>).</mixed-citation></ref><ref id="R182"><mixed-citation publication-type="journal"><name><surname>Matsumoto</surname><given-names>S</given-names></name>, <name><surname>Fang</surname><given-names>X</given-names></name>, <name><surname>Traber</surname><given-names>MG</given-names></name>, <name><surname>Jones</surname><given-names>KD</given-names></name>, <name><surname>Langelier</surname><given-names>C</given-names></name>, <name><surname>Hayakawa Serpa</surname><given-names>P</given-names></name>, <name><surname>Calfee</surname><given-names>CS</given-names></name>, <name><surname>Matthay</surname><given-names>MA</given-names></name>, <name><surname>Gotts</surname><given-names>JE</given-names></name>. <year>2020</year>. <article-title>Dose-Dependent Pulmonary Toxicity of Aerosolized Vitamin E Acetate [research tox]</article-title>. <source>Am J Respir Cell Mol Biol</source>. <volume>63</volume>(<issue>6</issue>):<fpage>748</fpage>&#x02013;<lpage>757</lpage>.<pub-id pub-id-type="pmid">32822237</pub-id></mixed-citation></ref><ref id="R183"><mixed-citation publication-type="journal"><name><surname>Matsumoto</surname><given-names>S</given-names></name>, <name><surname>Traber</surname><given-names>MG</given-names></name>, <name><surname>Leonard</surname><given-names>SW</given-names></name>, <name><surname>Choi</surname><given-names>J</given-names></name>, <name><surname>Fang</surname><given-names>X</given-names></name>, <name><surname>Maishan</surname><given-names>M</given-names></name>, <name><surname>Wick</surname><given-names>KD</given-names></name>, <name><surname>Jones</surname><given-names>KD</given-names></name>, <name><surname>Calfee</surname><given-names>CS</given-names></name>, <name><surname>Gotts</surname><given-names>JE</given-names></name>
<etal/>
<year>2022</year>. <article-title>Aerosolized Vitamin E Acetate Causes Oxidative Injury in Mice and in Alveolar Macrophages</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <comment>eng.</comment></mixed-citation></ref><ref id="R184"><mixed-citation publication-type="journal"><name><surname>Matta</surname><given-names>P</given-names></name>, <name><surname>Hamati</surname><given-names>JN</given-names></name>, <name><surname>Unno</surname><given-names>HL</given-names></name>, <name><surname>Fox</surname><given-names>MD</given-names></name>. <year>2020</year>. <article-title>E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) Without Respiratory Symptoms [case report]</article-title>. <source>Pediatrics</source>. <volume>145</volume>(<issue>5</issue>).</mixed-citation></ref><ref id="R185"><mixed-citation publication-type="journal"><name><surname>McCauley</surname><given-names>L</given-names></name>, <name><surname>Markin</surname><given-names>C</given-names></name>, <name><surname>Hosmer</surname><given-names>D</given-names></name>. <year>2012</year>. <article-title>An unexpected consequence of electronic cigarette use</article-title>. <source>Chest</source>. <volume>141</volume>(<issue>4</issue>):<fpage>1110</fpage>.<pub-id pub-id-type="pmid">22474155</pub-id></mixed-citation></ref><ref id="R186"><mixed-citation publication-type="journal"><name><surname>McGuigan</surname><given-names>M</given-names></name>, <name><surname>Chapman</surname><given-names>G</given-names></name>, <name><surname>Lewis</surname><given-names>E</given-names></name>, <name><surname>Watson</surname><given-names>CH</given-names></name>, <name><surname>Blount</surname><given-names>BC</given-names></name>, <name><surname>Valentin-Blasini</surname><given-names>L</given-names></name>. <year>2022</year>. <article-title>High-Performance Liquid Chromatography-Tandem Mass Spectrometry Analysis of Carbonyl Emissions from E-Cigarette, or Vaping, Products [chemical analysis]</article-title>. <source>ACS Omega</source>. <volume>7</volume>(<issue>9</issue>):<fpage>7655</fpage>&#x02013;<lpage>7661</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">35284728</pub-id></mixed-citation></ref><ref id="R187"><mixed-citation publication-type="journal"><name><surname>McKee</surname><given-names>RH</given-names></name>, <name><surname>Adenuga</surname><given-names>MD</given-names></name>, <name><surname>Carrillo</surname><given-names>JC</given-names></name>. <year>2015</year>. <article-title>Characterization of the toxicological hazards of hydrocarbon solvents</article-title>. <source>Crit Rev Toxicol</source>. <volume>45</volume>(<issue>4</issue>):<fpage>273</fpage>&#x02013;<lpage>365</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">25868376</pub-id></mixed-citation></ref><ref id="R188"><mixed-citation publication-type="journal"><name><surname>Meehan-Atrash</surname><given-names>J</given-names></name>, <name><surname>Luo</surname><given-names>W</given-names></name>, <name><surname>McWhirter</surname><given-names>KJ</given-names></name>, <name><surname>Strongin</surname><given-names>RM</given-names></name>. <year>2019</year>. <article-title>Aerosol Gas-Phase Components from Cannabis E-Cigarettes and Dabbing: Mechanistic Insight and Quantitative Risk Analysis</article-title>. <source>ACS Omega</source>. <volume>4</volume>(<issue>14</issue>):<fpage>16111</fpage>&#x02013;<lpage>16120</lpage>.<pub-id pub-id-type="pmid">31592479</pub-id></mixed-citation></ref><ref id="R189"><mixed-citation publication-type="journal"><name><surname>Messina</surname><given-names>MD</given-names></name>, <name><surname>Levin</surname><given-names>TL</given-names></name>, <name><surname>Conrad</surname><given-names>LA</given-names></name>, <name><surname>Bidiwala</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>Vaping associated lung injury: A potentially life-threatening epidemic in US youth [case series]</article-title>. <source>Pediatr Pulmonol</source>. <volume>55</volume>(<issue>7</issue>):<fpage>1705</fpage>&#x02013;<lpage>1711</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32251551</pub-id></mixed-citation></ref><ref id="R190"><mixed-citation publication-type="journal"><name><surname>Mikheev</surname><given-names>VB</given-names></name>, <name><surname>Ivanov</surname><given-names>A</given-names></name>. <year>2022</year>. <article-title>Analysis of the Aerosol Generated from Tetrahydrocannabinol, Vitamin E Acetate, and Their Mixtures</article-title>. <source>Toxics</source>. <volume>10</volume>(<issue>2</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R191"><mixed-citation publication-type="journal"><name><surname>Mikheev</surname><given-names>VB</given-names></name>, <name><surname>Klupinski</surname><given-names>TP</given-names></name>, <name><surname>Ivanov</surname><given-names>A</given-names></name>, <name><surname>Lucas</surname><given-names>EA</given-names></name>, <name><surname>Strozier</surname><given-names>ED</given-names></name>, <name><surname>Fix</surname><given-names>C</given-names></name>. <year>2020</year>. <article-title>Particle Size Distribution and Chemical Composition of the Aerosolized Vitamin E Acetate [research NP]</article-title>. <source>Aerosol Sci Technol</source>. <volume>54</volume>(<issue>9</issue>):<fpage>993</fpage>&#x02013;<lpage>998</lpage>.<pub-id pub-id-type="pmid">33132476</pub-id></mixed-citation></ref><ref id="R192"><mixed-citation publication-type="journal"><name><surname>Mikosz</surname><given-names>CA</given-names></name>, <name><surname>Danielson</surname><given-names>M</given-names></name>, <name><surname>Anderson</surname><given-names>KN</given-names></name>, <name><surname>Pollack</surname><given-names>LA</given-names></name>, <name><surname>Currie</surname><given-names>DW</given-names></name>, <name><surname>Njai</surname><given-names>R</given-names></name>, <name><surname>Evans</surname><given-names>ME</given-names></name>, <name><surname>Goodman</surname><given-names>AB</given-names></name>, <name><surname>Twentyman</surname><given-names>E</given-names></name>, <name><surname>Wiltz</surname><given-names>JL</given-names></name>
<etal/>
<year>2020</year>. <article-title>Characteristics of Patients Experiencing Rehospitalization or Death After Hospital Discharge in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>5152</issue>):<fpage>1183</fpage>&#x02013;<lpage>1188</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31895917</pub-id></mixed-citation></ref><ref id="R193"><mixed-citation publication-type="journal"><name><surname>Miskoff</surname><given-names>JA</given-names></name>, <name><surname>Chaudhri</surname><given-names>M</given-names></name>. <year>2020</year>. <article-title>E-cigarette or Vaping Product Use-associated Lung Injury: A Case of an Adult Female Leading to Hospitalization [case report]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>1</issue>):<fpage>e6765</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32140332</pub-id></mixed-citation></ref><ref id="R194"><mixed-citation publication-type="journal"><name><surname>Modi</surname><given-names>S</given-names></name>, <name><surname>Sangani</surname><given-names>R</given-names></name>, <name><surname>Alhajhusain</surname><given-names>A</given-names></name>. <year>2015</year>. <article-title>Acute Lipoid Pneumonia Secondary to E-Cigarettes Use: An Unlikely Replacement for Cigarettes</article-title>. <source>Chest</source>. <volume>148</volume>(<issue>4</issue>):<fpage>382A</fpage>.<pub-id pub-id-type="pmid">25569856</pub-id></mixed-citation></ref><ref id="R195"><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>K</given-names></name>, <name><surname>Young Ii</surname><given-names>H</given-names></name>, <name><surname>Ryan</surname><given-names>MF</given-names></name>. <year>2015</year>. <article-title>Bilateral Pneumonia and Pleural Effusions Subsequent to Electronic Cigarette Use [case report]</article-title>. <source>Open Journal of Emergency Medicine</source>. <volume>03</volume>(<issue>03</issue>):<fpage>18</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="R196"><mixed-citation publication-type="journal"><name><surname>Moritz</surname><given-names>ED</given-names></name>, <name><surname>Zapata</surname><given-names>LB</given-names></name>, <name><surname>Lekiachvili</surname><given-names>A</given-names></name>, <name><surname>Glidden</surname><given-names>E</given-names></name>, <name><surname>Annor</surname><given-names>FB</given-names></name>, <name><surname>Werner</surname><given-names>AK</given-names></name>, <name><surname>Ussery</surname><given-names>EN</given-names></name>, <name><surname>Hughes</surname><given-names>MM</given-names></name>, <name><surname>Kimball</surname><given-names>A</given-names></name>, <name><surname>DeSisto</surname><given-names>CL</given-names></name>
<etal/>
<year>2019</year>. <article-title>Update: Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injuries - United States, October 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>43</issue>):<fpage>985</fpage>&#x02013;<lpage>989</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31671085</pub-id></mixed-citation></ref><ref id="R197"><mixed-citation publication-type="journal"><name><surname>Moshensky</surname><given-names>A</given-names></name>, <name><surname>Du</surname><given-names>M</given-names></name>, <name><surname>Shin</surname><given-names>J</given-names></name>, <name><surname>Advani</surname><given-names>I</given-names></name>, <name><surname>Gunge</surname><given-names>D</given-names></name>, <name><surname>Mathew</surname><given-names>D</given-names></name>, <name><surname>Alkolla</surname><given-names>R</given-names></name>, <name><surname>Du</surname><given-names>A</given-names></name>, <name><surname>Javier</surname><given-names>C</given-names></name>, <name><surname>Ma</surname><given-names>L</given-names></name>. <year>2021</year>. <article-title>Vaping-induced metabolomic signatures in the circulation of mice are driven by device type, e-liquid, exposure duration and sex</article-title>. <source>ERJ Open Research</source>. <volume>7</volume>(<issue>3</issue>).</mixed-citation></ref><ref id="R198"><mixed-citation publication-type="journal"><name><surname>Mughal</surname><given-names>MS</given-names></name>, <name><surname>Dalmacion</surname><given-names>DLV</given-names></name>, <name><surname>Mirza</surname><given-names>HM</given-names></name>, <name><surname>Kaur</surname><given-names>IP</given-names></name>, <name><surname>Dela Cruz</surname><given-names>MA</given-names></name>, <name><surname>Kramer</surname><given-names>VE</given-names></name>. <year>2020</year>. <article-title>E-cigarette or vaping product use associated lung injury, (EVALI) - A diagnosis of exclusion [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>31</volume>:<fpage>101174</fpage>.<pub-id pub-id-type="pmid">32775191</pub-id></mixed-citation></ref><ref id="R199"><mixed-citation publication-type="journal"><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name>, <name><surname>Mehrad</surname><given-names>M</given-names></name>, <name><surname>Dammert</surname><given-names>P</given-names></name>, <name><surname>Arrossi</surname><given-names>AV</given-names></name>, <name><surname>Sarda</surname><given-names>R</given-names></name>, <name><surname>Brenner</surname><given-names>DS</given-names></name>, <name><surname>Maldonado</surname><given-names>F</given-names></name>, <name><surname>Choi</surname><given-names>H</given-names></name>, <name><surname>Ghobrial</surname><given-names>M</given-names></name>. <year>2020</year>. <article-title>Lung Biopsy Findings in Severe Pulmonary Illness Associated With E-Cigarette Use (Vaping) [case series]</article-title>. <source>Am J Clin Pathol</source>. <volume>153</volume>(<issue>1</issue>):<fpage>30</fpage>&#x02013;<lpage>39</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31621873</pub-id></mixed-citation></ref><ref id="R200"><mixed-citation publication-type="journal"><name><surname>Mull</surname><given-names>ES</given-names></name>, <name><surname>Erdem</surname><given-names>G</given-names></name>, <name><surname>Nicol</surname><given-names>K</given-names></name>, <name><surname>Adler</surname><given-names>B</given-names></name>, <name><surname>Shell</surname><given-names>R</given-names></name>. <year>2020</year>. <article-title>Eosinophilic Pneumonia and Lymphadenopathy Associated With Vaping and Tetrahydrocannabinol Use [case report]</article-title>. <source>Pediatrics</source>. <volume>145</volume>(<issue>4</issue>).</mixed-citation></ref><ref id="R201"><mixed-citation publication-type="journal"><name><surname>Mull</surname><given-names>ES</given-names></name>, <name><surname>Shell</surname><given-names>R</given-names></name>, <name><surname>Adler</surname><given-names>B</given-names></name>, <name><surname>Holtzlander</surname><given-names>M</given-names></name>. <year>2020</year>. <article-title>Bronchiectasis associated with electronic cigarette use: A case series [case series]</article-title>. <source>Pediatr Pulmonol</source>. <volume>55</volume>(<issue>12</issue>):<fpage>3443</fpage>&#x02013;<lpage>3449</lpage>.<pub-id pub-id-type="pmid">32902877</pub-id></mixed-citation></ref><ref id="R202"><mixed-citation publication-type="journal"><name><surname>Munagala</surname><given-names>R</given-names></name>, <name><surname>Ullah</surname><given-names>A</given-names></name>, <name><surname>Sharma</surname><given-names>C</given-names></name>, <name><surname>Bhatt</surname><given-names>AN</given-names></name>, <name><surname>Keshavamurthy</surname><given-names>J</given-names></name>. <year>2021</year>. <article-title>Smoky Diagnosis: Importance of Patient History in Vaping Associated Lung Injury [case report]</article-title>. <source>Cureus</source>. <volume>13</volume>(<issue>11</issue>):<fpage>e19596</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34926065</pub-id></mixed-citation></ref><ref id="R203"><mixed-citation publication-type="journal"><name><surname>Muthumalage</surname><given-names>T</given-names></name>, <name><surname>Friedman</surname><given-names>MR</given-names></name>, <name><surname>McGraw</surname><given-names>MD</given-names></name>, <name><surname>Ginsberg</surname><given-names>G</given-names></name>, <name><surname>Friedman</surname><given-names>AE</given-names></name>, <name><surname>Rahman</surname><given-names>I</given-names></name>. <year>2020</year>. <article-title>Chemical Constituents Involved in E-Cigarette, or Vaping Product Use-Associated Lung Injury (EVALI) [research tox]</article-title>. <source>Toxics</source>. <volume>8</volume>(<issue>2</issue>).</mixed-citation></ref><ref id="R204"><mixed-citation publication-type="journal"><name><surname>Muthumalage</surname><given-names>T</given-names></name>, <name><surname>Lucas</surname><given-names>JH</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Lamb</surname><given-names>T</given-names></name>, <name><surname>McGraw</surname><given-names>MD</given-names></name>, <name><surname>Rahman</surname><given-names>I</given-names></name>. <year>2020a</year>. <article-title>Pulmonary Toxicity and Inflammatory Response of E-Cigarette Vape Cartridges Containing Medium-Chain Triglycerides Oil and Vitamin E Acetate: Implications in the Pathogenesis of EVALI [research in vitro]</article-title>. <source>Toxics</source>. <volume>8</volume>(<issue>3</issue>).</mixed-citation></ref><ref id="R205"><mixed-citation publication-type="journal"><name><surname>Muthumalage</surname><given-names>T</given-names></name>, <name><surname>Lucas</surname><given-names>JH</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Lamb</surname><given-names>T</given-names></name>, <name><surname>McGraw</surname><given-names>MD</given-names></name>, <name><surname>Rahman</surname><given-names>I</given-names></name>. <year>2020b</year>. <article-title>Pulmonary toxicity and inflammatory response of e-cigarettes containing medium-chain triglyceride oil and vitamin E acetate: Implications in the pathogenesis of EVALI but independent of SARS-COV-2 COVID-19 related proteins</article-title>. <source>bioRxiv</source>. <comment>eng.</comment></mixed-citation></ref><ref id="R206"><mixed-citation publication-type="journal"><name><surname>Muthumalage</surname><given-names>T</given-names></name>, <name><surname>Rahman</surname><given-names>I</given-names></name>. <year>2019</year>. <article-title>Cannabidiol differentially regulates basal and LPS-induced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts [research in vitro]</article-title>. <source>Toxicol Appl Pharmacol</source>. <volume>382</volume>:<fpage>114713</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31437494</pub-id></mixed-citation></ref><ref id="R207"><mixed-citation publication-type="journal"><name><surname>Narimani</surname><given-names>M</given-names></name>, <name><surname>da Silva</surname><given-names>G</given-names></name>. <year>2020</year>. <article-title>Does &#x02018;Dry Hit&#x02019; vaping of vitamin E acetate contribute to EVALI? Simulating toxic ketene formation during e-cigarette use [research tox]</article-title>. <source>PLoS One</source>. <volume>15</volume>(<issue>9</issue>):<fpage>e0238140</fpage>.<pub-id pub-id-type="pmid">32881943</pub-id></mixed-citation></ref><ref id="R208"><mixed-citation publication-type="book"><collab>National Institute for Occupational Safety and Health NIOSH</collab>. <year>1994</year>. <publisher-name>Ketene</publisher-name>.</mixed-citation></ref><ref id="R209"><mixed-citation publication-type="journal"><name><surname>Navon</surname><given-names>L</given-names></name>, <name><surname>Jones</surname><given-names>CM</given-names></name>, <name><surname>Ghinai</surname><given-names>I</given-names></name>, <name><surname>King</surname><given-names>BA</given-names></name>, <name><surname>Briss</surname><given-names>PA</given-names></name>, <name><surname>Hacker</surname><given-names>KA</given-names></name>, <name><surname>Layden</surname><given-names>JE</given-names></name>. <year>2019</year>. <article-title>Risk Factors for E-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) Among Adults Who Use E-Cigarette, or Vaping, Products - Illinois, July-October 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>45</issue>):<fpage>1034</fpage>&#x02013;<lpage>1039</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31725708</pub-id></mixed-citation></ref><ref id="R210"><mixed-citation publication-type="book"><collab>NewYorkState</collab>. <year>2020</year>. <publisher-name>New York State Department of Health</publisher-name>. <source>Comprehensive Tobacco Control Policy</source>, <comment><ext-link xlink:href="https://health.ny.gov/press/releases/2020/2020-05-18_fl_nicotine_vapor_products_ban.htm" ext-link-type="uri">https://health.ny.gov/press/releases/2020/2020-05-18_fl_nicotine_vapor_products_ban.htm</ext-link></comment>.</mixed-citation></ref><ref id="R211"><mixed-citation publication-type="journal"><name><surname>Nicol</surname><given-names>J</given-names></name>, <name><surname>Fraser</surname><given-names>R</given-names></name>, <name><surname>Walker</surname><given-names>L</given-names></name>, <name><surname>Liu</surname><given-names>C</given-names></name>, <name><surname>Murphy</surname><given-names>J</given-names></name>, <name><surname>Proctor</surname><given-names>CJ</given-names></name>. <year>2020</year>. <article-title>Comprehensive Chemical Characterization of the Aerosol Emissions of a Vaping Product Based on a New Technology [research tox]</article-title>. <source>Chem Res Toxicol</source>. <volume>33</volume>(<issue>3</issue>):<fpage>789</fpage>&#x02013;<lpage>799</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32122129</pub-id></mixed-citation></ref><ref id="R212"><mixed-citation publication-type="journal"><name><surname>O&#x02019;Carroll</surname><given-names>O</given-names></name>, <name><surname>Sharma</surname><given-names>K</given-names></name>, <name><surname>Fabre</surname><given-names>A</given-names></name>, <name><surname>Murphy</surname><given-names>DJ</given-names></name>, <name><surname>Keane</surname><given-names>MP</given-names></name>, <name><surname>McCarthy</surname><given-names>C</given-names></name>. <year>2020</year>. <article-title>Vaping-associated lung injury [case report]</article-title>. <source>Thorax</source>. <volume>75</volume>(<issue>8</issue>):<fpage>706</fpage>&#x02013;<lpage>707</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32414864</pub-id></mixed-citation></ref><ref id="R213"><mixed-citation publication-type="journal"><name><surname>Ocampo-Gonzalez</surname><given-names>FA</given-names></name>, <name><surname>Park</surname><given-names>JW</given-names></name>. <year>2020</year>. <article-title>Cytologic features of vaping-induced lung injury: A case report [case report]</article-title>. <source>Diagn Cytopathol</source>. <volume>48</volume>(<issue>2</issue>):<fpage>174</fpage>&#x02013;<lpage>176</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31714032</pub-id></mixed-citation></ref><ref id="R214"><mixed-citation publication-type="journal"><name><surname>Odish</surname><given-names>MF</given-names></name>, <name><surname>Bellinghausen</surname><given-names>A</given-names></name>, <name><surname>Golts</surname><given-names>E</given-names></name>, <name><surname>Owens</surname><given-names>RL</given-names></name>. <year>2020</year>. <article-title>E-cigarette, or vaping, product use-associated lung injury (EVALI) treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO) and ultra-protective ventilator settings [case report]</article-title>. <source>BMJ Case Rep</source>. <volume>13</volume>(<issue>7</issue>).</mixed-citation></ref><ref id="R215"><mixed-citation publication-type="journal"><name><surname>Omaiye</surname><given-names>EE</given-names></name>, <name><surname>McWhirter</surname><given-names>KJ</given-names></name>, <name><surname>Luo</surname><given-names>W</given-names></name>, <name><surname>Pankow</surname><given-names>JF</given-names></name>, <name><surname>Talbot</surname><given-names>P</given-names></name>. <year>2019</year>. <article-title>High-Nicotine Electronic Cigarette Products: Toxicity of JUUL Fluids and Aerosols Correlates Strongly with Nicotine and Some Flavor Chemical Concentrations [research tox]</article-title>. <source>Chem Res Toxicol</source>. <volume>32</volume>(<issue>6</issue>):<fpage>1058</fpage>&#x02013;<lpage>1069</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">30896936</pub-id></mixed-citation></ref><ref id="R216"><mixed-citation publication-type="journal"><name><surname>Pajak</surname><given-names>A</given-names></name>, <name><surname>Bascoy</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>JC</given-names></name>, <name><surname>Benninghoff</surname><given-names>M</given-names></name>, <name><surname>Deitchman</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>E-cigarette or Vaping Product Use Associated Lung Injury Among Three Young Adults: A Retrospective Case Series From Delaware [cases series]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>10</issue>):<fpage>e11031</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33224641</pub-id></mixed-citation></ref><ref id="R217"><mixed-citation publication-type="journal"><name><surname>Panse</surname><given-names>PM</given-names></name>, <name><surname>Feller</surname><given-names>FF</given-names></name>, <name><surname>Butt</surname><given-names>YM</given-names></name>, <name><surname>Smith</surname><given-names>ML</given-names></name>, <name><surname>Larsen</surname><given-names>BT</given-names></name>, <name><surname>Tazelaar</surname><given-names>HD</given-names></name>, <name><surname>Harvin</surname><given-names>HJ</given-names></name>, <name><surname>Gotway</surname><given-names>MB</given-names></name>. <year>2020</year>. <article-title>Radiologic and Pathologic Correlation in EVALI [case series]</article-title>. <source>AJR Am J Roentgenol</source>. <volume>215</volume>(<issue>5</issue>):<fpage>1057</fpage>&#x02013;<lpage>1064</lpage>.<pub-id pub-id-type="pmid">32877245</pub-id></mixed-citation></ref><ref id="R218"><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>H-R</given-names></name>, <name><surname>O&#x02019;Sullivan</surname><given-names>M</given-names></name>, <name><surname>Vallarino</surname><given-names>J</given-names></name>, <name><surname>Shumyatcher</surname><given-names>M</given-names></name>, <name><surname>Himes</surname><given-names>BE</given-names></name>, <name><surname>Park</surname><given-names>J-A</given-names></name>, <name><surname>Christiani</surname><given-names>DC</given-names></name>, <name><surname>Allen</surname><given-names>J</given-names></name>, <name><surname>Lu</surname><given-names>Q</given-names></name>. <year>2019</year>. <article-title>Transcriptomic response of primary human airway epithelial cells to flavoring chemicals in electronic cigarettes</article-title>. <source>Scientific reports</source>. <volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">30626917</pub-id></mixed-citation></ref><ref id="R219"><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>HR</given-names></name>, <name><surname>Vallarino</surname><given-names>J</given-names></name>, <name><surname>O&#x02019;Sullivan</surname><given-names>M</given-names></name>, <name><surname>Wirth</surname><given-names>C</given-names></name>, <name><surname>Panganiban</surname><given-names>RA</given-names></name>, <name><surname>Webb</surname><given-names>G</given-names></name>, <name><surname>Shumyatcher</surname><given-names>M</given-names></name>, <name><surname>Himes</surname><given-names>BE</given-names></name>, <name><surname>Park</surname><given-names>JA</given-names></name>, <name><surname>Christiani</surname><given-names>DC</given-names></name>
<etal/>
<year>2021</year>. <article-title>Electronic cigarette smoke reduces ribosomal protein gene expression to impair protein synthesis in primary human airway epithelial cells [researh in vitro]</article-title>. <source>Sci Rep</source>. <volume>11</volume>(<issue>1</issue>):<fpage>17517</fpage>.<pub-id pub-id-type="pmid">34471210</pub-id></mixed-citation></ref><ref id="R220"><mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>VN</given-names></name>, <name><surname>Rouse</surname><given-names>M</given-names></name>, <name><surname>Brown</surname><given-names>C</given-names></name>, <name><surname>Pandya</surname><given-names>S</given-names></name>. <year>2020</year>. <article-title>Ground Glass Opacities Observed in a 26-Year-Old Coronavirus Disease 2019 (COVID-19) Rule-Out Patient With a History of Vape Use [case report]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>9</issue>):<fpage>e10302</fpage>.<pub-id pub-id-type="pmid">33052265</pub-id></mixed-citation></ref><ref id="R221"><mixed-citation publication-type="journal"><name><surname>Patten</surname><given-names>SB</given-names></name>. <year>2021</year>. <article-title>Vaping and Mental Health [commentary]</article-title>. <source>J Can Acad Child Adolesc Psychiatry</source>. <volume>30</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">33552167</pub-id></mixed-citation></ref><ref id="R222"><mixed-citation publication-type="journal"><name><surname>Perrenoud</surname><given-names>A</given-names></name>, <name><surname>Vetos</surname><given-names>D</given-names></name>, <name><surname>Wabwire</surname><given-names>G</given-names></name>. <year>2020</year>. <article-title>Vaping-induced lung injury in a 21-year-old woman [case report]</article-title>. <source>BMJ Case Rep</source>. <volume>13</volume>(<issue>11</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R223"><mixed-citation publication-type="journal"><name><surname>Perrine</surname><given-names>CG</given-names></name>, <name><surname>Pickens</surname><given-names>CM</given-names></name>, <name><surname>Boehmer</surname><given-names>TK</given-names></name>, <name><surname>King</surname><given-names>BA</given-names></name>, <name><surname>Jones</surname><given-names>CM</given-names></name>, <name><surname>DeSisto</surname><given-names>CL</given-names></name>, <name><surname>Duca</surname><given-names>LM</given-names></name>, <name><surname>Lekiachvili</surname><given-names>A</given-names></name>, <name><surname>Kenemer</surname><given-names>B</given-names></name>, <name><surname>Shamout</surname><given-names>M</given-names></name>
<etal/>
<year>2019</year>. <article-title>Characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping - United States, 2019</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>39</issue>):<fpage>860</fpage>&#x02013;<lpage>864</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31581168</pub-id></mixed-citation></ref><ref id="R224"><mixed-citation publication-type="journal"><name><surname>Phung</surname><given-names>B</given-names></name>, <name><surname>Lam</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>Pediatric Acute Respiratory Distress Syndrome and Hypersensitivity Pneumonitis Related to E-cigarette Vaping [case report]</article-title>. <source>J Pediatr Intensive Care</source>. <volume>9</volume>(<issue>2</issue>):<fpage>128</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">32351768</pub-id></mixed-citation></ref><ref id="R225"><mixed-citation publication-type="journal"><name><surname>Pitlick</surname><given-names>MM</given-names></name>, <name><surname>Lang</surname><given-names>DK</given-names></name>, <name><surname>Meehan</surname><given-names>AM</given-names></name>, <name><surname>McCoy</surname><given-names>CP</given-names></name>. <year>2021</year>. <article-title>EVALI: A Mimicker of COVID-19 [case report]</article-title>. <source>Mayo Clin Proc Innov Qual Outcomes</source>. <volume>5</volume>(<issue>3</issue>):<fpage>682</fpage>&#x02013;<lpage>687</lpage>. <comment>English.</comment><pub-id pub-id-type="pmid">33817560</pub-id></mixed-citation></ref><ref id="R226"><mixed-citation publication-type="journal"><name><surname>Podguski</surname><given-names>S</given-names></name>, <name><surname>Kaur</surname><given-names>G</given-names></name>, <name><surname>Muthumalage</surname><given-names>T</given-names></name>, <name><surname>McGraw</surname><given-names>MD</given-names></name>, <name><surname>Rahman</surname><given-names>I</given-names></name>. <year>2022</year>. <article-title>Noninvasive systemic biomarkers of e-cigarette or vaping use-associated lung injury: a pilot study</article-title>. <source>ERJ Open Res</source>. <volume>8</volume>(<issue>2</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R227"><mixed-citation publication-type="journal"><name><surname>Poschenrieder</surname><given-names>F</given-names></name>, <name><surname>Rotter</surname><given-names>M</given-names></name>, <name><surname>Gschwendtner</surname><given-names>A</given-names></name>, <name><surname>Hamer</surname><given-names>OW</given-names></name>. <year>2020</year>. <article-title>E-cigarette-induced lung disease: from acute to chronic [case report]</article-title>. <source>Lancet</source>. <volume>396</volume>(<issue>10250</issue>):<fpage>564</fpage>.<pub-id pub-id-type="pmid">32828188</pub-id></mixed-citation></ref><ref id="R228"><mixed-citation publication-type="journal"><name><surname>Pourchez</surname><given-names>J</given-names></name>, <name><surname>Parisse</surname><given-names>S</given-names></name>, <name><surname>Sarry</surname><given-names>G</given-names></name>, <name><surname>Perinel-Ragey</surname><given-names>S</given-names></name>, <name><surname>Vergnon</surname><given-names>J-M</given-names></name>, <name><surname>Clotagatide</surname><given-names>A</given-names></name>, <name><surname>Pr&#x000e9;v&#x000f4;t</surname><given-names>N</given-names></name>. <year>2018</year>. <article-title>Impact of power level and refill liquid composition on the aerosol output and particle size distribution generated by a new-generation e-cigarette device [research NP]</article-title>. <source>Aerosol Science and Technology</source>. <volume>52</volume>(<issue>4</issue>):<fpage>359</fpage>&#x02013;<lpage>369</lpage>.</mixed-citation></ref><ref id="R229"><mixed-citation publication-type="journal"><name><surname>Pray</surname><given-names>IW</given-names></name>, <name><surname>Atti</surname><given-names>SK</given-names></name>, <name><surname>Tomasallo</surname><given-names>C</given-names></name>, <name><surname>Meiman</surname><given-names>JG</given-names></name>. <year>2020</year>. <article-title>E-cigarette, or Vaping, Product Use-Associated Lung Injury Among Clusters of Patients Reporting Shared Product Use - Wisconsin, 2019 [MMWR report]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>69</volume>(<issue>9</issue>):<fpage>236</fpage>&#x02013;<lpage>240</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32134907</pub-id></mixed-citation></ref><ref id="R230"><mixed-citation publication-type="journal"><name><surname>Priemer</surname><given-names>DS</given-names></name>, <name><surname>Gravenmier</surname><given-names>C</given-names></name>, <name><surname>Batouli</surname><given-names>A</given-names></name>, <name><surname>Hooper</surname><given-names>JE</given-names></name>. <year>2020</year>. <article-title>Overview of Pathologic Findings of Vaping in the Context of an Autopsy Patient With Chronic Injury [case report]</article-title>. <source>Arch Pathol Lab Med</source>. <volume>144</volume>(<issue>11</issue>):<fpage>1408</fpage>&#x02013;<lpage>1413</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32383974</pub-id></mixed-citation></ref><ref id="R231"><mixed-citation publication-type="journal"><name><surname>Puebla Neira</surname><given-names>D</given-names></name>, <name><surname>Tambra</surname><given-names>S</given-names></name>, <name><surname>Bhasin</surname><given-names>V</given-names></name>, <name><surname>Nawgiri</surname><given-names>R</given-names></name>, <name><surname>Duarte</surname><given-names>AG</given-names></name>. <year>2020</year>. <article-title>Discordant bilateral bronchoalveolar lavage findings in a patient with acute eosinophilic pneumonia associated with counterfeit tetrahydrocannabinol oil vaping [case report]</article-title>. <source>Respir Med Case Rep</source>. <volume>29</volume>:<fpage>101015</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32071854</pub-id></mixed-citation></ref><ref id="R232"><mixed-citation publication-type="journal"><name><surname>Qarajeh</surname><given-names>R</given-names></name>, <name><surname>Kitchen</surname><given-names>J</given-names></name>. <year>2020</year>. <article-title>THC Vaping-Induced Acute Respiratory Distress Syndrome [case report commentary]</article-title>. <source>Am J Med</source>. <volume>133</volume>(<issue>4</issue>):<fpage>e147</fpage>&#x02013;<lpage>e148</lpage>.<pub-id pub-id-type="pmid">31794698</pub-id></mixed-citation></ref><ref id="R233"><mixed-citation publication-type="journal"><name><surname>Rao</surname><given-names>DR</given-names></name>, <name><surname>Maple</surname><given-names>KL</given-names></name>, <name><surname>Dettori</surname><given-names>A</given-names></name>, <name><surname>Afolabi</surname><given-names>F</given-names></name>, <name><surname>Francis</surname><given-names>JKR</given-names></name>, <name><surname>Artunduaga</surname><given-names>M</given-names></name>, <name><surname>Lieu</surname><given-names>TJ</given-names></name>, <name><surname>Aldy</surname><given-names>K</given-names></name>, <name><surname>Cao</surname><given-names>DJ</given-names></name>, <name><surname>Hsu</surname><given-names>S</given-names></name>
<etal/>
<year>2020</year>. <article-title>Clinical Features of E-cigarette, or Vaping, Product Use-Associated Lung Injury in Teenagers [case series]</article-title>. <source>Pediatrics</source>. <volume>146</volume>(<issue>1</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R234"><mixed-citation publication-type="journal"><name><surname>Reagan-Steiner</surname><given-names>S</given-names></name>, <name><surname>Gary</surname><given-names>J</given-names></name>, <name><surname>Matkovic</surname><given-names>E</given-names></name>, <name><surname>Ritter</surname><given-names>JM</given-names></name>, <name><surname>Shieh</surname><given-names>WJ</given-names></name>, <name><surname>Martines</surname><given-names>RB</given-names></name>, <name><surname>Werner</surname><given-names>AK</given-names></name>, <name><surname>Lynfield</surname><given-names>R</given-names></name>, <name><surname>Holzbauer</surname><given-names>S</given-names></name>, <name><surname>Bullock</surname><given-names>H</given-names></name>
<etal/>
<year>2020</year>. <article-title>Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series [case series]</article-title>. <source>Lancet Respir Med</source>. <volume>8</volume>(<issue>12</issue>):<fpage>1219</fpage>&#x02013;<lpage>1232</lpage>.<pub-id pub-id-type="pmid">32763198</pub-id></mixed-citation></ref><ref id="R235"><mixed-citation publication-type="journal"><name><surname>Reddy</surname><given-names>A</given-names></name>, <name><surname>Jenssen</surname><given-names>BP</given-names></name>, <name><surname>Chidambaram</surname><given-names>A</given-names></name>, <name><surname>Yehya</surname><given-names>N</given-names></name>, <name><surname>Lindell</surname><given-names>RB</given-names></name>. <year>2021</year>. <article-title>Characterizing e-cigarette vaping-associated lung injury in the pediatric intensive care unit [case report]</article-title>. <source>Pediatr Pulmonol</source>. <volume>56</volume>(<issue>1</issue>):<fpage>162</fpage>&#x02013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">32970368</pub-id></mixed-citation></ref><ref id="R236"><mixed-citation publication-type="journal"><name><surname>Register</surname><given-names>F</given-names></name>
<year>2016</year>. <article-title>Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products</article-title>; <source>Final Rule</source>. <comment>21 CFR Parts 1100, 1140, and 1143</comment>
<volume>81</volume>(<issue>90</issue>).</mixed-citation></ref><ref id="R237"><mixed-citation publication-type="journal"><name><surname>Regmi</surname><given-names>MR</given-names></name>, <name><surname>Tandan</surname><given-names>N</given-names></name>, <name><surname>Parajuli</surname><given-names>P</given-names></name>, <name><surname>Maini</surname><given-names>R</given-names></name>, <name><surname>Lara Garcia</surname><given-names>OE</given-names></name>, <name><surname>Jagtap</surname><given-names>P</given-names></name>, <name><surname>Kulkarni</surname><given-names>A</given-names></name>. <year>2021</year>. <article-title>Extracorporeal membranous oxygenation for a severe case of vaping associated lung injury</article-title>. <source>Pulmonology</source>. <volume>27</volume>(<issue>1</issue>):<fpage>69</fpage>&#x02013;<lpage>70</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32507701</pub-id></mixed-citation></ref><ref id="R238"><mixed-citation publication-type="webpage"><name><surname>Research</surname><given-names>GV</given-names></name>. <year>2021</year>. <source>E-cigarette And Vape Market Growth &#x00026; Trends</source>, <comment>Available online</comment>: <comment><ext-link xlink:href="https://www.grandviewresearch.com/press-release/global-e-cigarette-vaping-market#" ext-link-type="uri">https://www.grandviewresearch.com/press-release/global-e-cigarette-vaping-market#</ext-link></comment> (<date-in-citation>updated May 2021</date-in-citation>).</mixed-citation></ref><ref id="R239"><mixed-citation publication-type="journal"><name><surname>Ring Madsen</surname><given-names>L</given-names></name>, <name><surname>Vinther Krarup</surname><given-names>NH</given-names></name>, <name><surname>Bergmann</surname><given-names>TK</given-names></name>, <name><surname>Baerentzen</surname><given-names>S</given-names></name>, <name><surname>Neghabat</surname><given-names>S</given-names></name>, <name><surname>Duval</surname><given-names>L</given-names></name>, <name><surname>Knudsen</surname><given-names>ST</given-names></name>. <year>2016</year>. <article-title>A Cancer That Went Up in Smoke: Pulmonary Reaction to e-Cigarettes Imitating Metastatic Cancer [article]</article-title>. <source>Chest</source>. <volume>149</volume>(<issue>3</issue>):<fpage>e65</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">26965975</pub-id></mixed-citation></ref><ref id="R240"><mixed-citation publication-type="journal"><name><surname>Rodriguez</surname><given-names>JA</given-names></name>, <name><surname>Roa</surname><given-names>AA</given-names></name>, <name><surname>Lemos-Ramirez</surname><given-names>JC</given-names></name>. <year>2020</year>. <article-title>E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) Mimicking COVID-19 Disease [case report]</article-title>. <source>Case Rep Pulmonol</source>. <volume>2020</volume>:<fpage>8821289</fpage>. <comment>English.</comment><pub-id pub-id-type="pmid">33204563</pub-id></mixed-citation></ref><ref id="R241"><mixed-citation publication-type="journal"><name><surname>Roman</surname><given-names>S</given-names></name>, <name><surname>Millet</surname><given-names>C</given-names></name>, <name><surname>Geris</surname><given-names>S</given-names></name>, <name><surname>Manickam</surname><given-names>R</given-names></name>, <name><surname>Mechineni</surname><given-names>A</given-names></name>. <year>2021</year>. <article-title>Crazy vaping and crazy-paving, a case of E-Cigarette/Vaping-Associated Lung Injury (EVALI) with chest CT showing crazy-paving pattern</article-title>. <source>Radiol Case Rep</source>. <volume>16</volume>(<issue>11</issue>):<fpage>3208</fpage>&#x02013;<lpage>3212</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34484520</pub-id></mixed-citation></ref><ref id="R242"><mixed-citation publication-type="journal"><name><surname>Ronald</surname><given-names>AA</given-names></name>, <name><surname>Defta</surname><given-names>D</given-names></name>, <name><surname>Wright</surname><given-names>J</given-names></name>, <name><surname>Rothstein</surname><given-names>B</given-names></name>. <year>2020</year>. <article-title>Extensive Pneumorrhachis Associated with Vaping-Induced Lung Injury [case report]</article-title>. <source>World Neurosurg</source>. <volume>140</volume>:<fpage>308</fpage>&#x02013;<lpage>311</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32473332</pub-id></mixed-citation></ref><ref id="R243"><mixed-citation publication-type="journal"><name><surname>Rouabhia</surname><given-names>M</given-names></name>, <name><surname>Park</surname><given-names>HJ</given-names></name>, <name><surname>Semlali</surname><given-names>A</given-names></name>, <name><surname>Zakrzewski</surname><given-names>A</given-names></name>, <name><surname>Chmielewski</surname><given-names>W</given-names></name>, <name><surname>Chakir</surname><given-names>J</given-names></name>. <year>2017</year>. <article-title>E&#x02010;cigarette vapor induces an apoptotic response in human gingival epithelial cells through the caspase&#x02010;3 pathway</article-title>. <source>Journal of cellular physiology</source>. <volume>232</volume>(<issue>6</issue>):<fpage>1539</fpage>&#x02013;<lpage>1547</lpage>.<pub-id pub-id-type="pmid">27808425</pub-id></mixed-citation></ref><ref id="R244"><mixed-citation publication-type="journal"><name><surname>Rowell</surname><given-names>TR</given-names></name>, <name><surname>Keating</surname><given-names>JE</given-names></name>, <name><surname>Zorn</surname><given-names>BT</given-names></name>, <name><surname>Glish</surname><given-names>GL</given-names></name>, <name><surname>Shears</surname><given-names>SB</given-names></name>, <name><surname>Tarran</surname><given-names>R</given-names></name>. <year>2020</year>. <article-title>Flavored e-liquids increase cytoplasmic Ca(2+) levels in airway epithelia</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <volume>318</volume>(<issue>2</issue>):<fpage>L226</fpage>&#x02013;<lpage>L241</lpage>.<pub-id pub-id-type="pmid">31693394</pub-id></mixed-citation></ref><ref id="R245"><mixed-citation publication-type="journal"><name><surname>Sacci</surname><given-names>P</given-names></name>, <name><surname>Au</surname><given-names>A</given-names></name>, <name><surname>Hutchinson</surname><given-names>M</given-names></name>. <year>2020</year>. <article-title>E-cigarette or vaping product use-associated lung injury (EVALI) characterized by pulmonary ultrasound [case report]</article-title>. <source>J Am Coll Emerg Physicians Open</source>. <volume>1</volume>(<issue>5</issue>):<fpage>1101</fpage>&#x02013;<lpage>1103</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33145564</pub-id></mixed-citation></ref><ref id="R246"><mixed-citation publication-type="journal"><name><surname>Sakla</surname><given-names>NM</given-names></name>, <name><surname>Gattu</surname><given-names>R</given-names></name>, <name><surname>Singh</surname><given-names>G</given-names></name>, <name><surname>Sadler</surname><given-names>M</given-names></name>. <year>2020</year>. <article-title>Vaping-associated acute respiratory distress syndrome [case report]</article-title>. <source>Emerg Radiol</source>. <volume>27</volume>(<issue>1</issue>):<fpage>103</fpage>&#x02013;<lpage>106</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31820270</pub-id></mixed-citation></ref><ref id="R247"><mixed-citation publication-type="journal"><name><surname>Salam</surname><given-names>S</given-names></name>, <name><surname>Saliba</surname><given-names>NA</given-names></name>, <name><surname>Shihadeh</surname><given-names>A</given-names></name>, <name><surname>Eissenberg</surname><given-names>T</given-names></name>, <name><surname>El-Hellani</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>Flavor-toxicant correlation in e-cigarettes: a meta-analysis [review]</article-title>. <source>Chemical research in toxicology</source>. <volume>33</volume>(<issue>12</issue>):<fpage>2932</fpage>&#x02013;<lpage>2938</lpage>.<pub-id pub-id-type="pmid">33185445</pub-id></mixed-citation></ref><ref id="R248"><mixed-citation publication-type="journal"><name><surname>Salzman</surname><given-names>GA</given-names></name>, <name><surname>Alqawasma</surname><given-names>M</given-names></name>, <name><surname>Asad</surname><given-names>H</given-names></name>. <year>2019</year>. <article-title>Vaping Associated Lung Injury (EVALI): An Explosive United States Epidemic [case report]</article-title>. <source>Mo Med</source>. <volume>116</volume>(<issue>6</issue>):<fpage>492</fpage>&#x02013;<lpage>496</lpage>.<pub-id pub-id-type="pmid">31911735</pub-id></mixed-citation></ref><ref id="R249"><mixed-citation publication-type="journal"><name><surname>Sangani</surname><given-names>R</given-names></name>, <name><surname>Rojas</surname><given-names>E</given-names></name>, <name><surname>Forte</surname><given-names>M</given-names></name>, <name><surname>Zulfikar</surname><given-names>R</given-names></name>, <name><surname>Prince</surname><given-names>N</given-names></name>, <name><surname>Tasoglou</surname><given-names>A</given-names></name>, <name><surname>Goldsmith</surname><given-names>T</given-names></name>, <name><surname>Casuccio</surname><given-names>G</given-names></name>, <name><surname>Boyd</surname><given-names>J</given-names></name>, <name><surname>Olfert</surname><given-names>IM</given-names></name>
<etal/>
<year>2021</year>. <article-title>Electronic Cigarettes and Vaping-Associated Lung Injury (EVALI): A Rural Appalachian Experience [case report]</article-title>. <source>Hosp Pract (1995)</source>. <volume>49</volume>(<issue>2</issue>):<fpage>79</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">33136442</pub-id></mixed-citation></ref><ref id="R250"><mixed-citation publication-type="journal"><name><surname>Schaffer</surname><given-names>S</given-names></name>, <name><surname>Strang</surname><given-names>A</given-names></name>, <name><surname>Saul</surname><given-names>D</given-names></name>, <name><surname>Krishnan</surname><given-names>V</given-names></name>, <name><surname>Chidekel</surname><given-names>A</given-names></name>. <year>2022</year>. <article-title>Adolescent E-cigarette or Vaping Use-Associated Lung Injury in the Delaware Valley: A Review of Hospital-Based Presentation, Management, and Outcomes</article-title>. <source>Cureus</source>. <volume>14</volume>(<issue>2</issue>):<fpage>e21988</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">35282521</pub-id></mixed-citation></ref><ref id="R251"><mixed-citation publication-type="journal"><name><surname>Sharma</surname><given-names>M</given-names></name>, <name><surname>Anjum</surname><given-names>H</given-names></name>, <name><surname>Bulathsinghala</surname><given-names>CP</given-names></name>, <name><surname>Buch</surname><given-names>M</given-names></name>, <name><surname>Suran</surname><given-names>SR</given-names></name>. <year>2019</year>. <article-title>A Case Report of Secondary Spontaneous Pneumothorax Induced by Vape [case report]</article-title>. <source>Cureus</source>. <volume>11</volume>(<issue>11</issue>).</mixed-citation></ref><ref id="R252"><mixed-citation publication-type="journal"><name><surname>Shields</surname><given-names>PG</given-names></name>, <name><surname>Song</surname><given-names>M-A</given-names></name>, <name><surname>Freudenheim</surname><given-names>JL</given-names></name>, <name><surname>Brasky</surname><given-names>TM</given-names></name>, <name><surname>McElroy</surname><given-names>JP</given-names></name>, <name><surname>Reisinger</surname><given-names>SA</given-names></name>, <name><surname>Weng</surname><given-names>DY</given-names></name>, <name><surname>Ren</surname><given-names>R</given-names></name>, <name><surname>Eissenberg</surname><given-names>T</given-names></name>, <name><surname>Wewers</surname><given-names>MD</given-names></name>. <year>2020</year>. <article-title>Lipid laden macrophages and electronic cigarettes in healthy adults</article-title>. <source>EBioMedicine</source>. <volume>60</volume>:<fpage>102982</fpage>.<pub-id pub-id-type="pmid">32919101</pub-id></mixed-citation></ref><ref id="R253"><mixed-citation publication-type="journal"><name><surname>Shields</surname><given-names>PG</given-names></name>, <name><surname>Song</surname><given-names>MA</given-names></name>, <name><surname>Freudenheim</surname><given-names>JL</given-names></name>, <name><surname>Brasky</surname><given-names>TM</given-names></name>, <name><surname>McElroy</surname><given-names>JP</given-names></name>, <name><surname>Reisinger</surname><given-names>SA</given-names></name>, <name><surname>Weng</surname><given-names>DY</given-names></name>, <name><surname>Ren</surname><given-names>R</given-names></name>, <name><surname>Eissenberg</surname><given-names>T</given-names></name>, <name><surname>Wewers</surname><given-names>MD</given-names></name>
<etal/>
<year>2020</year>. <article-title>Lipid laden macrophages and electronic cigarettes in healthy adults [case series]</article-title>. <source>EBioMedicine</source>. <volume>60</volume>:<fpage>102982</fpage>.<pub-id pub-id-type="pmid">32919101</pub-id></mixed-citation></ref><ref id="R254"><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>A</given-names></name>
<year>2022</year>. <article-title>Adolescent e-cigarette or vaping product use-associated lung injury: A case series and review of the literature</article-title>. <source>Pediatr Pulmonol</source>. <volume>57</volume>(<issue>4</issue>):<fpage>1076</fpage>&#x02013;<lpage>1084</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">35072351</pub-id></mixed-citation></ref><ref id="R255"><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>A</given-names></name>, <name><surname>Tan</surname><given-names>Q</given-names></name>, <name><surname>Saccone</surname><given-names>NM</given-names></name>, <name><surname>Lindner</surname><given-names>DH</given-names></name>. <year>2020</year>. <article-title>A Case of Vaping TCH Oil Leading to Vaping Associated Pulmonary Injury: Our Approach to Its Diagnosis, Management, and Recommendations [case report]</article-title>. <source>Case Rep Pulmonol</source>. <volume>2020</volume>:<fpage>6138083</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31976113</pub-id></mixed-citation></ref><ref id="R256"><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>DP</given-names></name>, <name><surname>Begum</surname><given-names>R</given-names></name>, <name><surname>Kaur</surname><given-names>G</given-names></name>, <name><surname>Bagam</surname><given-names>P</given-names></name>, <name><surname>Kambiranda</surname><given-names>D</given-names></name>, <name><surname>Singh</surname><given-names>R</given-names></name>, <name><surname>Batra</surname><given-names>S</given-names></name>. <year>2021</year>. <article-title>E-cig vapor condensate alters proteome and lipid profiles of membrane rafts: impact on inflammatory responses in A549 cells [research in vitro/in vivo]</article-title>. <source>Cell Biol Toxicol</source>. <volume>37</volume>(<issue>5</issue>):<fpage>773</fpage>&#x02013;<lpage>793</lpage>.<pub-id pub-id-type="pmid">33469865</pub-id></mixed-citation></ref><ref id="R257"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>E</given-names></name>, <name><surname>Cherian</surname><given-names>R</given-names></name>, <name><surname>McGillen</surname><given-names>B</given-names></name>. <year>2020</year>. <article-title>A Case of E-cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) in a Previously Healthy Patient: Case Report and Literature Review [case report]</article-title>. <source>J Gen Intern Med</source>. <volume>35</volume>(<issue>9</issue>):<fpage>2767</fpage>&#x02013;<lpage>2770</lpage>.<pub-id pub-id-type="pmid">32440996</pub-id></mixed-citation></ref><ref id="R258"><mixed-citation publication-type="journal"><name><surname>Son</surname><given-names>Y</given-names></name>, <name><surname>Mishin</surname><given-names>V</given-names></name>, <name><surname>Laskin</surname><given-names>JD</given-names></name>, <name><surname>Mainelis</surname><given-names>G</given-names></name>, <name><surname>Wackowski</surname><given-names>OA</given-names></name>, <name><surname>Delnevo</surname><given-names>C</given-names></name>, <name><surname>Schwander</surname><given-names>S</given-names></name>, <name><surname>Khlystov</surname><given-names>A</given-names></name>, <name><surname>Samburova</surname><given-names>V</given-names></name>, <name><surname>Meng</surname><given-names>Q</given-names></name>. <year>2019</year>. <article-title>Hydroxyl radicals in e-cigarette vapor and e-vapor oxidative potentials under different vaping patterns</article-title>. <source>Chemical research in toxicology</source>. <volume>32</volume>(<issue>6</issue>):<fpage>1087</fpage>&#x02013;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">30977360</pub-id></mixed-citation></ref><ref id="R259"><mixed-citation publication-type="journal"><name><surname>Stephens</surname><given-names>D</given-names></name>, <name><surname>Patel</surname><given-names>JK</given-names></name>, <name><surname>Angelo</surname><given-names>D</given-names></name>, <name><surname>Frunzi</surname><given-names>J</given-names></name>. <year>2020</year>. <article-title>Cannabis Butane Hash Oil Dabbing Induced Lung Injury Mimicking Atypical Pneumonia [case report]</article-title>. <source>Cureus</source>. <volume>12</volume>(<issue>2</issue>):<fpage>e7033</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32211266</pub-id></mixed-citation></ref><ref id="R260"><mixed-citation publication-type="journal"><name><surname>Strongin</surname><given-names>RM</given-names></name>. <year>2019</year>. <article-title>E-Cigarette Chemistry and Analytical Detection [aerosol chemistry]</article-title>. <source>Annu Rev Anal Chem (Palo Alto Calif)</source>. <volume>12</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">30848928</pub-id></mixed-citation></ref><ref id="R261"><mixed-citation publication-type="journal"><name><surname>Tanz</surname><given-names>LJ</given-names></name>, <name><surname>Christensen</surname><given-names>A</given-names></name>, <name><surname>Knuth</surname><given-names>KB</given-names></name>, <name><surname>Hoffman</surname><given-names>MN</given-names></name>, <name><surname>Dandeneau</surname><given-names>D</given-names></name>, <name><surname>Koehler</surname><given-names>K</given-names></name>, <name><surname>Moore</surname><given-names>Z</given-names></name>, <name><surname>Herndon</surname><given-names>S</given-names></name>, <name><surname>Davidson</surname><given-names>K</given-names></name>, <name><surname>Fleischauer</surname><given-names>A</given-names></name>. <year>2021</year>. <article-title>Characteristics of an Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury-North Carolina, 2019 [report]</article-title>. <source>N C Med J</source>. <volume>82</volume>(<issue>6</issue>):<fpage>384</fpage>&#x02013;<lpage>392</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">34750211</pub-id></mixed-citation></ref><ref id="R262"><mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>J</given-names></name>, <name><surname>Wiens</surname><given-names>T</given-names></name>, <name><surname>Peterson</surname><given-names>J</given-names></name>, <name><surname>Saravia</surname><given-names>S</given-names></name>, <name><surname>Lunda</surname><given-names>M</given-names></name>, <name><surname>Hanson</surname><given-names>K</given-names></name>, <name><surname>Wogen</surname><given-names>M</given-names></name>, <name><surname>D&#x02019;Heilly</surname><given-names>P</given-names></name>, <name><surname>Margetta</surname><given-names>J</given-names></name>, <name><surname>Bye</surname><given-names>M</given-names></name>
<etal/>
<year>2019</year>. <article-title>Characteristics of E-cigarette, or Vaping, Products Used by Patients with Associated Lung Injury and Products Seized by Law Enforcement - Minnesota, 2018 and 2019 [MMWR REPORT]</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>68</volume>(<issue>47</issue>):<fpage>1096</fpage>&#x02013;<lpage>1100</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31774740</pub-id></mixed-citation></ref><ref id="R263"><mixed-citation publication-type="journal"><name><surname>Temas</surname><given-names>D</given-names></name>, <name><surname>Meyer</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>E-Cigarette- and Vaping-Related Lung Injury (EVALI) at a Regional Hospital System in South Carolina [case series]</article-title>. <source>Case Rep Pulmonol</source>. <volume>2020</volume>:<fpage>5370606</fpage>.<pub-id pub-id-type="pmid">32509369</pub-id></mixed-citation></ref><ref id="R264"><mixed-citation publication-type="journal"><name><surname>Thakrar</surname><given-names>PD</given-names></name>, <name><surname>Boyd</surname><given-names>KP</given-names></name>, <name><surname>Swanson</surname><given-names>CP</given-names></name>, <name><surname>Wideburg</surname><given-names>E</given-names></name>, <name><surname>Kumbhar</surname><given-names>SS</given-names></name>. <year>2020</year>. <article-title>E-cigarette, or vaping, product use-associated lung injury in adolescents: a review of imaging features [case series]</article-title>. <source>Pediatr Radiol</source>. <volume>50</volume>(<issue>3</issue>):<fpage>338</fpage>&#x02013;<lpage>344</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31897566</pub-id></mixed-citation></ref><ref id="R265"><mixed-citation publication-type="journal"><name><surname>Thota</surname><given-names>D</given-names></name>, <name><surname>Latham</surname><given-names>E</given-names></name>. <year>2014</year>. <article-title>Case report of electronic cigarettes possibly associated with eosinophilic pneumonitis in a previously healthy active-duty sailor [case report]</article-title>. <source>J Emerg Med</source>. <volume>47</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>17</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">24462024</pub-id></mixed-citation></ref><ref id="R266"><mixed-citation publication-type="journal"><name><surname>Tierney</surname><given-names>PA</given-names></name>, <name><surname>Karpinski</surname><given-names>CD</given-names></name>, <name><surname>Brown</surname><given-names>JE</given-names></name>, <name><surname>Luo</surname><given-names>W</given-names></name>, <name><surname>Pankow</surname><given-names>JF</given-names></name>. <year>2016</year>. <article-title>Flavour chemicals in electronic cigarette fluids</article-title>. <source>Tobacco control</source>. <volume>25</volume>(<issue>e1</issue>):<fpage>e10</fpage>&#x02013;<lpage>e15</lpage>.<pub-id pub-id-type="pmid">25877377</pub-id></mixed-citation></ref><ref id="R267"><mixed-citation publication-type="journal"><name><surname>Tommasi</surname><given-names>S</given-names></name>, <name><surname>Caliri</surname><given-names>AW</given-names></name>, <name><surname>Caceres</surname><given-names>A</given-names></name>, <name><surname>Moreno</surname><given-names>DE</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Siegmund</surname><given-names>KD</given-names></name>, <name><surname>Besaratinia</surname><given-names>A</given-names></name>. <year>2019</year>. <article-title>Deregulation of biologically significant genes and associated molecular pathways in the oral epithelium of electronic cigarette users</article-title>. <source>International journal of molecular sciences</source>. <volume>20</volume>(<issue>3</issue>):<fpage>738</fpage>.<pub-id pub-id-type="pmid">30744164</pub-id></mixed-citation></ref><ref id="R268"><mixed-citation publication-type="journal"><name><surname>Treon</surname><given-names>JF</given-names></name>, <name><surname>Sigmon</surname><given-names>HE</given-names></name>, <etal/>
<year>1949</year>. <article-title>Physiologic response of animals exposed to air-borne ketene</article-title>. <source>J Ind Hyg Toxicol</source>. <volume>31</volume>(<issue>4</issue>):<fpage>209</fpage>&#x02013;<lpage>219</lpage>.<pub-id pub-id-type="pmid">18153385</pub-id></mixed-citation></ref><ref id="R269"><mixed-citation publication-type="journal"><name><surname>Triantafyllou</surname><given-names>GA</given-names></name>, <name><surname>Tiberio</surname><given-names>PJ</given-names></name>, <name><surname>Zou</surname><given-names>RH</given-names></name>, <name><surname>Lamberty</surname><given-names>PE</given-names></name>, <name><surname>Lynch</surname><given-names>MJ</given-names></name>, <name><surname>Kreit</surname><given-names>JW</given-names></name>, <name><surname>Gladwin</surname><given-names>MT</given-names></name>, <name><surname>Morris</surname><given-names>A</given-names></name>, <name><surname>Chiarchiaro</surname><given-names>J</given-names></name>. <year>2019</year>. <article-title>Vaping-associated Acute Lung Injury: A Case Series [case series]</article-title>. <source>Am J Respir Crit Care Med</source>. <volume>200</volume>(<issue>11</issue>):<fpage>1430</fpage>&#x02013;<lpage>1431</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31574235</pub-id></mixed-citation></ref><ref id="R270"><mixed-citation publication-type="journal"><name><surname>Varlet</surname><given-names>V</given-names></name>, <name><surname>Concha-Lozano</surname><given-names>N</given-names></name>, <name><surname>Berthet</surname><given-names>A</given-names></name>, <name><surname>Plateel</surname><given-names>G</given-names></name>, <name><surname>Favrat</surname><given-names>B</given-names></name>, <name><surname>De Cesare</surname><given-names>M</given-names></name>, <name><surname>Lauer</surname><given-names>E</given-names></name>, <name><surname>Augsburger</surname><given-names>M</given-names></name>, <name><surname>Thomas</surname><given-names>A</given-names></name>, <name><surname>Giroud</surname><given-names>C</given-names></name>. <year>2016</year>. <article-title>Drug vaping applied to cannabis: Is &#x0201c;Cannavaping&#x0201d; a therapeutic alternative to marijuana? [chemical analysis]</article-title>. <source>Sci Rep</source>. <volume>6</volume>:<fpage>25599</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">27228348</pub-id></mixed-citation></ref><ref id="R271"><mixed-citation publication-type="journal"><name><surname>Vilanilam</surname><given-names>GK</given-names></name>, <name><surname>Purushothaman</surname><given-names>R</given-names></name>, <name><surname>Baskaran</surname><given-names>NP</given-names></name>, <name><surname>Vohra</surname><given-names>I</given-names></name>, <name><surname>Raghavan</surname><given-names>S</given-names></name>, <name><surname>Bean</surname><given-names>B</given-names></name>, <name><surname>Sajovitz</surname><given-names>L</given-names></name>. <year>2021</year>. <article-title>Imaging in Vaping-associated Lung Injury: Beyond the Haze [case series]</article-title>. <source>J Addict Med</source>. <volume>15</volume>(<issue>3</issue>):<fpage>258</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">33021553</pub-id></mixed-citation></ref><ref id="R272"><mixed-citation publication-type="journal"><name><surname>Villeneuve</surname><given-names>T</given-names></name>, <name><surname>Prevot</surname><given-names>G</given-names></name>, <name><surname>Le Borgne</surname><given-names>A</given-names></name>, <name><surname>Colombat</surname><given-names>M</given-names></name>, <name><surname>Collot</surname><given-names>S</given-names></name>, <name><surname>Ruiz</surname><given-names>S</given-names></name>, <name><surname>Lanot</surname><given-names>T</given-names></name>, <name><surname>Brouchet</surname><given-names>L</given-names></name>, <name><surname>Rabeau</surname><given-names>A</given-names></name>, <name><surname>Noel-Savina</surname><given-names>E</given-names></name>
<etal/>
<year>2020</year>. <article-title>Diffuse alveolar haemorrhage secondary to e-cigarette &#x0201c;vaping&#x0201d; associated lung injury (EVALI) in a young European consumer [case report]</article-title>. <source>Eur Respir J</source>. <volume>56</volume>(<issue>1</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R273"><mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Vrdoljak</surname><given-names>G</given-names></name>. <year>2020</year>. <article-title>Vaping cartridge heating element compositions and evidence of high temperatures [research tox]</article-title>. <source>PLoS One</source>. <volume>15</volume>(<issue>10</issue>):<fpage>e0240613</fpage>.<pub-id pub-id-type="pmid">33075091</pub-id></mixed-citation></ref><ref id="R274"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>G</given-names></name>, <name><surname>Wu</surname><given-names>L</given-names></name>. <year>2020</year>. <article-title>Healthy People 2020: Social Determinants of Cigarette Smoking and Electronic Cigarette Smoking among Youth in the United States 2010&#x02013;2018</article-title>. <source>Int J Environ Res Public Health</source>. <volume>17</volume>(<issue>20</issue>).</mixed-citation></ref><ref id="R275"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>KY</given-names></name>, <name><surname>Jadhav</surname><given-names>SP</given-names></name>, <name><surname>Yenduri</surname><given-names>NJS</given-names></name>, <name><surname>Lee</surname><given-names>SA</given-names></name>, <name><surname>Farber</surname><given-names>HJ</given-names></name>, <name><surname>Guillerman</surname><given-names>RP</given-names></name>. <year>2020</year>. <article-title>E-cigarette or vaping product use-associated lung injury in the pediatric population: imaging features at presentation and short-term follow-up [case series]</article-title>. <source>Pediatr Radiol</source>. <volume>50</volume>(<issue>9</issue>):<fpage>1231</fpage>&#x02013;<lpage>1239</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32495177</pub-id></mixed-citation></ref><ref id="R276"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Ho</surname><given-names>SY</given-names></name>, <name><surname>Leung</surname><given-names>LT</given-names></name>, <name><surname>Wang</surname><given-names>MP</given-names></name>, <name><surname>Lam</surname><given-names>TH</given-names></name>. <year>2020</year>. <article-title>Exposure to e-cigarette advertising, attitudes, and use susceptibility in adolescents who had never used e-cigarettes or cigarettes</article-title>. <source>BMC Public Health</source>. <volume>20</volume>(<issue>1</issue>):<fpage>1349</fpage>.<pub-id pub-id-type="pmid">32887586</pub-id></mixed-citation></ref><ref id="R277"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>TW</given-names></name>, <name><surname>Neff</surname><given-names>LJ</given-names></name>, <name><surname>Park-Lee</surname><given-names>E</given-names></name>, <name><surname>Ren</surname><given-names>C</given-names></name>, <name><surname>Cullen</surname><given-names>KA</given-names></name>, <name><surname>King</surname><given-names>BA</given-names></name>. <year>2020</year>. <article-title>E-cigarette Use Among Middle and High School Students - United States, 2020</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <volume>69</volume>(<issue>37</issue>):<fpage>1310</fpage>&#x02013;<lpage>1312</lpage>.<pub-id pub-id-type="pmid">32941408</pub-id></mixed-citation></ref><ref id="R278"><mixed-citation publication-type="journal"><name><surname>Wekon-Kemeni</surname><given-names>C</given-names></name>, <name><surname>Santhanam</surname><given-names>P</given-names></name>, <name><surname>Halani</surname><given-names>P</given-names></name>, <name><surname>Bradford</surname><given-names>L</given-names></name>, <name><surname>Loughlin</surname><given-names>CE</given-names></name>. <year>2021</year>. <article-title>A Gut Feeling: Abdominal Symptoms as an Initial Presentation of EVALI</article-title>. <source>Pediatrics</source>. <volume>147</volume>(<issue>1</issue>). <comment>eng.</comment></mixed-citation></ref><ref id="R279"><mixed-citation publication-type="journal"><name><surname>Werner</surname><given-names>AK</given-names></name>, <name><surname>Koumans</surname><given-names>EH</given-names></name>, <name><surname>Chatham-Stephens</surname><given-names>K</given-names></name>, <name><surname>Salvatore</surname><given-names>PP</given-names></name>, <name><surname>Armatas</surname><given-names>C</given-names></name>, <name><surname>Byers</surname><given-names>P</given-names></name>, <name><surname>Clark</surname><given-names>CR</given-names></name>, <name><surname>Ghinai</surname><given-names>I</given-names></name>, <name><surname>Holzbauer</surname><given-names>SM</given-names></name>, <name><surname>Navarette</surname><given-names>KA</given-names></name>
<etal/>
<year>2020</year>. <article-title>Hospitalizations and Deaths Associated with EVALI [case series]</article-title>. <source>N Engl J Med</source>. <volume>382</volume>(<issue>17</issue>):<fpage>1589</fpage>&#x02013;<lpage>1598</lpage>.<pub-id pub-id-type="pmid">32320569</pub-id></mixed-citation></ref><ref id="R280"><mixed-citation publication-type="journal"><name><surname>Wilhite</surname><given-names>R</given-names></name>, <name><surname>Patel</surname><given-names>T</given-names></name>, <name><surname>Karle</surname><given-names>E</given-names></name>, <name><surname>Shankar</surname><given-names>S</given-names></name>, <name><surname>Krvavac</surname><given-names>A</given-names></name>. <year>2019</year>. <article-title>Diffuse Alveolar Hemorrhage: An Uncommon Manifestation of Vaping-associated Lung Injury [case report]</article-title>. <source>Cureus</source>. <volume>11</volume>(<issue>12</issue>):<fpage>e6519</fpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32025438</pub-id></mixed-citation></ref><ref id="R281"><mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>M</given-names></name>, <name><surname>Villarreal</surname><given-names>A</given-names></name>, <name><surname>Bozhilov</surname><given-names>K</given-names></name>, <name><surname>Lin</surname><given-names>S</given-names></name>, <name><surname>Talbot</surname><given-names>P</given-names></name>. <year>2013</year>. <article-title>Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol</article-title>. <source>PloS one</source>. <volume>8</volume>(<issue>3</issue>):<fpage>e57987</fpage>.<pub-id pub-id-type="pmid">23526962</pub-id></mixed-citation></ref><ref id="R282"><mixed-citation publication-type="journal"><name><surname>Wing</surname><given-names>C</given-names></name>, <name><surname>Bradford</surname><given-names>AC</given-names></name>, <name><surname>Carroll</surname><given-names>AE</given-names></name>, <name><surname>Hollingsworth</surname><given-names>A</given-names></name>. <year>2020</year>. <article-title>Association of State Marijuana Legalization Policies for Medical and Recreational Use With Vaping-Associated Lung Disease</article-title>. <source>JAMA network open</source>. <volume>3</volume>(<issue>4</issue>):<fpage>e202187</fpage>&#x02013;<lpage>e202187</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32250431</pub-id></mixed-citation></ref><ref id="R283"><mixed-citation publication-type="journal"><name><surname>Wolf</surname><given-names>M</given-names></name>, <name><surname>Richards</surname><given-names>J</given-names></name>. <year>2020</year>. <article-title>Acute Eosinophilic Pneumonia Due to Vaping-Associated Lung Injury [case report]</article-title>. <source>J Crit Care Med (Targu Mures)</source>. <volume>6</volume>(<issue>4</issue>):<fpage>259</fpage>&#x02013;<lpage>262</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">33200099</pub-id></mixed-citation></ref><ref id="R284"><mixed-citation publication-type="journal"><name><surname>Works</surname><given-names>K</given-names></name>, <name><surname>Stack</surname><given-names>L</given-names></name>. <year>2020</year>. <article-title>E-cigarette or vaping product-use-associated lung injury (EVALI): A case report of a pneumonia mimic with severe leukocytosis and weight loss [case report]</article-title>. <source>J Am Coll Emerg Physicians Open</source>. <volume>1</volume>(<issue>1</issue>):<fpage>46</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">33000013</pub-id></mixed-citation></ref><ref id="R285"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>D</given-names></name>, <name><surname>O&#x02019;Shea</surname><given-names>DF</given-names></name>. <year>2020</year>. <article-title>Potential for release of pulmonary toxic ketene from vaping pyrolysis of vitamin E acetate [research tox]</article-title>. <source>Proc Natl Acad Sci U S A</source>. <volume>117</volume>(<issue>12</issue>):<fpage>6349</fpage>&#x02013;<lpage>6355</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32156732</pub-id></mixed-citation></ref><ref id="R286"><mixed-citation publication-type="journal"><name><surname>Youmans</surname><given-names>AJ</given-names></name>, <name><surname>Harwood</surname><given-names>J</given-names></name>. <year>2020</year>. <article-title>Gross and Histopathological Findings in the First Reported Vaping-Induced Lung Injury Death in the United States [case report]</article-title>. <source>Am J Forensic Med Pathol</source>. <volume>41</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>4</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">31977349</pub-id></mixed-citation></ref><ref id="R287"><mixed-citation publication-type="journal"><name><surname>Young-Wolff</surname><given-names>KC</given-names></name>, <name><surname>Adams</surname><given-names>SR</given-names></name>, <name><surname>Sterling</surname><given-names>SA</given-names></name>, <name><surname>Tan</surname><given-names>AS</given-names></name>, <name><surname>Salloum</surname><given-names>RG</given-names></name>, <name><surname>Torre</surname><given-names>K</given-names></name>, <name><surname>Carter-Harris</surname><given-names>L</given-names></name>, <name><surname>Prochaska</surname><given-names>JJ</given-names></name>. <year>2021</year>. <article-title>Nicotine and cannabis vaping among adolescents in treatment for substance use disorders [report]</article-title>. <source>Journal of Substance Abuse Treatment</source>. <volume>125</volume>:<fpage>108304</fpage>.<pub-id pub-id-type="pmid">34016296</pub-id></mixed-citation></ref><ref id="R288"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>V</given-names></name>, <name><surname>Rahimy</surname><given-names>M</given-names></name>, <name><surname>Korrapati</surname><given-names>A</given-names></name>, <name><surname>Xuan</surname><given-names>Y</given-names></name>, <name><surname>Zou</surname><given-names>AE</given-names></name>, <name><surname>Krishnan</surname><given-names>AR</given-names></name>, <name><surname>Tsui</surname><given-names>T</given-names></name>, <name><surname>Aguilera</surname><given-names>JA</given-names></name>, <name><surname>Advani</surname><given-names>S</given-names></name>, <name><surname>Alexander</surname><given-names>LEC</given-names></name>. <year>2016</year>. <article-title>Electronic cigarettes induce DNA strand breaks and cell death independently of nicotine in cell lines</article-title>. <source>Oral oncology</source>. <volume>52</volume>:<fpage>58</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">26547127</pub-id></mixed-citation></ref><ref id="R289"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>J</given-names></name>, <name><surname>Nelson</surname><given-names>J</given-names></name>, <name><surname>Dada</surname><given-names>O</given-names></name>, <name><surname>Pyrgiotakis</surname><given-names>G</given-names></name>, <name><surname>Kavouras</surname><given-names>IG</given-names></name>, <name><surname>Demokritou</surname><given-names>P</given-names></name>. <year>2018</year>. <article-title>Assessing electronic cigarette emissions: linking physico-chemical properties to product brand, e-liquid flavoring additives, operational voltage and user puffing patterns</article-title>. <source>Inhal Toxicol</source>. <volume>30</volume>(<issue>2</issue>):<fpage>78</fpage>&#x02013;<lpage>88</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">29564955</pub-id></mixed-citation></ref><ref id="R290"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>J</given-names></name>, <name><surname>Pyrgiotakis</surname><given-names>G</given-names></name>, <name><surname>Demokritou</surname><given-names>P</given-names></name>. <year>2016</year>. <article-title>Development and characterization of electronic-cigarette exposure generation system (Ecig-EGS) for the physico-chemical and toxicological assessment of electronic cigarette emissions</article-title>. <source>Inhal Toxicol</source>. <volume>28</volume>(<issue>14</issue>):<fpage>658</fpage>&#x02013;<lpage>669</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">27829296</pub-id></mixed-citation></ref><ref id="R291"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Sisler</surname><given-names>JD</given-names></name>, <name><surname>Shaffer</surname><given-names>J</given-names></name>, <name><surname>Leonard</surname><given-names>SS</given-names></name>, <name><surname>Morris</surname><given-names>AM</given-names></name>, <name><surname>Qian</surname><given-names>Y</given-names></name>, <name><surname>Bello</surname><given-names>D</given-names></name>, <name><surname>Demokritou</surname><given-names>P</given-names></name>. <year>2018</year>. <article-title>Assessment of reactive oxygen species generated by electronic cigarettes using acellular and cellular approaches</article-title>. <source>J Hazard Mater</source>. <volume>344</volume>:<fpage>549</fpage>&#x02013;<lpage>557</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">29102637</pub-id></mixed-citation></ref><ref id="R292"><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>SH</given-names></name>, <name><surname>Sun</surname><given-names>JY</given-names></name>, <name><surname>Bonnevie</surname><given-names>E</given-names></name>, <name><surname>Cummins</surname><given-names>SE</given-names></name>, <name><surname>Gamst</surname><given-names>A</given-names></name>, <name><surname>Yin</surname><given-names>L</given-names></name>, <name><surname>Lee</surname><given-names>M</given-names></name>. <year>2014</year>. <article-title>Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation</article-title>. <source>Tob Control</source>. <volume>23</volume>
<issue>Suppl 3(Suppl 3)</issue>:<fpage>iii3</fpage>&#x02013;<lpage>9</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">24935895</pub-id></mixed-citation></ref><ref id="R293"><mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>RH</given-names></name>, <name><surname>Tiberio</surname><given-names>PJ</given-names></name>, <name><surname>Triantafyllou</surname><given-names>GA</given-names></name>, <name><surname>Lamberty</surname><given-names>PE</given-names></name>, <name><surname>Lynch</surname><given-names>MJ</given-names></name>, <name><surname>Kreit</surname><given-names>JW</given-names></name>, <name><surname>McVerry</surname><given-names>BJ</given-names></name>, <name><surname>Gladwin</surname><given-names>MT</given-names></name>, <name><surname>Morris</surname><given-names>A</given-names></name>, <name><surname>Chiarchiaro</surname><given-names>J</given-names></name>
<etal/>
<year>2020</year>. <article-title>Clinical Characterization of E-Cigarette, or Vaping, Product Use-associated Lung Injury in 36 Patients in Pittsburgh, Pennsylvania [case series]</article-title>. <source>Am J Respir Crit Care Med</source>. <volume>201</volume>(<issue>10</issue>):<fpage>1303</fpage>&#x02013;<lpage>1306</lpage>. <comment>eng.</comment><pub-id pub-id-type="pmid">32023422</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1.</label><caption><p id="P88">Summary of the demographic, medical history and clinical symptoms at presentation in emergency department observed in EVALI patients (n=15,748 unless otherwise specified).</p></caption><graphic xlink:href="nihms-1848342-f0001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p id="P89">Relative frequencies of different vaping substances; e-cig device types, brand names and sources; and vaping behavioral patterns of EVALI patients.</p></caption><graphic xlink:href="nihms-1848342-f0002" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1.</label><caption><p id="P90">Results from the physical examination and biological specimen testing of EVALI patients.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Findings</th><th align="left" valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Physical exam</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diffuse bibasilar crackles</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R248" ref-type="bibr">Salzman et al. 2019</xref>; <xref rid="R251" ref-type="bibr">Sharma et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R193" ref-type="bibr">Miskoff and Chaudhri 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R259" ref-type="bibr">Stephens et al. 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R127" ref-type="bibr">Hoshina 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R237" ref-type="bibr">Regmi et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilateral wheezes</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R20" ref-type="bibr">Anderson Ryan P and Zechar Katie 2019</xref>; <xref rid="R248" ref-type="bibr">Salzman et al. 2019</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R40" ref-type="bibr">Bolona et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R200" ref-type="bibr">Mull, Erdem, et al. 2020</xref>; <xref rid="R245" ref-type="bibr">Sacci et al. 2020</xref>; <xref rid="R259" ref-type="bibr">Stephens et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rhonchi, use of accessory muscles and diminished but clear breath sounds bilaterally at the bases</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R20" ref-type="bibr">Anderson Ryan P and Zechar Katie 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R54" ref-type="bibr">Chapman et al. 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R139" ref-type="bibr">Jankharia et al. 2020</xref>; <xref rid="R200" ref-type="bibr">Mull, Erdem, et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R259" ref-type="bibr">Stephens et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Fever</bold> Temperature &#x02265;38 &#x000b0;C</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Maddock, et al. 2020</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R36" ref-type="bibr">Billa et al. 2020</xref>; <xref rid="R40" ref-type="bibr">Bolona et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R103" ref-type="bibr">Galo et al. 2020</xref>; <xref rid="R107" ref-type="bibr">Ghinai et al. 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R242" ref-type="bibr">Ronald et al. 2020</xref>; <xref rid="R246" ref-type="bibr">Sakla et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R293" ref-type="bibr">Zou et al. 2020</xref>; <xref rid="R5" ref-type="bibr">Adhikari, Koritala, et al. 2021</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Tachycardia</bold> Heart rate &#x0003e;100 beats per minute</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R20" ref-type="bibr">Anderson Ryan P and Zechar Katie 2019</xref>; <xref rid="R23" ref-type="bibr">Aokage et al. 2019</xref>; <xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R4" ref-type="bibr">Acharya et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R13" ref-type="bibr">Aldy et al. 2020</xref>; <xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R36" ref-type="bibr">Billa et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R56" ref-type="bibr">Chawla and Weiler 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R76" ref-type="bibr">Deliwala et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R85" ref-type="bibr">Edmonds et al. 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R242" ref-type="bibr">Ronald et al. 2020</xref>; <xref rid="R254" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R259" ref-type="bibr">Stephens et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R5" ref-type="bibr">Adhikari, Koritala, et al. 2021</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R127" ref-type="bibr">Hoshina 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>; <xref rid="R168" ref-type="bibr">Lim et al. 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Tachypnea</bold> respiratory rate &#x0003e;20 breaths per minute</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R20" ref-type="bibr">Anderson Ryan P and Zechar Katie 2019</xref>; <xref rid="R23" ref-type="bibr">Aokage et al. 2019</xref>; <xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R74" ref-type="bibr">Davidson et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R4" ref-type="bibr">Acharya et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R13" ref-type="bibr">Aldy et al. 2020</xref>; <xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R36" ref-type="bibr">Billa et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R52" ref-type="bibr">Cedano et al. 2020</xref>; <xref rid="R54" ref-type="bibr">Chapman et al. 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R76" ref-type="bibr">Deliwala et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>); <xref rid="R83" ref-type="bibr">Duffy B et al. (2020)</xref>; (<xref rid="R85" ref-type="bibr">Edmonds et al. 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R100" ref-type="bibr">Fedt et al. 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>); <xref rid="R141" ref-type="bibr">Jiang et al. (2020)</xref>; (<xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R170" ref-type="bibr">Lu MA et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R200" ref-type="bibr">Mull, Erdem, et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R242" ref-type="bibr">Ronald et al. 2020</xref>; <xref rid="R245" ref-type="bibr">Sacci et al. 2020</xref>; <xref rid="R246" ref-type="bibr">Sakla et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>; <xref rid="R5" ref-type="bibr">Adhikari, Koritala, et al. 2021</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R127" ref-type="bibr">Hoshina 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>High blood pressure (BP)&#x0003e;</bold> 120/80 mmHg</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R40" ref-type="bibr">Bolona et al. 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R76" ref-type="bibr">Deliwala et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R220" ref-type="bibr">Patel et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>White Blood Cells (WBC) count</bold> &#x0003e; 11000/mm<sup>3</sup> with neutrophils predominance (&#x0003e;60%)</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R20" ref-type="bibr">Anderson Ryan P and Zechar Katie 2019</xref>; <xref rid="R23" ref-type="bibr">Aokage et al. 2019</xref>; <xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R74" ref-type="bibr">Davidson et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R248" ref-type="bibr">Salzman et al. 2019</xref>; <xref rid="R251" ref-type="bibr">Sharma et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R3" ref-type="bibr">Aberegg, Maddock, et al. 2020</xref>; <xref rid="R9" ref-type="bibr">Ahmad et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R13" ref-type="bibr">Aldy et al. 2020</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R18" ref-type="bibr">Amin et al. 2020</xref>; <xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R41" ref-type="bibr">Bozkanat et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R56" ref-type="bibr">Chawla and Weiler 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R76" ref-type="bibr">Deliwala et al. 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R85" ref-type="bibr">Edmonds et al. 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R100" ref-type="bibr">Fedt et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R179" ref-type="bibr">Marliere et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>); <xref rid="R191" ref-type="bibr">Mikheev et al. (2020)</xref>; (<xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R246" ref-type="bibr">Sakla et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R259" ref-type="bibr">Stephens et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R293" ref-type="bibr">Zou et al. 2020</xref>; <xref rid="R5" ref-type="bibr">Adhikari, Koritala, et al. 2021</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R136" ref-type="bibr">Isakov et al. 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R237" ref-type="bibr">Regmi et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>; <xref rid="R168" ref-type="bibr">Lim et al. 2022</xref>; <xref rid="R226" ref-type="bibr">Podguski et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Inflammatory markers elevated:</bold><break/>Erythrocyte sedimentation rate ESR &#x0003e;30 mm/hr, C reactive protein CRP&#x0003e; 10 mg/l<break/>Procalcitonin &#x0003e;0.07 ng/ml<break/>LDH &#x0003e;280 U/L<break/>Pro-BNP &#x0003e;125 pg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R23" ref-type="bibr">Aokage et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R18" ref-type="bibr">Amin et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R40" ref-type="bibr">Bolona et al. 2020</xref>; <xref rid="R41" ref-type="bibr">Bozkanat et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R52" ref-type="bibr">Cedano et al. 2020</xref>; <xref rid="R56" ref-type="bibr">Chawla and Weiler 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R100" ref-type="bibr">Fedt et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R103" ref-type="bibr">Galo et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R179" ref-type="bibr">Marliere et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R212" ref-type="bibr">O&#x02019;Carroll et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R5" ref-type="bibr">Adhikari, Koritala, et al. 2021</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>; <xref rid="R226" ref-type="bibr">Podguski et al. 2022</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Oxygen saturation</bold> &#x0003c;95% on room air or with supplemental oxygen</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R23" ref-type="bibr">Aokage et al. 2019</xref>; <xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R248" ref-type="bibr">Salzman et al. 2019</xref>; <xref rid="R251" ref-type="bibr">Sharma et al. 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R18" ref-type="bibr">Amin et al. 2020</xref>; <xref rid="R36" ref-type="bibr">Billa et al. 2020</xref>; <xref rid="R40" ref-type="bibr">Bolona et al. 2020</xref>; <xref rid="R52" ref-type="bibr">Cedano et al. 2020</xref>; <xref rid="R54" ref-type="bibr">Chapman et al. 2020</xref>; <xref rid="R56" ref-type="bibr">Chawla and Weiler 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R92" ref-type="bibr">Farooq et al. 2020</xref>; <xref rid="R100" ref-type="bibr">Fedt et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R103" ref-type="bibr">Galo et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R170" ref-type="bibr">Lu MA et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R200" ref-type="bibr">Mull, Erdem, et al. 2020</xref>; <xref rid="R201" ref-type="bibr">Mull, Shell, et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R214" ref-type="bibr">Odish et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R232" ref-type="bibr">Qarajeh and Kitchen 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R245" ref-type="bibr">Sacci et al. 2020</xref>; <xref rid="R246" ref-type="bibr">Sakla et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R259" ref-type="bibr">Stephens et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R293" ref-type="bibr">Zou et al. 2020</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>) (<xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R6" ref-type="bibr">Adhikari, Koritala, et al. 2021</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R237" ref-type="bibr">Regmi et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Blood Gas Analysis (BGA):</bold><break/>Primary respiratory alkalosis: pH&#x02265; 7.45, PaCO2 &#x0003c; 35 mmHg.<break/>Normal range BGA: pH 7.35&#x02013;7.45, pCO2 35&#x02013;45 mmHg, pO2 80&#x02013;100 mmHg, and HCO3 22&#x02013;26 mMol/L.</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R20" ref-type="bibr">Anderson Ryan P and Zechar Katie 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R248" ref-type="bibr">Salzman et al. 2019</xref>; <xref rid="R251" ref-type="bibr">Sharma et al. 2019</xref>; <xref rid="R4" ref-type="bibr">Acharya et al. 2020</xref>; <xref rid="R13" ref-type="bibr">Aldy et al. 2020</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R201" ref-type="bibr">Mull, Shell, et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R5" ref-type="bibr">Adhikari, Koritala, et al. 2021</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Infectious diseases screening</bold> (bacteria, virus, fungi, mycobacters) = negative<break/><bold>Rheumatological and vasculitis serologic evaluation (</bold>ANA, ANCA, GBM-Ab, cryoglobulins, APA, RF, anti-CCPA, anti-MPO-Ab, anti-dsDNA, Anti-RNP) = negative.</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R20" ref-type="bibr">Anderson Ryan P and Zechar Katie 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R120" ref-type="bibr">Hallowell et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R248" ref-type="bibr">Salzman et al. 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R4" ref-type="bibr">Acharya et al. 2020</xref>; <xref rid="R9" ref-type="bibr">Ahmad et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R31" ref-type="bibr">Baxter et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R36" ref-type="bibr">Billa et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R52" ref-type="bibr">Cedano et al. 2020</xref>; <xref rid="R56" ref-type="bibr">Chawla and Weiler 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R76" ref-type="bibr">Deliwala et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R85" ref-type="bibr">Edmonds et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R103" ref-type="bibr">Galo et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R173" ref-type="bibr">Macedonia et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R201" ref-type="bibr">Mull, Shell, et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R227" ref-type="bibr">Poschenrieder et al. 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R232" ref-type="bibr">Qarajeh and Kitchen 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R127" ref-type="bibr">Hoshina 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R237" ref-type="bibr">Regmi et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Pulmonary function test abnormal</bold><break/>Restrictive or obstructive pattern</td><td align="left" valign="top" rowspan="1" colspan="1"><break/>(<xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R139" ref-type="bibr">Jankharia et al. 2020</xref>; <xref rid="R173" ref-type="bibr">Macedonia et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R293" ref-type="bibr">Zou et al. 2020</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Urine toxicological screening positive for cannabinoids</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>; <xref rid="R41" ref-type="bibr">Bozkanat et al. 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R76" ref-type="bibr">Deliwala et al. 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R170" ref-type="bibr">Lu MA et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R200" ref-type="bibr">Mull, Erdem, et al. 2020</xref>; <xref rid="R214" ref-type="bibr">Odish et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R245" ref-type="bibr">Sacci et al. 2020</xref>; <xref rid="R252" ref-type="bibr">Shields P. G. et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R127" ref-type="bibr">Hoshina 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P91">Abbreviations: ANA antinuclear antibodies, ANCA Antineutrophil cytoplasmic antibody, GBM-Ab Anti&#x02013;glomerular basement membrane antibodies, APA anti-phospholipid antibodies, RF rheumatoid factor anti&#x02013;CCPA Cyclic citrullinated peptide antibodies, anti MPO-Ab Myeloperoxidase-antibodies, anti-dsDNA Anti-double stranded DNA, Anti-RNP anti ribonucleoprotein.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p id="P92">Summary of the imaging characteristics of EVALI patients: Chest radiographs and CT.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Findings</th><th align="left" valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Lesions, pattern and distributions</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilateral ground-glass opacities</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R23" ref-type="bibr">Aokage et al. 2019</xref>; <xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R74" ref-type="bibr">Davidson et al. 2019</xref>; <xref rid="R120" ref-type="bibr">Hallowell et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R248" ref-type="bibr">Salzman et al. 2019</xref>; <xref rid="R251" ref-type="bibr">Sharma et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R4" ref-type="bibr">Acharya et al. 2020</xref>; <xref rid="R9" ref-type="bibr">Ahmad et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R13" ref-type="bibr">Aldy et al. 2020</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R18" ref-type="bibr">Amin et al. 2020</xref>; <xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R36" ref-type="bibr">Billa et al. 2020</xref>; <xref rid="R40" ref-type="bibr">Bolona et al. 2020</xref>; <xref rid="R41" ref-type="bibr">Bozkanat et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R52" ref-type="bibr">Cedano et al. 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R70" ref-type="bibr">Conuel et al. 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R76" ref-type="bibr">Deliwala et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R85" ref-type="bibr">Edmonds et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R103" ref-type="bibr">Galo et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R117" ref-type="bibr">Gutsche et al. 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R139" ref-type="bibr">Jankharia et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R170" ref-type="bibr">Lu MA et al. 2020</xref>; <xref rid="R173" ref-type="bibr">Macedonia et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R193" ref-type="bibr">Miskoff and Chaudhri 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R200" ref-type="bibr">Mull, Erdem, et al. 2020</xref>; <xref rid="R212" ref-type="bibr">O&#x02019;Carroll et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R214" ref-type="bibr">Odish et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R220" ref-type="bibr">Patel et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R232" ref-type="bibr">Qarajeh and Kitchen 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R246" ref-type="bibr">Sakla et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R259" ref-type="bibr">Stephens et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>; <xref rid="R275" ref-type="bibr">Wang KY et al. 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R293" ref-type="bibr">Zou et al. 2020</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R127" ref-type="bibr">Hoshina 2021</xref>; <xref rid="R136" ref-type="bibr">Isakov et al. 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R237" ref-type="bibr">Regmi et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>; <xref rid="R168" ref-type="bibr">Lim et al. 2022</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bibasilar parenchymal consolidation</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R23" ref-type="bibr">Aokage et al. 2019</xref>; <xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R120" ref-type="bibr">Hallowell et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>); <xref rid="R35" ref-type="bibr">Bhat et al. (2020)</xref>; (<xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R54" ref-type="bibr">Chapman et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R70" ref-type="bibr">Conuel et al. 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R100" ref-type="bibr">Fedt et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R227" ref-type="bibr">Poschenrieder et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>; <xref rid="R275" ref-type="bibr">Wang KY et al. 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R127" ref-type="bibr">Hoshina 2021</xref>; <xref rid="R136" ref-type="bibr">Isakov et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilateral pleural effusions</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>); <xref rid="R160" ref-type="bibr">Lanzarotta et al. (2020)</xref>; (<xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R275" ref-type="bibr">Wang KY et al. 2020</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilateral opacities</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R120" ref-type="bibr">Hallowell et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R248" ref-type="bibr">Salzman et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R9" ref-type="bibr">Ahmad et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R18" ref-type="bibr">Amin et al. 2020</xref>; <xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R36" ref-type="bibr">Billa et al. 2020</xref>; <xref rid="R41" ref-type="bibr">Bozkanat et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R52" ref-type="bibr">Cedano et al. 2020</xref>; <xref rid="R54" ref-type="bibr">Chapman et al. 2020</xref>; <xref rid="R56" ref-type="bibr">Chawla and Weiler 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R100" ref-type="bibr">Fedt et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R117" ref-type="bibr">Gutsche et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R139" ref-type="bibr">Jankharia et al. 2020</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R212" ref-type="bibr">O&#x02019;Carroll et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R232" ref-type="bibr">Qarajeh and Kitchen 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R242" ref-type="bibr">Ronald et al. 2020</xref>; <xref rid="R246" ref-type="bibr">Sakla et al. 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R275" ref-type="bibr">Wang KY et al. 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R136" ref-type="bibr">Isakov et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R237" ref-type="bibr">Regmi et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>; <xref rid="R124" ref-type="bibr">Helfgott et al. 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilateral pulmonary interstitial infiltrates</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R20" ref-type="bibr">Anderson Ryan P and Zechar Katie 2019</xref>; <xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R31" ref-type="bibr">Baxter et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R56" ref-type="bibr">Chawla and Weiler 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R87" ref-type="bibr">El Chebib et al. 2020</xref>; <xref rid="R91" ref-type="bibr">Fan et al. 2020</xref>; <xref rid="R92" ref-type="bibr">Farooq et al. 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; <xref rid="R126" ref-type="bibr">Hilton et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R179" ref-type="bibr">Marliere et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R240" ref-type="bibr">Rodriguez et al. 2020</xref>; <xref rid="R242" ref-type="bibr">Ronald et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R286" ref-type="bibr">Youmans and Harwood 2020</xref>; <xref rid="R5" ref-type="bibr">Adhikari, Koritala, et al. 2021</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R104" ref-type="bibr">Ganne et al. 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interlobular septal thickening</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R13" ref-type="bibr">Aldy et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R82" ref-type="bibr">Doukas et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R170" ref-type="bibr">Lu MA et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R179" ref-type="bibr">Marliere et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R200" ref-type="bibr">Mull, Erdem, et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R232" ref-type="bibr">Qarajeh and Kitchen 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R246" ref-type="bibr">Sakla et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R275" ref-type="bibr">Wang KY et al. 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R122" ref-type="bibr">Hassoun et al. 2021</xref>; <xref rid="R136" ref-type="bibr">Isakov et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R278" ref-type="bibr">Wekon-Kemeni et al. 2021</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pleural / Subpleural sparing</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R70" ref-type="bibr">Conuel et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R123" ref-type="bibr">Heinzerling et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R184" ref-type="bibr">Matta et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R212" ref-type="bibr">O&#x02019;Carroll et al. 2020</xref>; <xref rid="R216" ref-type="bibr">Pajak et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R275" ref-type="bibr">Wang KY et al. 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R29" ref-type="bibr">Ayoub et al. 2021</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R136" ref-type="bibr">Isakov et al. 2021</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fibrotic features</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pneumo-thorax</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R117" ref-type="bibr">Gutsche et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R242" ref-type="bibr">Ronald et al. 2020</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pneumo-mediastinum</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R13" ref-type="bibr">Aldy et al. 2020</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R242" ref-type="bibr">Ronald et al. 2020</xref>; <xref rid="R6" ref-type="bibr">Adhikari, Manduva, et al. 2021</xref>; <xref rid="R136" ref-type="bibr">Isakov et al. 2021</xref>; <xref rid="R149" ref-type="bibr">Khan et al. 2021</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R235" ref-type="bibr">Reddy et al. 2021</xref>; <xref rid="R261" ref-type="bibr">Tanz et al. 2021</xref>; <xref rid="R250" ref-type="bibr">Schaffer et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pulmonary emboli</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R26" ref-type="bibr">Artunduaga et al. 2020</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mediastinal/hilar lymphadenopathy</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R9" ref-type="bibr">Ahmad et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R91" ref-type="bibr">Fan et al. 2020</xref>; <xref rid="R103" ref-type="bibr">Galo et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R275" ref-type="bibr">Wang KY et al. 2020</xref>; <xref rid="R145" ref-type="bibr">Kalantary et al. 2021</xref>; <xref rid="R152" ref-type="bibr">Kligerman et al. 2021</xref>; <xref rid="R168" ref-type="bibr">Lim et al. 2022</xref>; <xref rid="R254" ref-type="bibr">Singh A 2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reverse halo sign</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R136" ref-type="bibr">Isakov et al. 2021</xref>)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p id="P93">Summary of the biochemical analyses of bronchoalveolar lavage (BAL) samples collected from EVALI patients.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Findings</th><th align="left" valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Macrophages predominance</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R70" ref-type="bibr">Conuel et al. 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R179" ref-type="bibr">Marliere et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R45" ref-type="bibr">O&#x02019;Carroll et al. 2020</xref>; <xref rid="R286" ref-type="bibr">Youmans and Harwood 2020</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Eosinophil predominance</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neutrophil predominance</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R23" ref-type="bibr">Aokage et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R74" ref-type="bibr">Davidson et al. 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R9" ref-type="bibr">Ahmad et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R34" ref-type="bibr">Bharat et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R70" ref-type="bibr">Conuel et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R214" ref-type="bibr">Odish et al. 2020</xref>; <xref rid="R222" ref-type="bibr">Perrenoud et al. 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R255" ref-type="bibr">Singh A et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R12" ref-type="bibr">Al-Hamdani et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymphocytic Predominance</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R74" ref-type="bibr">Davidson et al. 2019</xref>; <xref rid="R251" ref-type="bibr">Sharma et al. 2019</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R126" ref-type="bibr">Hilton et al. 2020</xref>; <xref rid="R227" ref-type="bibr">Poschenrieder et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diffuse alveolar hemorrhage</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Organizing pneumonia (activate type 2 pneumocytes)</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R198" ref-type="bibr">Mughal et al. 2020</xref>; <xref rid="R227" ref-type="bibr">Poschenrieder et al. 2020</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R241" ref-type="bibr">Roman et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lipid laden macrophages/ foamy macrophages</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R8" ref-type="bibr">Aftab et al. 2019</xref>; <xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R74" ref-type="bibr">Davidson et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R2" ref-type="bibr">Aberegg, Cirulis, et al. 2020</xref>; <xref rid="R9" ref-type="bibr">Ahmad et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R67" ref-type="bibr">Colesar and McCollum 2020</xref>; <xref rid="R70" ref-type="bibr">Conuel et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R103" ref-type="bibr">Galo et al. 2020</xref>; <xref rid="R106" ref-type="bibr">Gay et al. 2020</xref>; <xref rid="R110" ref-type="bibr">Girvin and Naidich 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R138" ref-type="bibr">Israel et al. 2020</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>; <xref rid="R153" ref-type="bibr">Kooragayalu et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R212" ref-type="bibr">O&#x02019;Carroll et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R227" ref-type="bibr">Poschenrieder et al. 2020</xref>; <xref rid="R253" ref-type="bibr">Shields P. G. et al. 2020</xref>; <xref rid="R264" ref-type="bibr">Thakrar et al. 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R121" ref-type="bibr">Harada et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R225" ref-type="bibr">Pitlick et al. 2021</xref>; <xref rid="R249" ref-type="bibr">Sangani et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RBC</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R280" ref-type="bibr">Wilhite et al. 2019</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R85" ref-type="bibr">Edmonds et al. 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R201" ref-type="bibr">Mull, Shell, et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R158" ref-type="bibr">Kupelian et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WBC</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R269" ref-type="bibr">Triantafyllou et al. 2019</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R272" ref-type="bibr">Villeneuve et al. 2020</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R137" ref-type="bibr">Ismail et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BACTERIA VIRUS FUNGI NEGATIVE</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R16" ref-type="bibr">Alqahtani et al. 2019</xref>; <xref rid="R25" ref-type="bibr">Arter et al. 2019</xref>; <xref rid="R37" ref-type="bibr">Blagev et al. 2019</xref>; <xref rid="R146" ref-type="bibr">Kalininskiy et al. 2019</xref>; <xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R175" ref-type="bibr">Maddock et al. 2019</xref>; <xref rid="R251" ref-type="bibr">Sharma et al. 2019</xref>; <xref rid="R1" ref-type="bibr">Abeles et al. 2020</xref>; <xref rid="R9" ref-type="bibr">Ahmad et al. 2020</xref>; <xref rid="R11" ref-type="bibr">Al-Abdouh et al. 2020</xref>; <xref rid="R13" ref-type="bibr">Aldy et al. 2020</xref>; <xref rid="R15" ref-type="bibr">Ali et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Alzghoul et al. 2020</xref>; <xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R31" ref-type="bibr">Baxter et al. 2020</xref>; <xref rid="R45" ref-type="bibr">Carroll et al. 2020</xref>; <xref rid="R46" ref-type="bibr">Casanova et al. 2020</xref>; <xref rid="R54" ref-type="bibr">Chapman et al. 2020</xref>; <xref rid="R56" ref-type="bibr">Chawla and Weiler 2020</xref>; <xref rid="R57" ref-type="bibr">Chen J et al. 2020</xref>; <xref rid="R59" ref-type="bibr">Chidambaram et al. 2020</xref>; <xref rid="R60" ref-type="bibr">Choe et al. 2020</xref>; <xref rid="R75" ref-type="bibr">DeCarli et al. 2020</xref>; <xref rid="R77" ref-type="bibr">Derespina et al. 2020</xref>; <xref rid="R80" ref-type="bibr">Dicpinigaitis et al. 2020</xref>; <xref rid="R92" ref-type="bibr">Farooq et al. 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R103" ref-type="bibr">Galo et al. 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R148" ref-type="bibr">Kass et al. 2020</xref>; <xref rid="R201" ref-type="bibr">Mull, Shell, et al. 2020</xref>; <xref rid="R213" ref-type="bibr">Ocampo-Gonzalez and Park 2020</xref>; <xref rid="R214" ref-type="bibr">Odish et al. 2020</xref>; <xref rid="R224" ref-type="bibr">Phung and Lam 2020</xref>; <xref rid="R227" ref-type="bibr">Poschenrieder et al. 2020</xref>; <xref rid="R231" ref-type="bibr">Puebla Neira et al. 2020</xref>; <xref rid="R233" ref-type="bibr">Rao et al. 2020</xref>; <xref rid="R257" ref-type="bibr">Smith et al. 2020</xref>; <xref rid="R263" ref-type="bibr">Temas and Meyer 2020</xref>; <xref rid="R283" ref-type="bibr">Wolf and Richards 2020</xref>; <xref rid="R284" ref-type="bibr">Works and Stack 2020</xref>; <xref rid="R10" ref-type="bibr">Ahmed et al. 2021</xref>; <xref rid="R155" ref-type="bibr">Krishnan et al. 2021</xref>; <xref rid="R271" ref-type="bibr">Vilanilam et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fibrin exudates within airspace</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R90" ref-type="bibr">Essa et al. 2020</xref>; <xref rid="R102" ref-type="bibr">Fryman et al. 2020</xref>; <xref rid="R150" ref-type="bibr">Kinney et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VEA</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R38" ref-type="bibr">Blount et al. 2019</xref>; <xref rid="R262" ref-type="bibr">Taylor et al. 2019</xref>; <xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">THC OR METABOLITES</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R38" ref-type="bibr">Blount et al. 2019</xref>; <xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NICOTINE</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R38" ref-type="bibr">Blount et al. 2019</xref>; <xref rid="R39" ref-type="bibr">Blount et al. 2020</xref>)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p id="P94">Summary of histo-pathology patterns from transbronchial lung biopsy of EVALI patients.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Findings</th><th align="left" valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Respiratory bronchiolitis</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R173" ref-type="bibr">Macedonia et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Organizing pneumonia</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R22" ref-type="bibr">Ansari-Gilani et al. 2020</xref>; <xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R52" ref-type="bibr">Cedano et al. 2020</xref>; <xref rid="R93" ref-type="bibr">Fathima and Zhang 2020</xref>; <xref rid="R170" ref-type="bibr">Lu MA et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R286" ref-type="bibr">Youmans and Harwood 2020</xref>; <xref rid="R71" ref-type="bibr">Cruz-Vidal et al. 2021</xref>; <xref rid="R167" ref-type="bibr">Lilley et al. 2021</xref>; <xref rid="R202" ref-type="bibr">Munagala et al. 2021</xref>; <xref rid="R237" ref-type="bibr">Regmi et al. 2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mild interstitial fibrosis</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alveolar fibrosis</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acute lung injury</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R93" ref-type="bibr">Fathima and Zhang 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lipoid pneumonia</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acute fibrinous pneumonitis with organization</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diffuse alveolar damage</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R43" ref-type="bibr">Butt et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>; <xref rid="R179" ref-type="bibr">Marliere et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R286" ref-type="bibr">Youmans and Harwood 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diffuse alveolar hemorrhage</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R120" ref-type="bibr">Hallowell et al. 2019</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R286" ref-type="bibr">Youmans and Harwood 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fibrinous pleuritic</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R120" ref-type="bibr">Hallowell et al. 2019</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Granulomatous inflammation</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R120" ref-type="bibr">Hallowell et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R174" ref-type="bibr">MacMurdo et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neutrophils and eosinophils</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R120" ref-type="bibr">Hallowell et al. 2019</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymphocytic infiltration</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R173" ref-type="bibr">Macedonia et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Foamy Macrophages in airspace</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R93" ref-type="bibr">Fathima and Zhang 2020</xref>; <xref rid="R101" ref-type="bibr">Freathy et al. 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R173" ref-type="bibr">Macedonia et al. 2020</xref>; <xref rid="R189" ref-type="bibr">Messina et al. 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>; <xref rid="R234" ref-type="bibr">Reagan-Steiner et al. 2020</xref>; <xref rid="R279" ref-type="bibr">Werner et al. 2020</xref>; <xref rid="R286" ref-type="bibr">Youmans and Harwood 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fibrinous exudates in airspaces</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R93" ref-type="bibr">Fathima and Zhang 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R286" ref-type="bibr">Youmans and Harwood 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interstitial chronic inflammation</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R30" ref-type="bibr">Baumann et al. 2020</xref>; <xref rid="R93" ref-type="bibr">Fathima and Zhang 2020</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R230" ref-type="bibr">Priemer et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No evidence of exogenous lipoid pneumonia</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acid-Fast Bacilli and Grocott-Gomori&#x02019;s methenamine silver stain (GMS) negative</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type II pneumocytes hyperplasia</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R93" ref-type="bibr">Fathima and Zhang 2020</xref>; <xref rid="R115" ref-type="bibr">Griffiths et al. 2020</xref>; <xref rid="R147" ref-type="bibr">Kaous et al. 2020</xref>; <xref rid="R217" ref-type="bibr">Panse et al. 2020</xref>; <xref rid="R286" ref-type="bibr">Youmans and Harwood 2020</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Focal acute inflammation in airspaces</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R159" ref-type="bibr">Landman et al. 2019</xref>; <xref rid="R161" ref-type="bibr">Layden Jennifer E. et al. 2019</xref>; <xref rid="R199" ref-type="bibr">Mukhopadhyay et al. 2020</xref>)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T5" orientation="landscape"><label>Table 5</label><caption><p id="P95">Summary of chemical analysis of counterfeit or <bold>patient-provided</bold> cartridges used by EVALI patients</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Author</th><th align="left" valign="top" rowspan="1" colspan="1">Method</th><th align="left" valign="top" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R203" ref-type="bibr">Muthumalage, Friedman, et al. 2020</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L1"><list-item><p id="P96">Chemical analysis of rinses or e-cigs liquids collected from:
<list list-type="order" id="L2"><list-item><p id="P97">Counterfeit or patient-provided e-cig vaping cartridges (n = 38),</p></list-item><list-item><p id="P98">CBD-containing e-cig vaping cartridges (n = 4)</p></list-item><list-item><p id="P99">Medical-grade (positive) e-cig vaping cartridges</p></list-item></list></p></list-item><list-item><p id="P100">Gas chromatography (GC) and mass spectrometry (MS).</p></list-item><list-item><p id="P101">Chemical analysis of aerosols from e-cig vaping cartridges sampled in 1L vacuum bottles, for 10 minutes with 10 puffs each.<list list-type="bullet" id="L3"><list-item><p id="P102">Elemental Analysis of cartridge liquids</p></list-item></list></p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L4"><list-item><p id="P103">Commonly present constituents in all cartridges: majority were terpenes, silicon compounds. Other compounds included flavors, additives, cannabinoids, plasticizer/ polycaprolactone/ drugs/ manufacturing, humectants/ oil/ plant components, vitamins, and conjugates, miscellaneous.</p></list-item><list-item><p id="P104">Chemicals unique to e-cig counterfeit: 2,2-dimethoxybutane, tetramethyl silicate, decane, methyl esters, ethyl esters, siloxanes, acetates, and &#x003b1;-tocopherol/vitamin E acetate (VEA).</p></list-item><list-item><p id="P105">Vapor phase constituents in counterfeit cartridge: terpenes, majority were manufacturing/pesticides/automotive/industrial active and inert agents and solvents. Others: PCP-polycaprolactone/ household, miscellaneous.</p></list-item><list-item><p id="P106">Most abundant elements In counterfeit cartridges: Si, Cu, Ni, and Pb (up to 600 ppm)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R273" ref-type="bibr">Wagner et al. 2020</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L5"><list-item><p id="P107">Characterization of 6 THC vape cartridges and 2 nicotine e-cigarette devices.</p></list-item><list-item><p id="P108">Among the THC cartridges, 2 were used by EVALI patients in 2019, 2 were unused and filled. 2 THC unused and empty cartridges, and 2 nicotine devices were used as comparison/control.</p></list-item><list-item><p id="P109">Extraction of liquid for chemical analysis.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L6"><list-item><p id="P110">Cartridges from EVALI patients exhibited severe burn marks, due to the high operating temperature.</p></list-item><list-item><p id="P111">The combination of ceramics, metals and high temperatures in newer THC cartridges is consistent with conditions hypothesized to produce VEA reactions during vaping.</p></list-item><list-item><p id="P112">Analysis of metals present in filaments and battery contact: Ni and Cr (all devices); Cu, Pb, Au, Sn, Fe, Zr, silicon-rich rubbers, or fluorinated microplastics. The ceramics in the CCell cartridges contained Si, and various amount of Al, Na, K, P.</p></list-item><list-item><p id="P113">Metals Ni, Cr, Zn, Cu, Pb, Au, and Sn can also be inhaled when heated at high temperatures.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R83" ref-type="bibr">Duffy B et al. 2020</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L7"><list-item><p id="P114">Analyses of 38 samples from the first 10 New York cases of EVALI</p></list-item><list-item><p id="P115">GC-MS Untargeted Analysis</p></list-item><list-item><p id="P116">LC-HRMS/MS Untargeted Analysis</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L8"><list-item><p id="P117">VEA contained in 23/38 samples, concentration range 16&#x02013;57%</p></list-item><list-item><p id="P118">MCT present in 14/38 cartridges, concentration 2&#x02013;24%</p></list-item><list-item><p id="P119">Synthetic cannabinoids and opioids not present</p></list-item><list-item><p id="P120">Fungicide myclobutanil: 22/36, 61% - concentration range 0.28&#x02013; 28.30 &#x003bc;g/g</p></list-item><list-item><p id="P121">Pesticide piperonyl butoxide- d9 (PBO-d9): 19/36, 53% -concentration range 0.54&#x02013; 24.1 &#x003bc;g/g.</p></list-item><list-item><p id="P122">Most common chemicals found in 6 commercially available cannabis oil diluent and thickener: D) VEA, Squalane, MCT oil, triethyl citrate (minor), T) bisabolol, isophytol (minor)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R84" ref-type="bibr">Duffy BC et al. 2021</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L9"><list-item><p id="P123">Analysis of 175 cartridges submitted to the Wadsworth Center of the New York State Department of Health (NYSDOH) by medical practitioners and poison control centers across New York State as part of the statewide 2019&#x02013;2020 EVALI investigation</p></list-item><list-item><p id="P124">HPLC for cannabinoids</p></list-item><list-item><p id="P125">For untargeted analysis GC-MS and LC-HRMS</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L10"><list-item><p id="P126">28 cartridges were found to contain THC, of whom 7 clusters contained a similar cannabinoids ratio.</p></list-item><list-item><p id="P127">THC mass from 15&#x02013;54%.</p></list-item><list-item><p id="P128">D9THC concentration range 90.4&#x02013;2%, D8THC concentration range 98&#x02013;9.6%.</p></list-item><list-item><p id="P129">All the cartridges were diluted with VEA (11), VEA + MCT (11), MCT (4), VEA+MCT+PEG (1), None (1).</p></list-item><list-item><p id="P130">Additional cannabinoids: cannabichromene (CBC), cannabidiol (CBD) cannabidivarin (CBDV), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabinol (CBN), tetrahydrocannabinolic acid (THCA) and tetrahydrocannabivarin (THCV).</p></list-item><list-item><p id="P131">Clusters were also similar for point of origin in the New York area (manufacturing sources)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R116" ref-type="bibr">Guo et al. 2021</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L11"><list-item><p id="P132">12 cannabis vape cartridges obtained through the California state surveillance program from September 2018 to December 2019</p></list-item><list-item><p id="P133">Nontargeted GC-MS for cannabis cartridge vape oil</p></list-item><list-item><p id="P134">Headspace GC-MS Screen for Cannabis Vape Oil Vapor</p></list-item><list-item><p id="P135">SPME GC-MS Screen for Cannabis Vape Oil Aerosol (aerosol was generated from 5 puffs ranged from 15&#x02013;31 mg)</p></list-item><list-item><p id="P136">LIMITATIONS:<list list-type="order" id="L12"><list-item><p id="P137">vacuum flow used to generate aerosol different from inhaling by a person&#x02019;s breath.</p></list-item><list-item><p id="P138">SPME fiber used can only absorb limited amount of volatile and semivolatile compounds.</p></list-item><list-item><p id="P139">exact vape temperature cannot be measured, and it can be different as used by consumers;</p></list-item><list-item><p id="P140">the same vape device with the same voltage was used which may be different from consumers that use various vape devices with different voltage settings.</p></list-item><list-item><p id="P141">various constituents and additives were not accurately quantified in this study.</p></list-item></list></p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L13"><list-item><p id="P142">Terpenes, terpenoids, flavor, fragrance, cannabinoids, additives were investigated in liquid, vapor, aerosol.</p></list-item><list-item><p id="P143"><bold>LIQUIDS</bold>. Flavor names and cannabinoids were mislabeled on the packages.</p></list-item><list-item><p id="P144">TERPENES: Found around 60 chemicals, concentration &#x0003c;1&#x02013;7%. Major terpenes found were consistent with the ones found in Cannabis plants.</p></list-item><list-item><p id="P145">CANNABINOIDS: Most common D9THC (concentration 4.5&#x02013;70%) CBN (1&#x02013;20%), CBT, CBG, THCV, CBC, D10THC, Cannabifuran. D8THC (&#x0003e;30%)</p></list-item><list-item><p id="P146">In samples containing lower cannabinoids, VEA was &#x0003e;30%, MCT 25&#x02013;39%, PEG 2&#x02013;15%.</p></list-item><list-item><p id="P147"><bold>VAPOR.</bold> When vape oil samples were heated at 200&#x000b0;C :</p></list-item><list-item><p id="P148">TERPENES: Increased number of terpenes released (&#x0003e;100), Concentration 60%</p></list-item><list-item><p id="P149">CANNABINOIDS: most common CBT, CBN, D9THC (concentration 15%), CBC, D8THC, CBV, THCV.</p></list-item><list-item><p id="P150">VEA, PEG, MCT were much lower concentration in vapor: VEA and MCT in vapors were found &#x0003c;7%.</p></list-item><list-item><p id="P151"><bold>AEROSOL.</bold> Inconsistency in aerosol generation between cartridges, and between puffs from the same cartridge.</p></list-item><list-item><p id="P152">TERPENES. &#x0003e;100 terpenes and natural extract were found in aerosols, &#x0003e;75% total peak area.</p></list-item><list-item><p id="P153">CANNABINOIDS. Most common D9THC (concentration 27&#x02013;63%), CBN, CBC, CBG, THVC, CBT, D10THC, minor cannabinoids were also found. Lower amount compared to oil.</p></list-item><list-item><p id="P154">VEA, MCT, PGE were found concentration similar to vapor. Ketene was not found.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R63" ref-type="bibr">Ciolino, Ranieri, et al. 2021</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L14"><list-item><p id="P155">Around 300 cartridges received from the Forensic Chemistry Center, US Food and Drug Administration, in Cincinnati Ohio in 2019&#x02013;2020.</p></list-item><list-item><p id="P156">Chemical analysis of e-liquids for <bold>unnatural THC isomers</bold>: Fourier transform infrared (FT-IR) and Raman spectroscopy, HPLC-DAD, GC-MS, LC-HRMS, and DART-HRMS.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L15"><list-item><p id="P157">Compounds found in 214 samples:<list list-type="bullet" id="L16"><list-item><p id="P158">D9THC up to 80% w/w (frequently &#x0003e;50% w/w) (38 samples).</p></list-item><list-item><p id="P159">D8THC (58 samples)</p></list-item><list-item><p id="P160">Major levels of d6a,10aTHC/d10THC isomers (26 samples),</p></list-item><list-item><p id="P161">Minor levels of the d6a, 10aTHC/d10THC isomers (138 samples)</p></list-item><list-item><p id="P162">CBD, CBN, CBG, CBC, and varinol cannabinoids (d9THCV and CBDV</p></list-item></list></p></list-item><list-item><p id="P163">Compounds found in 299 samples:<list list-type="bullet" id="L17"><list-item><p id="P164">D9THC and THCA (18 samples)</p></list-item><list-item><p id="P165">CBD or CBN (few samples)</p></list-item></list></p></list-item><list-item><p id="P166">Other compounds :<list list-type="bullet" id="L18"><list-item><p id="P167">D6a,10aTHC, 6aR,9R-D10THC, 6aR,9S-D10THC, exoTHC.</p></list-item></list></p></list-item><list-item><p id="P168">Different THC isomer patterns represent different processes to produce high THC source materials</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R62" ref-type="bibr">Ciolino, Falconer, et al. 2021</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L19"><list-item><p id="P169">Around 300 cartridges received from the Forensic Chemistry Center, US Food and Drug Administration, in Cincinnati Ohio in 2019&#x02013;2020, half associated with EVALI patients, other obtained in the US through independent investigations.</p></list-item><list-item><p id="P170">Chemical analysis of <bold>additives</bold> in THC based e-liquids: GC-MS, LC-HRMS, DART-HRMS</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L20"><list-item><p id="P171">Compounds found:<list list-type="bullet" id="L21"><list-item><p id="P172">VEA (50&#x02013;60% samples), No additives (20% samples), MCT oils (30% samples), PEGs (5% samples), other (20% samples).</p></list-item><list-item><p id="P173">Terpenes (85% of samples)</p></list-item><list-item><p id="P174">Single component: vitamin E acetate (alpha-tocopherol acetate), triethyl citrate, trioctanoin, or squalane.</p></list-item><list-item><p id="P175">Multiple components (in 60 samples): MCT oils, PEG oligomers, pine rosin acids, pine rosin derived methyl esters, dipropylene glycol dibenzoate (DPG dibenzoate) isomers, and sucrose acetate isobutyrate (SAIB) compounds.</p></list-item><list-item><p id="P176">Most frequent combination: VEA+MCT</p></list-item><list-item><p id="P177">Less frequent combinations: MCT + SAIB, MCT + PEG, MCT + pine rosin acids, and VEA + DPG dibenzoate.</p></list-item><list-item><p id="P178">A few vaping liquids contained VEA + MCT oil + SAIB.</p></list-item></list></p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R112" ref-type="bibr">GGonzalez-Jimenez et al. 2021</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L22"><list-item><p id="P179">E-<bold>liquid</bold>: 50 cartridges from 2019 EVALI patients, collected from federal and state partners, both nicotine and THC.</p></list-item><list-item><p id="P180"><bold>Device:</bold> Jupiter CCELL<sup>&#x000ae;</sup> Liquid6 510 Thread Cartridge glass tank system with unknown voltage</p></list-item><list-item><p id="P181"><bold>Puff topography:</bold> Puff duration 3 s, interval 30 s, puff volume 55 mL, collected 15 puffs.</p></list-item><list-item><p id="P182"><bold>Chemical analysis:</bold> triple quadrupole inductively coupled plasma mass spectrometry (QQQ-ICP-MS) for analysis of aluminum, chromium, iron, cobalt, nickel, copper, cadmium, tin, barium, lead.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L23"><list-item><p id="P183">Results reported pr 10 puffs.</p></list-item><list-item><p id="P184">For most samples, the metal concentration were &#x0003c;LOD.</p></list-item><list-item><p id="P185">5 samples reported levels fir toxic metals:<list list-type="bullet" id="L24"><list-item><p id="P186">Cu= concentr range 15.4, 73.15, 447 ng/10 puffs (nicotine samples); 16.1 ng/10 puffs (THC sample)</p></list-item><list-item><p id="P187">Ni= 15.5, 36 ng/10 puffs (nicotine samples)</p></list-item><list-item><p id="P188">Sn= 4.77, 202.7 ng/10 puffs (nicotine samples)</p></list-item><list-item><p id="P189">Pb= 6.71 ng/10 puffs (nicotine samples)</p></list-item></list></p></list-item><list-item><p id="P190">39 samples THC (+), CBD (+), THC+CBD (+)</p></list-item><list-item><p id="P191">11 samples Nicotine (+)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R171" ref-type="bibr">Lu SJ et al. 2021</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L25"><list-item><p id="P192">Analysis of 284 vaping products from 83 EVALI patients to the Wadsworth Center of the New York State Department of Health (NYSDOH) or by medical practitioners and poison control centers across New York State as part of the statewide 2019&#x02013;2020 EVALI investigation</p></list-item><list-item><p id="P193">HPLC for cannabinoids</p></list-item><list-item><p id="P194">For untargeted analysis GC-MS, LC-HRMS/MS, for targeted analysys HPLC for cannabidiolic acid (CBDA), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabidiol (CBD), tetrahydrocannabivarin (THCV), cannabinol (CBN), &#x00394;9tetrahydrocannabinol (&#x00394;9-THC), &#x00394;8-tetrahydrocannabinol (&#x00394;8THC), cannabichromene (CBC), cannabidivarin (CBDV), and &#x00394;9-tetrahydrocannabinolic acid-A (THCA).</p></list-item><list-item><p id="P195">Untargeted analysis for pesticides: UHPLC coupled with a a quadrupole-orbitrap mass spectrometer (QE-Orbitrap-MS);</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L26"><list-item><p id="P196">Cannabinoids only n=39 cases (47%)</p></list-item><list-item><p id="P197">Both Cannabinoids and nicotine n=24 cases (28.9%)</p></list-item><list-item><p id="P198">Nicotine only n=20 cases (24.1%)</p></list-item><list-item><p id="P199">202 cannabis vaping products were illicit or black-market products and contained:</p><p id="P200">
<table-wrap position="float" id="T6"><table frame="box" rules="cols"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><list list-type="bullet" id="L27"><list-item><p id="P201">&#x00394;9-THC n=194 range 1.1&#x02013;88.7%</p></list-item><list-item><p id="P202">CBG n=102 range 1.2&#x02013;5.3%</p></list-item><list-item><p id="P203">CBN n=86 range 1.1&#x02013;16.9%</p></list-item><list-item><p id="P204">&#x00394;8-THC n=29 range 1.9&#x02013;88.8%</p></list-item><list-item><p id="P205">CBD n=25 range 0.8&#x02013;44.9%</p></list-item></list></td><td align="left" valign="top" rowspan="1" colspan="1"><list list-type="bullet" id="L28"><list-item><p id="P206">THCA n=17 range 1.9&#x02013;87.9%</p></list-item><list-item><p id="P207">CBC n=11 range 1.2&#x02013;2.6%</p></list-item><list-item><p id="P208">THCV n=1 range 2.3%</p></list-item><list-item><p id="P209">CBDA n=1 range 4%</p></list-item><list-item><p id="P210">CBDV &#x02013; CBGA ND</p></list-item></list></td></tr></tbody></table></table-wrap>
</p></list-item><list-item><p id="P211">Diluents identified in 185 vaping liquids:</p><p id="P212">
<table-wrap position="float" id="T7"><table frame="box" rules="cols"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">No diluents 17 samples, 12 cases<break/>VEA only 107 samples, 51 cases<break/>MCT only 42 samples, 18 cases<break/>PEG only 8 samples 4 cases<break/>Castor oil 2 samples 2 cases</td><td align="left" valign="top" rowspan="1" colspan="1">VEA+MCT 19 samples, 8 cases<break/>VEA+PEG 4 samples 3 cases<break/>MCT+PEG 1 sample 1 cases<break/>VEA+MCT+PEG 2 samples 1 case</td></tr></tbody></table></table-wrap>
</p></list-item><list-item><p id="P213">VEA/THC ratio 0.07&#x02013;5.33, average 1.35</p></list-item><list-item><p id="P214">VEA concentration 37.0 &#x000b1; 15.4 mass%, range 2.0&#x02013;67.8.</p></list-item><list-item><p id="P215">159/202 THC vaping products contained pesticides and pesticides metabolites, including: Myclobutanil (101 samples), piperonyl butoxide (75), bifenazate (59), bifenthrin (38), trifloxytrobin (29), metalaxyl (25), tecubonazole (19), malathion (11), propamocarb (10, etoxazole (9), triticonazole (6), boscalid (5), propiconazole (3).</p></list-item><list-item><p id="P216">Diluents: Terpenes: Caryophyllene (8/9 samples), limonene (7/9 samples), myrcene (5/9 samples), etc.</p></list-item><list-item><p id="P217">82 NICOTINE samples were also tested:<list list-type="bullet" id="L29"><list-item><p id="P218">Additive: Benzoic Acid</p></list-item><list-item><p id="P219">Carriers: Glycerin, Propylene glycol, Benzyl alcohol</p></list-item><list-item><p id="P220">Flavors: Triacetin, Vanillin, Levomenthol, menthol, Triethyl Citrate, Ethyl maltol</p></list-item><list-item><p id="P221">Cooling agents: WS-3, WS-23</p></list-item></list></p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R186" ref-type="bibr">McGuigan et al. 2022</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L30"><list-item><p id="P222">E-<bold>liquid/device</bold>: 77 e-cig/vaping products collected from 37 EvAlI patients.</p></list-item><list-item><p id="P223"><bold>Puff topography:</bold> 55 mL puff volume, 3 s puff duration, 30 s puff interval, square puff profile, operated at the higher voltage (max 4 V). 15 puffs collected for each product</p></list-item><list-item><p id="P224"><bold>Chemical analysis:</bold> HPLC-MS aerosol carbonyl content.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L31"><list-item><p id="P225">CDC EVALI 45 samples were examined: 34 containing THC, 10 containing nicotine, (nicotine, CBD and THC), 1 containing no appreciable amount of THC, nicotine or CBD.</p></list-item><list-item><p id="P226">Carbonyls detected:<list list-type="bullet" id="L32"><list-item><p id="P227">Acetaldehyde (89% of samples) = range 0.0856&#x02013;5.59 ug/15 puffs = ND-0.373 ug/puff</p></list-item><list-item><p id="P228">Acrolein (71% of samples) = range 0.00646&#x02013;1.05 ug/15 puffs = ND-0.070 ug/puff</p></list-item><list-item><p id="P229">Crotonaldehyde (87% of samples) = range 0.00168&#x02013;0.108 ug/15 puffs = ND-0.00720 ug/puff</p></list-item><list-item><p id="P230">Formaldehyde (42% of samples) = range 0.0533&#x02013;12.6 ug/15 puffs = ND-0.840 ug/puff</p></list-item></list></p></list-item><list-item><p id="P231">34 THC samples= Acetaldehyde 0.0856&#x02013; 2.58 ug in 29 samples</p><p id="P232">&#x02003;Acrolein 0.00646&#x02013; 1.05 ug in 25 samples</p><p id="P233">&#x02003;Crotonaldehyde 0.00213&#x02013; 0.108 ug in 33 samples</p><p id="P234">&#x02003;Formaldehyde 0.0533&#x02013; 12.6 ug in 8 samples</p></list-item><list-item><p id="P235">10 Nicotine samples= Acetaldehyde 0.301&#x02013; 5.59 ug in 10 samples</p><p id="P236">&#x02003;Acrolein 0.0383&#x02013; 0.805 ug in 7 samples</p><p id="P237">&#x02003;Crotonaldehyde 0.00168&#x02013; 0.00549 ug in 6 samples</p><p id="P238">&#x02003;Formaldehyde 0.930&#x02013; 5.00 ug in 10 samples</p></list-item><list-item><p id="P239">1 No THC, No Nicotine samples= Acetaldehyde 0.414 ug in 1 sample</p><p id="P240">&#x02003;Acrolein N/A</p><p id="P241">&#x02003;Crotonaldehyde N/A</p><p id="P242">&#x02003;Formaldehyde 2.22 ug in 1 sample</p></list-item></list>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T8" orientation="landscape"><label>Table 6</label><caption><p id="P243">Summary of physicochemical characterization of vapor/aerosol generated from <bold>in-house prepared</bold> e-cigs containing THC and/or VEA.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Author</th><th align="left" valign="top" rowspan="1" colspan="1">Method</th><th align="left" valign="top" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R191" ref-type="bibr">Mikheev et al. 2020</xref>),</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L33"><list-item><p id="P244"><bold>E-liquid: VEA</bold> 100%.</p></list-item><list-item><p id="P245"><bold>Device</bold>: 4 vaping pens (Kind Dab, Kind Discreet, Kind Mist, and Joyetech eVic)</p></list-item><list-item><p id="P246"><bold>Puff topography</bold>: duration 5 sec, interval 60 sec, flow rate of 20 or 40 ml/s (1.2 or 2.4 liter/min), low and high voltage for each device.</p></list-item><list-item><p id="P247"><bold>Aerosol size distribution characterization</bold>: Differential Mobility Spectrometer (DMS500) in combination with the Smoking Cycle Simulator (SCS)</p></list-item><list-item><p id="P248"><bold>Chemical analysis</bold>: two-dimensional gas-chromatography&#x02013;time-of-flight mass-spectrometry (GC&#x000d7;GC-TOFMS)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"><p id="P249"><bold>Aerosol size distribution characterization</bold>:<list list-type="bullet" id="L34"><list-item><p id="P250">Particle number concentration = 10<sup>7</sup> &#x02013; 10<sup>8</sup> particles/cm<sup>3</sup>.</p></list-item><list-item><p id="P251">Count median diameter = 50 to 200 nm</p></list-item><list-item><p id="P252">Mass median aerodynamic diameter average = 370 nm.</p></list-item><list-item><p id="P253">Aerosol size is dependent upon the device type, heating power, and puffing topography.</p></list-item></list></p>
<p id="P254"><bold>Chemical analysis</bold> of intermediate of VEA degradation not conclusive.</p>
<p id="P255"><bold>Identified vaping emission product</bold> (not confirmed with standards): 1-pristene, durohydroquinone monoacetate (DHQMA), and duroquinone (DQ). No direct evidence for ATMMC, DQM, and ketene.</p></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L35"><list-item><p id="P256"><bold>E-liquids</bold>: Propylene glycol (PG), vegetable glycerin (VG), vitamin E acetate (VEA), Vitamin E (VE), medium-chain triglyceride (MCT) oil, squalane (SQL), triethyl citrate (TEC).</p></list-item><list-item><p id="P257"><bold>Device</bold>: vape pen connected to a CCell cartridge</p></list-item><list-item><p id="P258"><bold>Puff topography:</bold>duration 4 sec, interval 60 sec. Total puffs collected 10. Flow rate 0.18 liter/min operated at 3.6 V.</p></list-item><list-item><p id="P259"><bold>Chemical analysis</bold> of liquid diluents and vapors using mass spectrometry analysis.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"><p id="P260"><list list-type="bullet" id="L36"><list-item><p id="P261">Significant changes in chemical composition between e-liquid and vapor.</p></list-item><list-item><p id="P262">Toxic byproducts formed during the vaping process likely resulting from thermal decomposition and oxidation of liquid diluents.</p></list-item></list></p>
<p id="P263"><bold>Identified vaping emission product</bold>:<list list-type="bullet" id="L37"><list-item><p id="P264">PG and VG &#x02192; Carbonyls; alkyl alcohols</p></list-item><list-item><p id="P265">MCT OIL and SQL&#x02192; Short-chain esters, short-chain carbonyls, short-chain alkanes, alkyl alcohols</p></list-item><list-item><p id="P266">VE and VEA&#x02192; carbonyls, long-chain alcohol, quinone-like products</p></list-item><list-item><p id="P267">TEC&#x02192; small esters, carboxylic acids.</p></list-item></list></p></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R160" ref-type="bibr">Lanzarotta et al. 2020</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L38"><list-item><p id="P268"><bold>E-liquids</bold>: Combination of &#x00394;-9-THC/VEA (~50:50 w/w), vs THC or VEA (100% controls)</p></list-item><list-item><p id="P269"><bold>Device:</bold> CCell cartridge connected to a vaping device</p></list-item><list-item><p id="P270"><bold>Puff topography:</bold> duration 4 sec, interval 30 sec, flow rate 1 liter/min, operating voltage 3.7 V.</p></list-item><list-item><p id="P271"><bold>Chemical analysis</bold> of e-liquids and vapors: 1) Infrared spectra collected on a Nicolet 8700 FT-IR spectrometer, 2) Direct analysis in real-time ionization coupled to a high-resolution mass spectrometer (DART-HRMS)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L39"><list-item><p id="P272">The liquid form of THC/VEA exhibits sufficient differences compared to the individual THC and VEA controls.<list list-type="bullet" id="L40"><list-item><p id="P273">No carbonyl peak observed in the THC control spectrum.</p></list-item><list-item><p id="P274">VEA control spectrum exhibited a carbonyl peak at 169.760 ppm.</p></list-item><list-item><p id="P275">THC/VEA pre-vape mixture and THC/VEA post-vape condensate spectra exhibited a carbonyl peak downfield at 169.775 ppm</p></list-item></list></p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R188" ref-type="bibr">Meehan-Atrash et al. 2019</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L41"><list-item><p id="P276"><bold>E-liquids</bold>: pure THC, synthetic distillate (SND) THC/Terpenes 90:10 (v/v)</p></list-item><list-item><p id="P277"><bold>Dabbing Device</bold>: Jibtronix Corp. Errlectric Concentration Station</p></list-item><list-item><p id="P278"><bold>Dabbing protocol</bold>: single dab of 11 &#x000b1; 2.5 mg of either THC or SND, Temp 370 &#x000b0;C (pure THC or SND)</p></list-item><list-item><p id="P279"><bold>Vaping device</bold>: CCell TH2 oil cartridge</p></list-item><list-item><p id="P280"><bold>Puff topography</bold>: 3 voltages 3.2 V, 4.0V, and 4.8V, 1 puff, duration 3 sec, 55 uL puff volume, 1.4&#x02013;1.5 &#x003a9;.</p></list-item><list-item><p id="P281"><bold>Chemical analysis</bold> of aerosol gas phase ATD-GCMS</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L42"><list-item><p id="P282"><bold>Identified vaping emission product</bold>: methacrolein, benzene, xylenes, toluene, styrene, ethylbenzene, isoprene, other nontarget hydrocarbons, and total VOCs.</p></list-item><list-item><p id="P283">Release of each component, other hydrocarbons, and total VOC increased in a voltage-dependent manner</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R172" ref-type="bibr">Lynch et al. 2021</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L43"><list-item><p id="P284"><bold>E-liquids</bold>: THC/VEA 50/50 (w/w),</p></list-item><list-item><p id="P285"><bold>Vaping Device</bold>: six 510 threaded vaping cartridges ceramic coil connected to Eleaf iStick 30W, + 1 black-market ceramic coil cartridge and 1 authentic cartridge containing D9THC from EVALI investigation</p></list-item><list-item><p id="P286"><bold>Puff topography</bold>: puff duration 4 sec, interval 30s, flow 1L/min, 3 puffs/voltage, voltage started at 3.0 V and increased by 0.5 V up to 4.5 or 5 V. Black-market cartridge 1.5 &#x003a9; resistance and voltage of 3.7 V.</p></list-item><list-item><p id="P287"><bold>Temperature measurement:</bold> Type-K thermocouple probe</p></list-item><list-item><p id="P288"><bold>Chemical analysis:</bold> GC/MS, GC/FT-IR/MS, and LC-APCI-HRMS/MS</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L44"><list-item><p id="P289"><bold>Temperature:</bold> clear difference within the cartridges depending on the distance from the center of the cartridge.</p></list-item><list-item><p id="P290"><bold>Temperature increase was voltage dependent:</bold> ranges of 217&#x02013;300&#x000b0; C at 3.0 V and 415&#x02013;476&#x000b0; C at 5.0 V, 454&#x02013;510&#x000b0;C at 5.5 V, 548&#x02013;632&#x000b0;C at 6V (illegal and authentic)</p></list-item><list-item><p id="P291"><bold>Identified vaping emission product:</bold> D9THC, VEA, 1-pristene, durohydroquinone monoacetate (DHQMA), 4-acetoxy-2,3,5trimethyl-6-methylene-2,4-cyclohexadienone (ATMMC)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R154" ref-type="bibr">Kovach et al. 2021</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L45"><list-item><p id="P292"><bold>E-liquids</bold>: VEA 100%,</p></list-item><list-item><p id="P293"><bold>Vaping Device</bold>: V8 X-Baby M2 atomizers using 0.25ohm, 40W, 3 V; Exxus EX6 1.6ohm ceramic oil cartridges 12W, 4 V. Smoking machine Bordwaldy LX 5.1</p></list-item><list-item><p id="P294"><bold>Puff topography</bold>: puff duration 3 sec, interval 30s, puff volume 55ml, for 50 puffs approximately.</p></list-item><list-item><p id="P295"><bold>Chemical analysis:</bold> aerosol collected on Cambridge Filter Pads; GC-HRMS for durohydroquinone (DHQ), duroquinone (DQ), 2,6,10,14-tetramethyl-1-pentadecene (TMPD)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L46"><list-item><p id="P296">DQ and TMPD are 2 major thermal degradants of aerosolized VEA.</p></list-item><list-item><p id="P297">Third major degradant is similar to DQ. (maybe ethyl-DQ).</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R190" ref-type="bibr">Mikheev and Ivanov 2022</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L47"><list-item><p id="P298"><bold>E-liquid:</bold> VEA 100%, THC 100%, THC/VEA 20%/80%, THC/VEA 50%/50%, THC/VEA 80%/20%.</p></list-item><list-item><p id="P299"><bold>Device</bold>: Kind Dream (dab-type ceramic with two horizontally positioned coils)</p></list-item><list-item><p id="P300"><bold>Puff topography</bold>: duration 5 sec, interval 60 sec, flow rate of 20 or 40 ml/s (1.2 or 2.4 liter/min), low and high voltage for each device. Temperatures: low 177&#x000b0;C, high 221&#x000b0;C. Number of puffs collected = 8.</p></list-item><list-item><p id="P301"><bold>Aerosol size distribution characterization</bold>: Differential Mobility Spectrometer (DMS500) in combination with the Smoking Cycle Simulator (SCS)</p></list-item><list-item><p id="P302"><bold>Chemical analysis</bold>: two-dimensional gas-chromatography&#x02013;time-of-flight mass-spectrometry (GC&#x000d7;GC-TOFMS)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"><p id="P303"><bold>Temperature measurement depends on chemical liquids and temperature setting.</bold><list list-type="bullet" id="L48"><list-item><p id="P304"><bold>THC 100% at 177C and 221C=</bold> temperature &#x0003c;250&#x000b0;C</p></list-item><list-item><p id="P305"><bold>THC/VEA 50/50 at 177C=</bold> temperature &#x0003c;250&#x000b0;C</p></list-item><list-item><p id="P306"><bold>THC/VEA 50/50 at 221C=</bold> temperature increased up to 500C toward the ends of the 8 puffs.</p></list-item><list-item><p id="P307"><bold>VEA 100% at 117C =</bold> temperature &#x0003c;250C</p></list-item><list-item><p id="P308"><bold>VEA 100% at 221C =</bold> temperature increased puff to puff reaching platau shortly at 500&#x02013;555</p></list-item></list></p>
<p id="P309"><bold>Aerosol size distribution characterization:</bold><list list-type="bullet" id="L49"><list-item><p id="P310"><bold>CMD =</bold> range 73&#x02013;186 nm, geometrical SD 1.6 &#x02013; 1.8</p></list-item><list-item><p id="P311"><bold>PNC</bold> = ~2&#x000d7;10^7 to ~1&#x000d7;10^8 particles/cm3, increase flow resulted in increased PNC. No influence of eliquid composition or heating power.</p></list-item><list-item><p id="P312"><bold>VEA 100% =</bold> smallest particle size: average 118 nm at 20 ml/s, and 84 nm at 40 ml/s. No influence of heating power.</p></list-item><list-item><p id="P313"><bold>Chemical analysis:</bold> no evidence of chemical reaction between THC and VEA.</p></list-item></list></p></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>E-liquids:</bold>
<list list-type="bullet" id="L50"><list-item><p id="P314">D8THC +VEA+ Terpene</p><p id="P315">&#x02003;(80%+ 0% +20%) 3.7 V</p><p id="P316">&#x02003;(63% + 27% +10%) 3.7 &#x02013; 5 V</p><p id="P317">&#x02003;(36% + 54% +10%) 3.7 &#x02013; 5 V</p><p id="P318">&#x02003;(0%+100% + 0%) 3.7 &#x02013; 5 V</p></list-item><list-item><p id="P319">Nic + PG + VG + Menthol</p><p id="P320">(2% + 48% + 50% +0%) 3.7 V</p><p id="P321">(5% + 45% + 50% +0%) 3.7 V</p><p id="P322">(5% + 43% + 50% +2%) 3.7 &#x02013; 5 V</p></list-item><list-item><p id="P323"><bold>Device</bold>: CCell cartridge 510 thread (1ml) for THC e-liquids, KangerTech refillable cartridges T3S series clear cartomizer 1.8ohm for nicotine e-liquids</p></list-item><list-item><p id="P324"><bold>Puff topography</bold>: duration 4 sec, interval 30 sec, flow rate of 1 l/min, puff volume 55 ml.</p></list-item><list-item><p id="P325"><bold>Aerosol size distribution characterization</bold>: scanning mobility particle sizer spectrometer (NanoScan SMPS), aerodynamic particle sizer spectrometer (APS), CO and CO2 (Q-Trak Indoor Air Quality (IAQ) Monitor), volatile organic compound (tVOC) (photo-ionization detector sensor (TG-502 probe), Time-integrated mass-size distribution (Harvard Compact Cascade Impactor)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L51"><list-item><p id="P326">
<bold>D8THC/VEA</bold>
<list list-type="bullet" id="L52"><list-item><p id="P327">nano-PNC (4.7&#x02013;8.6) &#x000d7; 10<sup>6</sup> particles/cm<sup>3</sup>, MPD 115&#x02013;212 nm</p></list-item><list-item><p id="P328">micro-PNC 3,364&#x02013; 7,865 particles/cm<sup>3</sup>, APD 1.25&#x02013;1.43 &#x003bc;m.</p></list-item><list-item><p id="P329">tVOC range 0.173&#x02013;24.5 ppm depending on VEA concentration and operational voltage</p></list-item><list-item><p id="P330">average CO2 level 650&#x02013;925 ppm, CO 10 ppm (VEA 27%) and 46 ppm (VEA 100%)</p></list-item><list-item><p id="P331">total PM mass concentration 67&#x02013;910 mg/m<sup>3</sup>, depending on VEA concentration and operational voltage (highest PM mass concentration for VEA 100% 5V).</p></list-item></list>
</p></list-item><list-item><p id="P332">
<bold>NICOTINE</bold>
<list list-type="bullet" id="L53"><list-item><p id="P333">nano-PNC (5.2&#x02013;9.2) &#x000d7; 10<sup>6</sup> particles/cm<sup>3</sup>, mean-MPD 110&#x02013;125 nm.</p></list-item><list-item><p id="P334">micro-PNC 4,052&#x02013;7,048 particles/cm<sup>3</sup>, mean-APD 1.25&#x02013;1.31 &#x003bc;m.</p></list-item><list-item><p id="P335">tVOC range 0.044&#x02013;0.707 ppm depending on menthol concentration</p></list-item><list-item><p id="P336">CO2 average ~900 ppm, CO not detectable.</p></list-item><list-item><p id="P337">total PM mass concentration 240&#x02013;668 mg/m<sup>3</sup>, depending on menthol concentration and operational voltage</p></list-item></list>
</p></list-item></list>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T9" orientation="landscape"><label>Table 7</label><caption><p id="P338">Summary of the <italic toggle="yes">in vivo/in vitro</italic> toxicological experiments conducted on various e-liquids or the generated aerosols/vapors.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">AUTHOR</th><th align="left" valign="top" rowspan="1" colspan="1">Cell/Animal model</th><th align="left" valign="top" rowspan="1" colspan="1">EXPOSURE</th><th align="left" valign="top" rowspan="1" colspan="1">FINDINGS:</th><th align="left" valign="top" rowspan="1" colspan="1">COMMENT:</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R205" ref-type="bibr">Muthumalage, Lucas, et al. 2020b</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L54"><list-item><p id="P339">Bronchial epithelial cells (BEAS-2B)</p></list-item><list-item><p id="P340">Monocytes, Mono-Mac-6 cells (MM6)</p></list-item><list-item><p id="P341">Epithelial cells (16-HBE)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"><p id="P342">Aerosols generated from:<list list-type="bullet" id="L55"><list-item><p id="P343">MCT oil 0.25% <italic toggle="yes">v/v</italic></p></list-item><list-item><p id="P344">VEA 0.025% (<italic toggle="yes">w/v</italic>) or 50 &#x003bc;M for MM6</p></list-item><list-item><p id="P345">VEA 50% <italic toggle="yes">w/v</italic> in MCT for BEAS-2B</p></list-item><list-item><p id="P346">Cannabidiol/Counterfeit vape Cartridge (CBD) 0.25%</p></list-item></list></p>
<p id="P347">Operated voltages: 3.8V</p>
<p id="P348">70 mL puffs &#x000d7;10 minutes in air-liquid interface.</p>
<p id="P349">Time-point 24 hours</p></td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L56"><list-item><p id="P350">Cellular and acellular ROS generation increased by MCT and VEA more than CBD.</p></list-item><list-item><p id="P351">CBD aerosol caused the greatest cytotoxicity in BEAS-2B cells (34% cell death), while CBD liquid in MM6 (98% cell death)</p></list-item><list-item><p id="P352">IL-6 and IL-8 secretion increased by CBD in BEAS-2B, and by VEA in MM6.</p></list-item><list-item><p id="P353">VEA, CBD and MCT had the same effect on barrier dysfunction.</p></list-item><list-item><p id="P354">MM6 lipid-laden index: MCT 56.7, CBD 30.8, VEA 1.2, Control 3.4</p></list-item></list>
</td><td align="left" valign="top" rowspan="4" colspan="1">
<list list-type="bullet" id="L57"><list-item><p id="P355">Acute exposure to VEA and CBD induce <italic toggle="yes">in vitro</italic> cytotoxicity, barrier dysfunction, and inflammation.</p></list-item><list-item><p id="P356"><italic toggle="yes">In vivo</italic> mouse exposure induces acute inflammation with elevated pro-inflammatory markers.</p></list-item><list-item><p id="P357">Both VEA and CBD may have caused acute respiratory distress inducing eosinophilic pneumonia.</p></list-item><list-item><p id="P358">Prolonged exposure to VEA and CBD may cause significant lung damage, which is involved in the pathogenesis of EVALI.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L58"><list-item><p id="P359">C57BL/6 mice, M and F, 4 months old</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"><p id="P360"><list list-type="bullet" id="L59"><list-item><p id="P361">MCT oil</p></list-item><list-item><p id="P362">VEA 50% w/v in MCT,</p></list-item><list-item><p id="P363">VEA 1.06 M</p></list-item></list></p>
<p id="P364">6 Cartridges</p>
<p id="P365">70 ml puff, 2 puff/min, for 1 h/day &#x000d7; 3 consecutive days</p></td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L60"><list-item><p id="P366">Mouse arterial oxygen saturation: AIR 96%, MCT 92%, VEA 94%, and CBD 95%</p></list-item><list-item><p id="P367">BALF total cells, neutrophils and CD4 lymphocytes increased by CBD</p></list-item><list-item><p id="P368">CBD and VEA increased IL-6, EOTAXIN, G-CSF.</p></list-item><list-item><p id="P369">CBD and MCT decreased MCP-1, RANTES, IL4.</p></list-item><list-item><p id="P370">CBD/CVC, VEA and MCT decreased IL-17A, IL-12p40.</p></list-item><list-item><p id="P371">VEA decreased lung surfactant protein A (SP-A)</p></list-item><list-item><p id="P372">VEA and CBD altered the lipidomic profile altered by in BALF.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><bold>VOCs</bold> release: CBD =20.03 ppm, MCT= 10.33 ppm, VEA= 9.67 ppm.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Human Plasma</td><td align="left" valign="top" rowspan="1" colspan="1">E-cig users vs non-smokers</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L61"><list-item><p id="P373">E-cig users had less TXB2, AA, and Acetic Acid and increased levels of 5HETE, 11HERE, 12HETE, and 17OHDHA in their plasma compared to non-smokers</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R206" ref-type="bibr">Muthumalage and Rahman 2019</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L62"><list-item><p id="P374">Human monocytic cell line (U937)</p></list-item><list-item><p id="P375">Normal primary human bronchial epithelial cells (NHBE) cells (CC-2540)</p></list-item><list-item><p id="P376">Human bronchial epithelial cells (BEAS-2B)</p></list-item><list-item><p id="P377">Human lung fibroblasts cells (HFL-1)</p></list-item></list>
</td><td align="left" valign="top" rowspan="2" colspan="1"><list list-type="bullet" id="L63"><list-item><p id="P378">1. CBD liquid 10.6 &#x003bc;M, 21.2 &#x003bc;M, 31.8 &#x003bc;M, or 42.4 &#x003bc;M.</p></list-item><list-item><p id="P379">2. CBD aerosol (1000 mg)</p></list-item><list-item><p id="P380">3. Dexamethasone (DEX) 10 Mm + CBD 10.6 &#x003bc;M</p></list-item><list-item><p id="P381">4. (Lipopolisaccharide) LPS 1 &#x003bc;g/ml +CBD liquid 10.6 &#x003bc;M</p></list-item><list-item><p id="P382">5. TNF-&#x003b1; + CBD liquid 10.6 &#x003bc;M</p></list-item></list>
<list list-type="bullet" id="L64"><list-item><p id="P383"><bold>ALI: Propylene glycol/Vegetable glycerin (50:50)</bold> or <bold>CBD aerosol</bold>: 51 mL volume, 2 puffs/min, 2 L/min flow for 30 minutes. Heating temperature of the e-liquid 230 &#x000b0;C with a 0.55 &#x003a9; atomizer.</p></list-item><list-item><p id="P384"><bold>LPS</bold> 1 &#x003bc;g/ mL or 10 &#x003bc;g/mL.</p></list-item></list></td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L65"><list-item><p id="P385">CBD liquid decreased cell viability in U937 (any dose), HFL-1 (42.4 &#x003bc;M), and BEAS-2b (31.8 &#x003bc;M).</p></list-item><list-item><p id="P386">CBD liquid 10.6 &#x003bc;M differently altered the secretion of inflammatory cytokines among the cell lines: dose-dependent increase of IL-8 and dose-dependent decrease of MCP-1/CCL2 in U937- BEAS-2B - HFL-1. NHBE is not affected.</p></list-item><list-item><p id="P387">BEAS-2B exposed to CBD vapor: elevated Eotaxin, MCP-1, CXCL1, CXCL2, IL-8, and IL-6 levels compared to PG/VG.</p></list-item><list-item><p id="P388">DEX reduced CBD-mediated inflammation in U937.</p></list-item><list-item><p id="P389">CBD attenuated the LPS-induced release of IL-8, MCP-1, CCL3, CCL4, and TNF-&#x003b1;, CXCL2, IL-33, IL-6, and RANTES in U937.</p></list-item><list-item><p id="P390">CBD reduced the TNFa-induced release of CXCL1, G-CSF, and IL-6 levels, and increased CXCL2, IL-8, GM-CSF in NHBE</p></list-item><list-item><p id="P391">In BEAS-2B, CBD decreased the TNFa-induced release of MCP-1, CXCL-1, IL-6, G-CSF, and GM-CSF. DEX reduced the TNFa-induced release of CXCL1, CXCL2, IL-6, IL-8, and GM-CSF. CBD + DEX significantly reduce almost all cytokines except IL-8.</p></list-item></list>
</td><td align="left" valign="top" rowspan="2" colspan="1">
<list list-type="bullet" id="L66"><list-item><p id="P392"><italic toggle="yes">In-vitro</italic> cell exposure to CBD induces a varying degree of toxicity depending on the cell type. Monocytes and fibroblasts were particularly prone to cell death and damage by exposure to CBD.</p></list-item><list-item><p id="P393">Cells treated with CBD showed increased IL-8 response, hallmark of acute inflammation, recruitment, and activation of na&#x000ef;ve inflammatory cells.</p></list-item><list-item><p id="P394">CBD liquids, as well as aerosols, generated significant amounts of acellular/cellular ROS (potential cause of oxidative stress), and mitochondrial ROS (potential mitochondrial dysfunction).</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L67"><list-item><p id="P395">Mouse macrophage RAW 264.7</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L68"><list-item><p id="P396"><bold>Cellular and mitochondrial ROS</bold> generation were higher with CBD at 21.2 &#x003bc;M and 42.4 &#x003bc;M respectively. CBD liquids (350 mg and 550 mg by Green Roads) and aerosol (Green Roads 100 mg) induced a dose-dependent increasing generation of <bold>acellular ROS.</bold></p></list-item><list-item><p id="P397"><bold>CBD liquid</bold> significantly elevated G-CSF, GM-CSF, IFN-&#x003b3;, IL-1a, IL-6, IL-27, I-TAC, M-CSF, MCP-1, RANTES, and TNF-&#x003b1;., and decreased eotaxin, IL-1ra, and IL-2.</p></list-item><list-item><p id="P398"><bold>CBD liquid</bold> 21.2 &#x003bc;M inhibited NF-&#x003ba;B activity and decreased MCP-1/CCL2 cytokine in LPS-activated 10 &#x003bc;g/mL macrophages.</p></list-item><list-item><p id="P399"><bold>CBD liquid</bold> upregulated MCP1 protein even after LPS inhibition</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R35" ref-type="bibr">Bhat et al. 2020</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L69"><list-item><p id="P400">3 groups of C57BL/6NCr mice n=10 (5 males and 5 females) 6 weeks old.</p></list-item><list-item><p id="P401">Animals were sacrificed 16 h after the last exposure.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L70"><list-item><p id="P402">VEA, PG:VG, or fresh air</p></list-item><list-item><p id="P403">Mice exposed for 5 hr/day, 5 days/week for 2 weeks</p></list-item><list-item><p id="P404">Puff Protocol: 10 puffs (3 sec each) every 15 sec, volume 55 ml. Interval between clusters 7.5 min (total 240 puffs/day). 4.8V</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L71"><list-item><p id="P405">VEA levels in BAL fluid: only in VEA exposed mice (5&#x000d7;10<sup>3</sup> ng/ml)</p></list-item><list-item><p id="P406">ALBUMIN levels in BAL fluid: in VEA exposed mice 1.5&#x000d7;10<sup>5</sup>ng/ml, in AIR and PG: VG &#x0003c;5.0&#x000d7;10<sup>4</sup> ng/ml.</p></list-item><list-item><p id="P407">CD45+ CELLS in Lung: in VEA exposed mice 1.5&#x000d7;10<sup>5</sup> ng/ml, AIR &#x0003c;5.0&#x000d7;10<sup>5</sup> ng/ml, PG:VG &#x0003e;5.0&#x000d7;10<sup>5</sup> ng/ml.</p></list-item><list-item><p id="P408">Lipid-laden macrophages are often in clusters only in BAL from VEA-exposed mice.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Limitation of the study:<list list-type="bullet" id="L72"><list-item><p id="P409">No exposure to THC or THC/VEA.</p></list-item><list-item><p id="P410">No chemical evaluation of aerosol to evaluate by-products of VEA.</p></list-item></list></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R141" ref-type="bibr">Jiang et al. 2020</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Human bronchial epithelial cells (BEAS-2B)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L73"><list-item><p id="P411">PG, VG, MCT, SQL, VE, VEA, TEC e-liquid, or 100 puffs/15ml (LHC-9 medium) vaping emission samples for 48h.</p></list-item><list-item><p id="P412">CCell cartridge (510 thread, 0.5 mL, TH205, 1.4 &#x003a9;) 3.6 V 9.25W</p></list-item><list-item><p id="P413">Puff topography: duration 4 sec, interval 60 sec, volume 12 ml, flow rate 0.18 liter/mi.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L74"><list-item><p id="P414">Cells exposed for 48 hours to a higher concentration of vapor showed higher cell death compared to liquid exposure, except for TEC (cell death similarly increased with both TEC liquid and vapor).</p></list-item><list-item><p id="P415">LDH released from cells exposed to MCT oil and TEC did not differ much between e-liquid and vaping emissions.</p></list-item><list-item><p id="P416">PG and VG <bold>e-liquid</bold> induced a higher LDH release compared to vaping emission.</p></list-item><list-item><p id="P417">SQL, VE, and VEA <bold>vaping emission</bold> increased the LDH release compared to e-liquid; however, VE induced a stronger cytotoxic effect.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L75"><list-item><p id="P418">vaping topography does not mimic the real vaping scenarios.</p></list-item><list-item><p id="P419">The liquid diluents were studied individually in an isolated system.</p></list-item><list-item><p id="P420">Only the acute cytotoxic effects of vaping emissions from commonly used liquid diluents were examined</p></list-item><list-item><p id="P421">Collection efficiency of impinger 80% for aerosols.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R182" ref-type="bibr">Matsumoto et al. 2020</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL6 mice<break/><break/>Human primary AT-II cells (from 1 single adult human lung donor)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L76"><list-item><p id="P422"><bold>VEA 100%</bold> aerosolized with a ShenZen aerosolizer, 1.5 V ceramic coil, using a Gram Universal Vaping Machine, at 9.4 W.</p></list-item><list-item><p id="P423">Puff volume 80 ml, duration 4 sec.</p></list-item><list-item><p id="P424">Mice exposed for 1 hour twice daily for 6 or 15 days</p></list-item><list-item><p id="P425"><bold>JUUL</bold> (VG:PG 30:70) + Nicotine 5%</p></list-item><list-item><p id="P426">10 puffs initially injected over 1 minute, followed by 110 puffs over 1 hour.</p></list-item><list-item><p id="P427">To generate ketene in that study, a metal coil was operated at 30 W or 50 W (11.0 or 15.5 A, respectively)</p></list-item><list-item><p id="P428">VEA aerosol for 20 &#x02013; 120 min/day for 3 days in humans</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"><p id="P429">VEA aerosol 1-hour &#x000d7; 2/day for 6 or 15 days:<list list-type="bullet" id="L77"><list-item><p id="P430">Progressive increase in excess extravascular lung water, BAL total protein, and SP-D (surfactant protein-D).</p></list-item></list></p>
<p id="P431">15 days of VEA exposure:<list list-type="bullet" id="L78"><list-item><p id="P432">BAL fluid and cells analysis: increased total BAL cell count (mono/macrophages and neutrophils), presence of large vacuolated macrophages, and Increased release of inflammatory cytokines (IL-8, MCP-3).</p></list-item><list-item><p id="P433">Histological analysis: monocytic and neutrophilic alveolar and interstitial inflammation in a bronchiolocentric pattern with increased large, foamy, and vacuolated macrophages in the airspaces, in association with a dense inflammatory infiltrate affecting the alveolar septa. Pulmonary blood vessels are frequently surrounded by lymphocyte-rich cell aggregates, with progression between 6 and 15 days of VEA exposure.</p></list-item><list-item><p id="P434">Human AT-II exposed to VEA aerosol: Dose-dependent cell death, LDH release, and TUNEL staining; increased chemokines release from monocyte and neutrophil; punctate cytoplasmic staining with Oil Red O; Dose-dependent increase in VEA and a-TP.</p></list-item><list-item><p id="P435">JUUL aerosol: Well tolerated in mice and humans.</p></list-item></list></p></td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L79"><list-item><p id="P436">micece exposed to VEA develop diffuse acute lung injury.</p></list-item><list-item><p id="P437">Surfactant-producing human AT-II cells are directly injured by VEA aerosol.</p></list-item><list-item><p id="P438">Lack of: THC experiments due to ongoing strict federal research restrictions; aerosol VEA byproducts measurement; assessment of potential synergistic toxicity between VEA and nicotine-containing aerosols.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R180" ref-type="bibr">Marrocco et al. 2022</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Human lung epithelial cell line (Calu-3)<break/><break/>Human peripheral blood monocytes (THP-1)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>E-liquids:</bold>
<list list-type="bullet" id="L80"><list-item><p id="P439">D8THC +VEA+ Terpene</p><p id="P440">&#x02003;(80%+ 0% +20%) 3.7 V</p><p id="P441">&#x02003;(63% + 27% +10%) 3.7 &#x02013; 5 V</p><p id="P442">&#x02003;(36% + 54% +10%) 3.7 &#x02013; 5 V</p><p id="P443">&#x02003;(0%+ 100% + 0%) 3.7 &#x02013; 5 V</p></list-item><list-item><p id="P444">Nic + PG + VG + Menthol</p><p id="P445">(2% + 48% + 50% +0%)3.7 V</p><p id="P446">(5% + 45% + 50% +0%)3.7 V</p><p id="P447">(5% + 43% + 50% +2%)3.7&#x02013;5V</p><p id="P448">2 doses: 85 &#x02013; 257 puffs/m<sup>2</sup> (1&#x02013;3 months), 24 h</p></list-item><list-item><p id="P449"><bold>Device</bold>: CCell cartridge 510 thread (1ml) for THC e-liquids, KangerTech refillable cartridges T3S series clear cartomizer 1.8ohm for nicotine e-liquids</p></list-item><list-item><p id="P450"><bold>Puff topography</bold>: duration 4 sec, interval 30 sec, the flow rate of 1 l/min, puff volume 55 ml</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"><p id="P451"><bold>Cell viability</bold><list list-type="bullet" id="L81"><list-item><p id="P452"><bold>VEA 54% 5V and Nic 5%+Menthol 2% 5V at a higher dose</bold> increased the LDH release and decreased the metabolic activity of Calu 3 epithelial cells.</p></list-item><list-item><p id="P453"><bold>VEA 54% 3.7&#x02013;5V and all nicotine both doses=</bold> dose-dependent diminution on the metabolic activity of THP-1.</p></list-item></list></p>
<p id="P454"><bold>ROS</bold><list list-type="bullet" id="L82"><list-item><p id="P455"><bold>VEA 100% 3.7% low dose</bold> increased ROS generation in Calu-3 cells.</p></list-item><list-item><p id="P456"><bold>VEA 54% and All Nicotine both doses</bold> increased ROS generation in THP-1 cells.</p></list-item></list></p>
<p id="P457"><bold>Apoptosis</bold><list list-type="bullet" id="L83"><list-item><p id="P458"><bold>VEA 27% 5V and 54% 3.7 &#x02013; 5V high dose and all nicotine higher dose</bold> significantly decreased the mitochondrial membrane potential in Calu-3</p></list-item><list-item><p id="P459"><bold>VEA 54%, VEA 100%, Nicotine 3.7 &#x02013; 5 V high dose</bold> increased caspase 3 activation in Calu-3</p></list-item></list></p>
<p id="P460"><bold>Inflammatory response</bold><list list-type="bullet" id="L84"><list-item><p id="P461">Cytokine release was overall suppressed by THC or nicotine treatment.</p></list-item><list-item><p id="P462"><bold>VEA 54% 3.7 &#x02013; 5 V</bold> upregulated FGF-2, G-CSF, IL-1a, IL-1RA, IL-18, M-CSF, PDGF AB/BB, and downregulated GRO-a, IL-4, IL-22, MDC, RANTES, TNF-b, VEGF-A.</p></list-item><list-item><p id="P463"><bold>-NIC 5%+Menthol 2%</bold> increased FGF-2, IL-1&#x003b1;, IL-1RA, IL-18, and M-CSF. G-CSF, GM-CSF, IL-8, MCP-1, PDGF-AB/BB, IL-15, TGF-a, and inhibited IL-6.</p></list-item></list></p></td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L85"><list-item><p id="P464">aerosol generated from THC 36% +VEA 54% + Terp 10% and Nicotine 5% +Menthol 2% increased a limited number of pro-inflammatory cytokines and suppressed the majority of them while inducing a higher level of cytotoxicity.</p></list-item><list-item><p id="P465">Possible dysregulation of the immune response, which is possible in the context of EVALI.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="R183" ref-type="bibr">Matsumoto et al. 2022</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">C57BL6 mice<break/><break/>Primary human alveolar macrophages from adult human lungs</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L86"><list-item><p id="P466"><bold>VEA 100%</bold> aerosolized with a ShenZen aerosolizer, 1.5 V ceramic coil, using a Gram Universal Vaping Machine, at 9.4 W.</p></list-item><list-item><p id="P467">Puff volume 80 ml, duration 4 sec,</p></list-item><list-item><p id="P468">1 puff was injected into the chamber every 30 seconds for 1 hour twice daily for up to 28 days.</p></list-item><list-item><p id="P469">Mice sacrificed either 12 hours or 6 days after the last exposure.</p></list-item><list-item><p id="P470">Some mice were intranasally treated with 400 FFU influenza Puerto Rico/8/34 (PR8) or PBS control 12 hours after the last exposure, then sacrificed 7 days after the inoculation.</p></list-item><list-item><p id="P471">AM exposed to VEA aerosol for 1 hour daily for 3 consecutive days</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L87"><list-item><p id="P472">BAL: increased protein concentration, macrophage/monocyte counts, vacuolization of macrophages, MCP3, KC, IL-6 starting at day 15 of exposure.</p></list-item><list-item><p id="P473">Lung Histology: mixed acute and chronic inflammation in the distal bronchioles, diffuse foamy macrophages, and neutrophil infiltration in thickened septa. Increased Angiopoietin-2 (ARDS), ICAM1, and MMP8 (sepsis). Presence of VE, and VEQ in the airspace. Dose-dependent increase of plasma MDA.</p></list-item><list-item><p id="P474">After 6 days from exposure: persistent lung edema; decreased BAL protein, total cells, and neutrophils, smaller macrophages, constant number, lower cytokines.</p></list-item><list-item><p id="P475">VEA cytotoxic on alveolar macrophages in vitro, increased vacuolization after a 3-day exposure.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="L88"><list-item><p id="P476">VEA exposure induces systemic inflammation and increased susceptibility to viral infection in mice.</p></list-item><list-item><p id="P477">VEA aerosol is phagocytosed by alveolar cells, then hydrolyzed to free tocopherol, likely resulting in oxidative stress in mice.</p></list-item><list-item><p id="P478">VEA aerosol is cytotoxic to primary human alveolar macrophages, impairs efferocytotic function, and induces AM chemokine release.</p></list-item></list>
</td></tr></tbody></table></table-wrap></floats-group></article>